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Abstract
Telomere shortening and an increased telomerase activity are associated with poor 
prognosis and disease progression in many cancers. In Chronic Myeloid Leukaemia 
(CML) telomere shortening has a strong correlation with disease progression. 
Expression of hTERT, the catalytic component of telomerase, was evaluated in the 
CD34+ cells of CML patients. This revealed that expression of hTERT was significantly 
reduced in chronic phase CML and decreased with disease progression to accelerated 
phase and blast crisis. It could therefore be concluded that reduced hTERT expression 
contributes to reduced telomere length in CML. Additionally, expression of c-Myc, 
which increases hTERT transcription, correlated with hTERT expression suggesting 
decreased hTERT is partly caused by reduced c-Myc. hTERT promoter methylation and 
mutation status were investigated and this revealed that the hTERT promoter was not 
methylated and mutation rates were low suggesting that these are not contributing to 
reduced hTERT expression. cDNA microarrays were used to analyse gene expression in 
neutrophils of patients with Essential Thrombocythaemia (ET) harbouring the JAK2 
V617F mutation which, like the BCR/ABL translocation in CML, results in an activated 
kinase. Neutrophils of ET patients exhibited a gene expression profile close to that of 
controls despite the presence of the mutation. Affymetrix microarrays were used to 
investigate the role of telomerase related genes in Myelodysplastic Syndromes (MDS). 
Genes decreased in patients with del(5q) include positive regulators of telomere length 
and genes with higher expression were associated with increased telomerase activity. 
Inferring that in these patients telomere length would be reduced but counteracted by 
increased expression of genes promoting telomerase activity. Genes that could 
differentiate between RA and RAEB2 subtypes were mostly related to telomere
maintenance. These results demonstrate the complex role of telomerase and telomere 
length in malignancy and challenge the view that hTERT is always increased in cancer.
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Chapter 1 
Introduction
1.1 The Discovery o f Telomeres and Telomerase
The study of telomeres began in the 1930s with the proposals of Herman Muller and 
Barbara McLintock suggesting the presence of a structure to protect chromosome ends 
from fusing to one another (Muller 1938; McClintock 1941). Muller named these 
structures telomeres, from the Greek “telos” meaning end and “meros” meaning part.
The first telomere sequence to be discovered was that of Tetrahymena thermophila by 
Blackburn and Gall (Blackburn and Gall 1978). This was shown to be the tandomly 
repeated sequence CCCCTT. It was then demonstrated by Szostak and Blackburn that 
the telomeric sequences of Tetrahymena could protect DNA ends from fusion (Szostak 
and Blackburn 1982). By transfecting Tetrahymena telomere sequences into yeast on a 
linear plasmid they created a functional telomere that would replicate in yeast. These 
telomeres showed different lengths in a clonal population of yeast cells and did not fuse 
to form a circular plasmid, thus confirming the ideas put forward by Muller and 
McLintock. It was not until 1988 that the human telomere sequence was elucidated by 
Moyzis et al. (Moyzis et al. 1988). Fluorescent in situ hybridisation and nuclease 
digestion experiments allowed them to demonstrate that human telomeres consist of a 
tandemly repeated 5’-TTAGGG-3’ sequence. These sequences were identified as 
functional human telomeres and serve to protect chromosome ends and solve the “end 
replication problem” (Watson 1972; Olovnikov 1973). This problem results from the 
semiconservative replication of DNA in the 5’ to 3’ direction and the use of short RNAs 
to prime DNA synthesis. This results in a loss of nucleotides at the 5’ end of the DNA 
strand that cannot be filled and which would lead to the degradation of important 
genetic material if telomere DNA was not present. For human telomeres this gives rise 
to a shortening rate of about 50bp per chromosome end per cell division (Harley et al.
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1990). If this erosion is not balanced by elongation then telomeres will shorten with 
each cell division. It was recognised that human cells are limited in the number of cell 
divisions they can undergo (Hayflick and Moorhead 1961). This limit is known as the 
Hayflick limit and is the phenomenon of replicative senescence. Senescence occurs 
when cells enter permanent growth arrest in the Go/Gi phase of the cell cycle while 
remaining metabolically active (Artandi and DePinho 2000). Telomere shortening leads 
to chromosome instability and the replicative senescence described by Hayflick.
Further work by Blackburn and Grieder on Tetrahymena revealed the presence of a 
ribonucleoprotein complex that was capable of de novo telomere synthesis (Greider and 
Blackburn 1987). They named this new reverse transcriptase Telomerase. Shortly after 
this discovery mutation of telomerase in yeast demonstrated that the enzyme was able to 
maintain the telomeric DNA at chromosome termini (Lundblad and Szostak 1989). 
Studies of the human cell line HeLa identified the presence of telomerase in human cells 
and its ability to add telomere repeats in these cells (Morin 1989). The enzyme was 
then implicated in human cellular senescence when work on human fibroblasts revealed 
that a loss of telomeric DNA was associated with serial passaging of the cells (Harley et 
al 1990). Evidence that shortening of telomeres was the cause of cellular senescence 
was presented in 1998 by Bodnar et al. (Bodnar et al. 1998). They transfected the gene 
encoding the human telomerase reverse transcriptase enzyme {hTERT) into telomerase 
negative human cell lines and observed the restoration of telomerase activity leading to 
elongated telomeres and increased cell division when compared to the telomerase 
negative control cells which showed telomere shortening and senescence.
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The importance of the work of Elizabeth Blackburn, Carol Greider and Jack Szostak 
was recognised in 2009 when they were awarded the Nobel Prize in physiology or 
medicine for their work on telomeres and telomerase.
1.2 Structure of Human Telomeres
Human telomeres consist of between 10 and 15 kb of double stranded telomeric 
TTAGGG repeats (Blasco 2005). At the terminal of the double stranded telomere there 
is a further single stranded 3’ G-rich overhang of 100-200 nucleotides. This overhang 
has been shown, with the aid of electron microscopy, to loop back and anneal with the 
double stranded telomere region to form a “t-loop” structure (Griffith et a l 1999). It is 
thought that the t-loop forms when the single stranded 3’ telomere overhang invades the 
double stranded region of the telomere repeats (Fig 1.1). This loop is proposed to 
protect the telomere ends by preventing the 3’ overhang from being identified as a site 
of DNA damage or a double strand break (de Lange 2002).
Telomeres are bound by two telomere repeat binding factors known as TRF1 and TRF2 
as represented in Fig 1.1. TRF1 binds double stranded telomere repeats and the longer 
the telomere the more TRF1 molecules that bind to the telomere (Smogorzewska et a l 
2000). TRF1 is thought to function to limit telomere length by preventing telomerase 
from binding individual telomeres (van Steensel and de Lange 1997). This indicates 
that shorter telomeres would have reduced binding of TRF1 allowing telomerase to 
access the telomere repeats and lengthen shorter telomeres (Smogorzewska and de 
Lange 2004). In addition to its function of telomere length regulation TRF1 interacts 
with several telomerase related proteins. One of these is the enzyme Tankyrase, which 
is a poly(ADP-Ribose) polymerase (Smith et a l 1998). Tankyrase directly binds to
TRF1 at the telomere and ADP-ribosylates TRF1 to inhibit it’s binding to the telomere 
(Smith and de Lange 2000). This results in a reduction of TRF1 binding to telomeres 
and an increase in telomere elongation. Therefore, Tankyrase is a positive regulator of 
telomere length. The interaction between Tankyrase and TRF1 is modulated by TIN2. 
TIN2 stabilises the interaction between the two proteins and protects TRF1 from 
poly(ADP-Ribosylation) by tankyrase (Ye and de Lange 2004).
Figure 1.1 Human telomere t-loop structure bound by telomere binding proteins.
Telomeric DNA is represented by the red and green lines and the single stranded 3’ 
overhang is shown to be invading the double stranded region of telomere repeats. The 
displaced single stranded telomere repeats are bound by POT1 to maintain the t-loop 
structure (Yang et al. 2005). Figure modified from (Carroll and Ly 2009).
Like TRF1, TRF2 also binds to double stranded telomere repeats, is more abundant on
POT1
TRF1
9
long telomeres and negatively regulates telomere length (Smogorzewska et al. 2000). 
Overexpression of TRF2 leads to a reduction in telomere length suggesting a function 
similar to that of TRF1 of restricting elongation of telomeres (Smogorzewska et al. 
2000). TRF2 has a second important function to protect the ends of individual 
telomeres and reduction of TRF2 results in loss of the G-strand overhang at telomere 
ends (van Steensel et a l 1998). TRF2 is thought to possess a DNA remodelling activity 
that would facilitate the formation of telomeres into the t-loop structure which can 
protect chromosome ends (Stansel et al. 2001; Khan et al. 2007). It is thought that loss 
of TRF2 results in reduced G-strand overhangs after DNA replication leading the 
chromosome ends to remain unprotected.
When telomeres become critically shortened the length of the G-strand overhang is 
reduced and this is thought to disrupt the formation of the T-loop (Stewart et al. 2003). 
In the absence of telomerase the telomeric overhang is not maintained and the telomeres 
become uncapped and unprotected by telomere binding proteins such as TRF2. These 
uncapped telomeres are recombinogenic and if a cell with critically shortened telomeres 
continues to divide unchecked then this may lead to chromosome end to end fusions as 
double strand break repair mechanisms are acting at telomeres (de Lange 2002). This 
can lead to chromosome breakages and other structural abnormalities such as loss or 
gain of parts of the chromosome which contribute to genomic instability (Boukamp et 
al. 2005). However, the cell possesses mechanisms to prevent these aberrations 
multiplying. Critically shortened telomeres with reduced overhangs and no TRF2 
binding are recognised by the cell as dysfunctional and a DNA damage response is 
induced (Cosme-Blanco et al. 2007). This involves the well characterised tumour 
suppressor gene p53 is that is activated by DNA damage and cellular stress (Meek and 
Anderson 2009). Activation of p53 induces cellular senescence or cell death through
10
apoptosis both of which protect from tumour formation (Deng et a l 2008). The 
progressive telomere shortening observed in normal somatic cells leads to activation of 
p53 (Cosme-Blanco et al. 2007). This means that when the telomeres become 
sufficiently shortened further cell division is blocked, resulting in replicative senescence 
(Harley et a l 1990). This telomere shortening is thought to be a molecular mechanism 
to count the number of times a cell has divided (Wright and Shay 2001). Telomere 
sequences appear to have the function to protect human cells against the development of 
cancer by limiting the maximum number of permitted divisions (Sager 1991).
1.3 Human Telomerase Reverse Transcriptase
Human telomerase is a ribonucleoprotein complex that minimally consists of hTERT, 
the catalytic component, and hTR, the RNA template (Wenz et a l 2001). hTR is a short 
RNA template of 11 nucleotides that are complimentary to the telomere repeat sequence 
(Feng et a l  1995). hTERT is the reverse transcriptase subunit and the rate limiting 
factor for telomerase activity (Counter et a l  1998). Both the RNA template and the 
catalytic component are necessary for telomerase activity and without them both there is 
no functional enzyme activity (Wenz et a l  2001). Although sufficient for telomerase 
activity there is a requirement for accessory proteins in the telomerase holoenzyme 
complex to control enzyme assembly, regulation and activity.
11
hTERT
Template
Dyskerin
Figure 1.2 Human telomerase holoenzyme. The secondary structure of the 451 
nucleotide telomerase RNA component is represented as a solid black line with the 11 
nucleotide telomere repeat template shown as a red box (Chen et al. 2000). hTERT, the 
catalytic component is represented in blue and shown interacting with the chaperone 
proteins Hsp90 and p23. Dyskerin is shown interacting with hTR to stabilize the RNA. 
The binding site of TEP1 with hTERT and hTR is not known as present and it is 
thought that TEP1 may have multiple binding sites on hTERT (Beattie et al. 2000).
Telomerase associated protein 1 (TEP1) is an RNA binding protein that interacts with 
the telomerase RNA component (Harrington et al. 1997). TEP1 is not the rate limiting 
factor for telomerase activity but it is involved in enzyme activity and is thought to be 
required for full activity of the enzyme (Chang et al. 2002). TEP1 also binds hTERT 
and is associated with telomerase activity although TEP1 is not required to reconstitute 
telomerase activity (Beattie et al. 2000). As shown in Fig 1.2, TEP1 assembles with 
hTERT, hTR, hsp90, p23 and dyskerin to form the telomerase holoenzyme complex
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(Chang et a l  2002). Hsp90 and p23 are chaperone proteins that contribute to 
telomerase activity by aiding assembly of hTERT with hTR (Holt et a l 1999). 
Dyskerin binds hTR and has been implicated in stability of hTR (Mitchell et a l 1999). 
Interestingly, mutations of dyskerin lead to a form of the disease dyskeratosis congenita 
in which patients exhibit reduced telomerase activity, short telomeres, chromosome end 
to end fusions and increased incidence of cancer (Mitchell et a l 1999). During the 
telomerase reaction hTERT uses hTR as an RNA template to add single nucleotides to 
the 3’ end of the telomere sequence resulting in telomere elongation (Blackburn et a l 
1989). The access of telomerase to this 3’ end is regulated by telomere repeat binding 
factors as described above.
1.4 Telomeres and Telomerase in normal human cells
A sensitive method of detection of telomerase activity was developed by Kim et a l and 
is known as the TRAP assay (telomere repeat amplification protocol) (Kim et a l 1994). 
This has been developed into a PCR ELISA assay that detects the presence of 
telomerase in cells from the addition of telomeric repeats onto a synthetic primer. The 
PCR product then hybridises to a labelled probe which is detected by immunolabelling 
methods. Using this method it has been shown that telomerase is expressed during early 
human development and activity has been detected in most human somatic tissues up to 
16-20 weeks of development (Wright et a l 1996). Telomerase activity is not detected 
in the majority of adult somatic tissues and in these cells where telomerase is not 
expressed progressive telomere shortening with each cell division is observed.
Telomerase has been shown to remain active in proliferative tissues such as bone 
marrow, skin, gastrointestinal tract, liver, testis and activated lymph nodes (Burger et a l
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1997; Yui et al. 1998; Bachor et a l 1999; Liu et al. 1999; Forsyth et al. 2002). Of these 
tissues it has been observed that telomerase is activity is highest in the stem and 
progenitor cell compartments, such as early haematopoietic progenitor cells, and is 
increased with proliferation and differentiation of these cells (Yui et a l 1998). 
However, these cells do exhibit progressive telomere shortening and it is thought that 
although expression of telomerase activity reduces telomere shortening it is not efficient 
to prevent telomere shortening as a result of proliferation (Engelhardt et a l 1997).
1.5 Telomeres and telomerase in cancer
Telomere shortening was first implicated in human cancer in 1990. Telomeres can be 
measured by first digesting genomic DNA with frequent cutting restriction 
endonucleases, such as Hinfl, that do not cut telomeric DNA. The digested DNA is 
then subjected to southern blotting and telomere repeats are detected with a telomere 
specific probe. Hastie et a l showed that in patients with colorectal carcinomas 
telomere length was reduced when compared to normal colonic mucosa from the same 
patient (Hastie et a l 1990). While de Lange et a l demonstrated that in two Wilms’ 
tumour samples, DNA from the tumour had significantly shorter telomeres than DNA 
from the surrounding normal kidney tissue and that telomere length was reduced in 
breast carcinoma when compared with normal breast tissue in the same patient (de 
Lange et a l 1990). These initial findings lead to extensive investigation into the role of 
telomere shortening in human cancer and since this initial work shortened telomeres 
have now been detected in the majority of human cancers (Blasco 2005). Not only are 
shorter telomeres detected in cancer when compared to normal tissues but telomeres 
shorten progressively as disease progresses. For example, in hepatocellular carcinoma 
progressive telomere shortening is observed as the disease progresses from normal to
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chronic active hepatitis to hepatocellular carcinoma (Miura et a l 1997). Progressive 
telomere shortening is particularly well demonstrated in the leukaemias where serial 
blood samples can easily be obtained. For example in Chronic Myeloid Leukaemia 
telomere length in advanced disease stage is reduced when compared to chronic phase 
disease (Boultwood et al. 1999). Additionally, shorter telomeres at diagnosis often 
correlate with reduced survival in cancer and this has been demonstrated in many 
cancers including B cell chronic lymphocytic leukaemia, prostate cancer and lung 
cancer (Bechter et a l 1998; Donaldson et a l 1999; Frias et a l 2008). However, this is 
not always the case, and in tumours where patients have significantly shorter telomeres 
than normal tissues patients with longer telomeres relative to other cancer samples are 
predictive of reduced survival. For example, in colorectal and head and neck cancer 
those patients with longest telomeres have poor disease free survival (Patel et a l 2002; 
Garcia-Aranda et a l 2006). In other tumours the prognostic value of telomere length is 
not always clear. Short telomeres in neuroblastoma have been reported to correlate with 
both favourable and unfavourable prognosis (Hiyama et a l 1992; Ohali et a l 2006). 
Similarly in breast cancer some authors report no significant association with telomere 
length and disease prognosis while others suggest a correlation between shorter 
telomeres and poor prognosis (Griffith et a l 1999; Lu et a l 2011).
The first association of increased telomerase activity with human cancer came in 1994 
with the development of the TRAP assay by Kim et a l (Kim et a l 1994). They 
demonstrated that telomerase activity was not present in normal somatic tissues or 
cultured cells. They showed that telomerase appeared to be reactivated in cancer 
biopsies and immortal cultured cells. Since then telomerase activity has been detected 
in at least 90% of human tumours (Kim et a l 1994; Shay and Bacchetti 1997). The 
detection of telomerase activity has been used as an important predictor of poor clinical
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outcome in many different cancers. For example, in neuroblastoma, telomerase activity 
is not detected in normal adrenal tissue or in benign ganglioneuromas but is detected at 
in almost all cancer samples. Additionally, those patients with highest telomerase 
activity exhibited additional genetic changes and had an unfavourable prognosis 
(Hiyama et al. 1995). Similarly in colorectal cancer high telomerase activity levels are 
associated with significantly poor prognosis and reduced disease free survival when 
compared with patients with low or moderate telomerase activity (Tatsumoto et al. 
2000). Telomeres in colon cancer are reported to be longer in patients with advanced 
disease and high telomerase activity than those with early stage disease and low 
telomerase activity leading the authors to suggest that telomerase has been up-regulated 
in order to stabilise telomeres in these patients (Engelhardt et al. 1997). A correlation 
of increased telomerase activity and poor disease prognosis has been presented in many 
other cancers including lung cancer and acute leukaemia (Ohyashiki et al. 1997; 
Marchetti et al. 1999). However, this is not always the case and in cervical cancer 
telomerase activity is detected in 79% of samples but it has been reported that 
telomerase activity measurements do not correlate with disease stage, histotype, 
metastasis or overall disease prognosis (Wisman et al. 2001). This implies that 
presence of telomerase activity can distinguish normal from neoplastic cells but does 
not always predict disease outcome.
Telomerase activity can be employed as an additional screen for diagnosis of cancer. In 
bladder cancer early stage tumours can be missed due to the lack of effective cytological 
markers for detection. However, analysis of bladder washings revealed that telomerase 
activity can be detected in up to 90% of bladder cancers in bladder washings (Kinoshita 
et al. 1997). The authors show that measuring telomerase activity is more sensitive for 
cancer detection than cytologic analysis alone and using these methods in combination
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is important for early cancer diagnosis in these cases. Similar results have been 
obtained in breast cancer. The measurement of telomerase activity in fine needle 
aspirates of breast cancer patients has improved diagnosis rates to 86% from 70% using 
cytology alone (Hiyama et al. 2000). The authors suggest that the technique is 
especially useful in detecting false negative results from cytological samples and 
increases diagnostic accuracy.
Telomerase levels and telomere length have been investigated in haematological 
malignancies. In patients with Myelodysplastic Syndromes (MDS) expression of 
hTERT and telomerase activity is increased in bone marrow of patients and those 
patients with highest telomerase have worst prognosis (Fu and Chen 2002; Briatore et 
al. 2009). Telomere length in MDS is variable but shortened telomeres are related to 
complex karyotypic abnormalities which indicates genomic instability and poor 
prognosis (Ohyashiki et al. 1994; Boultwood et al. 1997). In Acute Myeloid 
Leukaemia (AML) telomere length is significantly decreased and higher telomerase 
activity is associated with higher rates of complete remission (Seol et al. 1998; 
Hartmann et al. 2005). Telomerase levels are heterogeneous in lymphoma but in 
general telomerase is increased in lymphoma and telomeres are shortened (Davison 
2007).
Telomerase activity is increased in the majority of cancer while telomere length is 
decreased. This apparent paradox is explained by tumours having multiplied to such an 
extent that telomerase activation is essential for cell survival to stabilise telomere length 
and halt the loss of further telomeric DNA (Counter et al. 1992).
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1.6 Alternative Lengthening of Telomeres
Although telomerase activity has been detected in the majority of human cancers there 
remain some 10% without detectable telomerase activity. These cancers maintain 
telomere length without telomerase activity using an Alternative Lengthening of 
Telomeres (ALT) mechanism. Telomeres of telomerase negative immortal human cells 
can be maintained by ALT and this gives rise to very long or short heterogeneous 
telomeres (Bryan et a l 1995). The mechanism of this telomere maintenance has been 
liked with recombination as individual telomere lengths can increase or decrease rapidly 
in these cells (Mumane et al. 1994). Furthermore, it has been demonstrated that 
telomeres in ALT cells can copy telomere sequences from one telomere to another but 
this does not occur in telomerase positive cells (Dunham et al. 2000). Additionally, 
telomere mutations observed in ALT cells are thought to be propagated by 
recombination and contribute to genomic instability (Varley et al. 2002).
Cells that maintain telomeres through ALT exhibit some distinct characteristics from 
normal telomerase positive cells. Extrachromosomal circular DNA fragments 
containing telomeric DNA have been observed in ALT nuclei and it is suggested that 
these are caused by homologous recombination (Cesare and Griffith 2004; Wang et al. 
2004). Promyelocytic leukaemia (PML) nuclear bodies are characteristic of ALT cells 
and these PML bodies contain PML protein, telomeric DNA sequences and the telomere 
binding proteins TRF1 and TRF2 (Yeager et al. 1999). Although the function of ALT 
PML bodies remains unclear they also contain proteins that are involved in 
recombination and are required for ALT so it has been suggested that they are the site 
for ALT activity (Yeager et al. 1999).
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ALT can be detected using combined immunofluorescence for PML and telomere 
fluorescence in situ hybridisation. This approach has been employed to demonstrate 
that ALT is acting in a substantial proportion of soft tissue sarcomas, osteosarcomas and 
astrocycomas (Henson et al. 2005). Gene expression profiling of cell lines has revealed 
a likely mesenchymal stem cell origin for tumours maintaining telomeres by ALT 
(Lafferty-Whyte et al. 2009). In fact, ALT is detected in carcinomas of mesenchymal 
stem cell origin such as liposarcoma, glioblastoma multiforme and peritoneal 
mesothelioma (Hakin-Smith et al. 2003; Johnson et al. 2005; Villa et al. 2008). ALT 
has also been detected in a small percentage of breast carcinomas that overexpress 
HER-2 by genomic amplification and the authors suggest a common mechanism for 
ALT and HER-2 overexpression (Subhawong et al. 2009).
1.7 Telomerase inhibitors
The association of increased telomerase activity with cancer has led to the suggestion 
that inhibiting telomerase in malignancies would reduce telomerase activity and 
telomere length to a level that would induce apoptosis in cancer cells resulting in a 
novel treatment option for many malignancies (Shay and Wright 2002). Several 
approaches to targeting telomerase have been investigated as anti-cancer therapies. 
These include agents to directly inhibit the telomerase enzyme such as small molecule 
oligonucleotides against hTERT or hTR and immunotherapy against hTERT. The most 
clinically advanced of these approaches in terms of clinical trials is immunotherapy 
against hTERT. Immunotherapy using peptides corresponding to regions of the hTERT 
protein relies on the patients potential to mount an immune response to the peptide. It 
has been shown that when immunised with a telomerase peptide most cancer patients 
subsequently have circulating T lymphocytes specific for the peptide, however, not all
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of these patients produce cytotoxic T lymphocytes that have the ability to kill 
telomerase positive tumour cells (Filaci et al. 2006). The hTERT peptide vaccine 
GV1001 has been tested in clinical trials of patients with inoperable pancreatic cancer. 
Results from non randomised phase I and II clinical trials revealed that patients could 
mount an immune response and that the immune response could be correlated with 
increased survival (Bernhardt et al. 2006). A phase III study of GV1001 was then 
carried out with the aim of recruiting 520 patients with inoperable and metastatic 
pancreatic cancer. However, the study was halted after 365 patients had been enrolled 
when it was shown that treatment with GV1001 conferred no survival benefit (Buanes 
and Nemunaitis 2009). A further phase III study of GV1001 in patients with advanced 
or metastatic pancreatic cancer is recruiting at present with estimated enrolment of 1110 
patients (clinicaltrials.gov identifier NCT00425360). The primary end point of this 
study would be survival at one year.
Inhibition of telomerase by small molecules and oligonucleotides has also been 
investigated for therapeutic use. One example of this is GRN163L which is a 
complimentary hTR oligonucleotide that directly binds hTR so that the RNA template is 
not accessible and this causes a reduction of telomerase activity (Dikmen et al. 2005). 
Initial investigation of this compound in telomerase positive lung cancer cells showed a 
decrease in telomerase activity and prevention of lung cancer metastases in animal 
models (Dikmen et al. 2005). Currently GRN163L is involved in thirteen on-going 
clinical trials including randomised phase II trials for breast cancer and non-small cell 
lung cancer (Genron Corporation). Results of these trials are not yet available. Results 
from a phase I trial in advanced solid tumours indicates that the drug causes 
thrombocytopenia at high doses but does not result in any other major toxicities leading
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to GRN163L to be anticipated as a universal cancer therapeutic with minimal side 
effects (Shay and Wright 2006; Ratain et a l 2008).
Telomerase inhibitors are an attractive treatment option for the majority of cancers that 
express telomerase. However, it has been suggested that telomerase inhibitors might 
result in drug resistant telomerase independent cancer cells emerging. ALT 
mechanisms could be activated by the inhibition of telomerase or the telomerase 
inhibitors may select for those cells that maintain telomeres using ALT (Keith et a l 
2002).
1.8 Aims of the study
Telomerase regulation and telomere length clearly play an important role in the 
progression of the majority of human cancers. This study aims to gain further insight 
into the role of telomerase regulation and expression in the pathogenesis of CML. Real 
time PCR has been used to quantify gene expression of hTERT, the catalytic component 
of telomerase, it’s accessory components {hTR and TEP1) it’s regulators (c-Myc and 
PinXl) and the telomere associated proteins TRF1, TRF2 and tankyrase in CML. 
Regulation of hTERT was further investigated by analysis of promoter methylation and 
mutation status. The BCR/ABL translocation was monitored by real time PCR to 
identify any correlation with levels of telomerase associated genes. cDNA microarray 
technology was used to analyse gene expression in the neutrophils of patients with 
Essential Thrombocythaemia harbouring the JAK2 V617F mutation which, like the 
BCR/ABL translocation in CML, results in an activated kinase. Affymetrix gene 
expression analysis was used to investigate the role of telomerase related genes in 
different subtypes of MDS. The identification of aberrant regulation of telomerase and
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associated genes may provide novel insights into the role of telomerase and telomeres in 
the pathogenesis of these diseases.
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Chapter 2 
Materials and Methods
2.1 Preparation o f Granulocyte Fractions from Peripheral Blood
Forty milliliters of peripheral blood was routinely collected and granulocyte fractions 
were separated in two batches of 20 ml. The method below describes separation of 40 
ml peripheral blood.
2.1.1 Separation o f Granulocytes by Density Gradient Centrifugation
1. 40 ml of peripheral blood was collected into Tri-Sodium EDTA tubes.
2. The blood was separated into two aliquots of 20 ml and each aliquot was gently 
layered onto 20 ml of room temperature Histopaque-1077 (Sigma Aldrich, Cheshire, 
UK) in a 50 ml polypropylene centrifuge tube and centrifuged at 1,600 rpm (400g, 
Sorvall RT6000B benchtop centrifuge) for 30 minutes at room temperature.
3. The serum and Histopaque layers were carefully aspirated using a Pasteur
pipette and discarded to leave the red blood cell/granulocyte layers.
4. The red blood cell/granulocyte layers were washed by adding Ice-cold 
Phosphate Buffered Saline (PBS) containing 5 mM EDTA to a total volume of 50 ml 
and the tubes were mixed by gentle inversion.
5. The tubes were centrifuged at 1,650 rpm at 4°C for 10 min.
6. The supernatant was removed and discarded using a Pasteur pipette.
7. Wash steps 4, 5 and 6 were repeated.
8. To lyse the red cells, the packed red blood cell/granulocyte layer was distributed 
into centrifuge tubes containing freshly prepared ice-cold red cells lysis buffer (0.1 mM 
EDTA, 150mM NH4CI, lOmM NaHCOs). Approximately 2 ml of red blood cells were 
added to each 50 ml of red cell lysis buffer and left on ice for 15 min with occasional 
mixing.
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10. The tubes were centrifuged at 1,650 rpm for 10 min at 4°C and the supernatant 
was poured off and discarded.
11. Each granulocyte pellet was resuspended in 1 ml of ice-cold PBS and the pellets 
were pooled into two centrifuge tubes.
12. The tubes were filled to 50 ml with ice-cold PBS and centrifuged at 1,600 rpm 
for 10 min at 4°C. The supernatant was poured off and discarded.
13. The granulocyte pellets were resuspended in 1 ml of ice-cold PBS and pooled 
into one centrifuge tube.
14. The tube was filled to 50 ml with ice-cold PBS.
15. An aliquot of the granulocyte suspension was taken and serial dilutions were 
prepared.
16. Cytocentrifuge preparations were made in a Shandon Cytospin 2 using 100 pi of 
granulocyte suspension and one drop of 22% Bovine Serum Albumin (BSA) per slide. 
Samples were spun for 5 min at 800 rpm.
17. The centrifuge tube was centrifuged at 1,600 rpm for 10 min at 4°C. The 
supernatant was poured off and discarded.
18. The granulocyte pellet was then resuspended in TRIzol reagent (Invitrogen, 
Paisley, UK) as described in section 2.4.
2.1.2 Wright-Giemsa Staining of Cytocentrifuge Preparations
Granulocyte cytocentrifuge slides were stained with Wright-Giemsa staining solution in 
a Miles Hema-Tek 2000 automated slide stainer. The slides were subjected to the 
following steps:
1. Wright-Giemsa stain (Wright-Giemsa stain 0.15% in methanol)
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2. Rinse solution 1 (PBS)
3. Rinse solution 2 (Ethanol 18% v/v with surfactant)
4. Air drying
The stained cytocentrifuge slides were then inspected to determine the purity of the 
granulocyte preparations.
2.2 Preparation o f CD34+ progenitor cells from bone marrow samples
CD34+ progenitor cells were isolated from bone marrow samples using the CD34 
MicroBead Kit from Miltenyi Biotec (Bergisch Gladbach, Germany).
2.2.1 Isolation Strategy
The CD34 microbead kit allows positive selection of CD34 expressing cells using 
MACS MicroBeads conjugated to mouse anti-human CD34 antibody. Bone marrow 
samples were separated by density gradient centrifugation over Histopaque-1077 to 
isolate the mononuclear cells. CD34+ haematopoietic progenitor cells were then 
magnetically labelled with the CD34 MicroBeads and enriched on positive separation 
columns in the magnetic field of a MidiMACS system. This kit allows isolation of 
haematopoietic progenitor cells which make up 0.5 -  3% of total bone marrow cells to 
be enriched to a purity of 90-98%.
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2.2.2 Preparation o f Bone Marrow Cells
1. Bone marrow samples were obtained using a heparinised syringe and collected 
in a sterile 50 ml tube containing 5 ml PBS supplemented with 2mM EDTA.
2. The sample was diluted in 50 ml RPMI-1640 medium with 10 mg of DNase I 
and 10 mg of Collagenase B in order to dissociate the cells.
3. The sample was incubated for 45 min in a 37°C water bath and mixed 
occasionally.
4. The cell suspension was passed through a 70 pm cell strainer.
5. The cell suspension was carefully layered over Histopaque-1077 (approximately
25 ml of cell suspension over 15 ml of Histopaque-1077) in sterile 50 ml centrifuge 
tubes.
6. The tubes were centrifuged at 1,600 rpm for 30 min at room temperature.
7. The upper layer was carefully removed leaving the mononuclear cell layer 
undisturbed at the interphase.
8. The interphase mononuclear cells were collected and transferred to a new 50 ml 
centrifuge tube, Hanks’ Balanced Salt solution (HBSS) was added to a total volume of 
50 ml and the tube was mixed by gentle inversion.
9. The tube was centrifuged at 1,450 rpm for 12 min at room temperature and the 
supernatant was poured off.
10. The mononuclear cell pellet was resuspended in 1 ml of HBSS.
11. The tube was filled to 50 ml with HBSS and centrifuged at 1,450 rpm for 12 min
at room temperature. The supernatant was discarded.
12. The mononuclear cell pellet was resuspended in 25 ml of MACS buffer (PBS +
0.5% BSA). A 10 pi aliquot was taken and cells were counted in a haemocytometer.
27
13. The tube was centrifuged at 1,300 rpm for 10 min at room temperature and the 
supernatant was discarded.
14. The mononuclear cell pellet was resuspended in 300 pi of MACS buffer (the
n
volume of MACS buffer was reduced by half if mononuclear cells were < 5x10 , or
o
doubled if mononuclear cells were >8x10 ).
2.2.3 Magnetic Labelling of CD34+ Progenitor Cells
1. 100 pi of FcR Blocking Reagent was added to the cell suspension to inhibit 
unspecific binding of the CD34 MicroBeads to Fc-receptors on other cells. If necessary 
the volume was adjusted according to cell number.
2. Cells were labelled by adding 100 pi of CD34 Microbeads. Again, if necessary, 
the volume was adjusted according to cell number. Samples were then mixed gently 
and incubated for 30 min at 4°C.
3. The tube was filled with MACS buffer to 25 ml and centrifuged at 1,300 rpm for 
5 min at room temperature. The supernatant was discarded.
4. The cell pellet was resuspended in 1 ml of MACS buffer.
2.2.4 Magnetic Separation of Mononuclear Cells
1. A magnetic MidiMACS Separation Unit was attached to a MACS MultiStand.
2. One LS Separation Column was placed in the magnetic field of the MidiMACS 
Separation Unit and a collection tube was placed under the column.
3. The column was prepared by rinsing with 3 ml of MACS buffer.
4. The magnetically labelled cell suspension was passed through a 30-pm nylon 
pre-separation filter to remove cell clumps.
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5. The cells were added to the column and allowed to pass through.
6. The column was washed three times with 1 ml of MACS buffer.
7. The column was removed from the separator and placed in a new collection
tube.
8. 3 ml of MACS buffer was added to the column and the magnetically labelled 
cells were firmly flushed out using the plunger supplied with the column.
9. The magnetic separation was repeated with a second LS Separation Column to
increase the purity of the positive fraction and the cells were flushed out in a new 
collection tube with 2.5 ml of MACS buffer.
10. A 10 pi aliquot of cells was taken and the cells were counted in a 
haemocytometer.
11. Two aliquots of 5xl04 cells were taken for evaluation of CD34+ cell purity by 
flow cytometry (see section 2.2.5).
12. The sample was centrifuged at 1,450 rpm for 10 min at room temperature and 
the supernatant was carefully removed.
13. The cell pellet was resuspended in TRIzol reagent as described in section 2.4.
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Figure 2.1 Determination of CD34+ cell purity by flow cytometry. Gate M l was 
used to identify levels of nonspecific binding in the IgGl labelled sample. This was 
then superimposed to the CD34 labelled sample and the number of positive cells 
calculated.
2.2.5 Evaluation o f CD34+ Cell Purity by Flow Cytometry
1. The two aliquots of 5xl04 eluted cells were transferred to flow cytometry tubes 
and the volume adjusted to 45 pi with MACS buffer.
2. 5 pi of PE-conjugated anti-mouse IgGl antibody was added to the first aliquot 
of cells to correspond to the negative control; while 5 pi of PE-conjugated anti-CD34 
antibody was added to the second aliquot to label the positive cells.
3. The samples were mixed gently and incubated at 4°C for at least 30 min.
4. CD34+ cell purity was determined by loading the samples into a FACScalibur 
flow cytometer and acquiring 10,000 events for both negative and positive samples
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(Figure 2.1). The positive and negative plots were examined using cellquest software. 
The negative sample shows the levels of non-specific binding of the antibodies to the 
cells.
2.3 Preparation o f Platelet Fractions from Peripheral Blood
Platelets were isolated from whole blood from patient or normal control samples using 
the method described by Wang et al. (Wang et a l 2003). Platelet purity was assessed by 
flow cytometry.
2.3.1 Separation o f Platelets
1. 50 ml of peripheral blood was collected into Tri-Sodium EDTA tubes.
2. The blood was transferred to a 50 ml centrifuge tube and a 2 pi aliquot of sample 
was taken for flow cytometry.
3. The tube was centrifuged at 150 g for 20 min.
4. The top 75% of the platelet rich plasma layer was transferred carefully to a fresh
tube. A 5 pi aliquot of sample was taken for flow cytometry.
5. The plasma was centrifuged at 150 g for 10 min.
6. The plasma was removed to a fresh tube and any pelleted cells were discarded.
A 5 pi aliquot of sample was taken for flow cytometry.
7. The platelets were pelleted by centrifugation at 800 g for 15 min and the 
supernatant was discarded.
8. The pellet was washed in 10 ml of PBS and a 5 pi aliquot of sample was taken 
for flow cytometry.
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9. The platelets were pelleted by centrifugation at 800 g for 15 min and the
supernatant was discarded. The pellet was resuspended in TRIzol reagent as described 
in section 2.4.
2.3.2 Evaluation o f Platelet Purity by Flow Cytometry
1. The aliquots of cells removed for flow cytometry were each added to a separate 
flow cytometry tube.
2. 5 pi of each of the following antibodies were added to each tube: 
FITC-conjugated anti-human CD41 to label platelets (Dako, Glostrup, Denmark) 
PerCP-conjugated anti-human CD45 to label leukocytes (BD Biosciences, San Jose, 
USA)
PE-conjugated anti-human Glycophorin A to label red blood cells (BD Biosciences)
3. Pharmingen Stain Buffer (BSA) (BD Biosciences) was added to each sample to
a final volume of 50 pi.
4. The samples were incubated at room temperature for 30 min then 950 pi of
Pharmingen Stain Buffer (BSA) was added to each sample.
5. The samples were loaded on to the FACScalibur flow cytometer.
2.4 Extraction o f nucleic acids from cell preparations
2.4.1 Nucleic Acid Extraction using TRIZOL Reagent
Total RNA and genomic DNA were extracted from pre separated cell preparations using 
the TRIZOL reagent from Invitrogen (Paisley, UK).
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1. 1 ml of TRIZOL reagent was added per 107 cells and the cells were lysed by 
vortexting in a 15 ml tube.
2. The lysed sample was incubated at room temperature for 5 min. The lysate was 
then split into 1.25 ml aliquots in 1.5 ml microcentrifuge tubes.
2.4.1.1 RNA isolation
3. 0.25 ml of chloroform was added per 1.25 ml of TRIZOL reagent used.
4. The samples were mixed vigorously for 15 sec and incubated at room
temperature for 2-3 min.
5. The samples were centrifuged at 12,000 g for 15 min at 4°C.
6. The aqueous upper phase was transferred to a new 1.5 ml microcentrifuge tube 
and the interphase and phenol phase were set aside for subsequent DNA extraction.
7. 0.625 ml of Isopropanol per 1.25 ml TRIZOL reagent used was added to the 
aqueous phase and mixed by inversion.
8. The samples were incubated for 10 min at room temperature and then
centrifuged at 12,000 g for 15 min at 4°C. The RNA precipitate could then be visualised 
as a pellet at the bottom of the tube.
9. The supernatant was removed carefully and the pellet was washed with 75%
ethanol adding 1.25 ml per 1.25 ml TRIZOL reagent used. The sample was vortexed 
and centrifuged at 10,000 g for 5 min at 4°C.
10. The supernatant was removed and the pellet was air-dried.
11. The pellet was resuspended in 50-100 pi DEPC H2O and incubated at 60°C until
the pellet had completely dissolved. The samples were stored at -70°C.
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2.4.1.2 DNA Isolation
1. 0.375 ml of 100% ethanol was added to the interphase and phenol phase from 
the RNA isolation.
2. The samples were mixed by inversion and incubated for 2-3 min at room 
temperature then centrifuged at 10,000 g for 5 min at 4°C.
3. A pellet was then visible and the supernatant was carefully removed.
4. 1.25 ml of 0.1 M Sodium Citrate in 10% Ethanol was added to the pellet and the 
samples were incubated at room temperature for 30 min.
5. The samples were centrifuged at 10,000 g for 5 min at 4°C and the supernatant 
was removed.
6. Steps 4 and 5 were repeated.
7. The pellets were washed in 1.4 ml of 75% ethanol and incubated for 10-20 min 
at room temperature. The pellets were centrifuged at 10,000 g for 5 min at 4°C.
8. The supernatant was removed and the pellets were air dried then resuspended in 
molecular grade H2O. DNA was stored at -20°C.
2.4.2 DNA Extraction using the Qiagen QIAamp DNA Blood Maxi Kit
The Qiagen QIAamp DNA blood maxi kit allows for the rapid purification of total DNA 
from whole blood and related body fluids using a spin column procedure.
1. 5 ml of peripheral blood was collected in Tri-Sodium EDTA tubes.
2. The blood was added to a 50 ml centrifuge tube containing 500 pi of QIAGEN 
Protease and mixed briefly.
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3. 12 ml of Buffer AL was added and the tube mixed thoroughly by inverting 15
times. The tube was then shaken vigorously for 1 min.
4. The sample was incubated at 70°C for 10 min in a waterbath.
5. 10 ml 100% ethanol was added to the sample and the tube was inverted 10 times 
then shaken vigorously.
6. Half of the solution from step 5 was transferred to the QIAamp Maxi column 
placed in a 50 ml centrifuge tube then centrifuged at 3000 rpm for 3 min.
7. The QIAamp Maxi column was removed and the flow through discarded. The 
QIAamp Maxi column was then placed back into the 50 ml centrifuge tube and the 
remainder of the solution from step 5 added to the column and centrifuged at 3000 rpm 
for 3 min.
8 The QIAamp Maxi column was removed and the flow through discarded. The
QIAamp Maxi column was then placed back into the 50 ml centrifuge tube and 5 ml of 
Buffer AW1 was added to the column and centrifuged at 5000 rpm for 1 min.
9. 5 ml of Buffer AW2 was added to the QIAamp Maxi column and centrifuged at 
5000 rpm for 15 min.
10. The QIAamp Maxi column was placed in a clean 50 ml centrifuge tube and the 
collection tube containing the flow through was discarded
11. 1 ml of molecular grade H2O equilibrated to room temperature (15-25°C) was 
added directly onto the membrane of the QIAamp Maxi column and incubated at room 
temperature for 5 min then centrifuged at 5000 rpm for 2 min.
12. The eluate containing the DNA was then reloaded onto the membrane of the 
QIAamp Maxi column and incubated at room temperature for 5 min then centrifuged at 
5000 rpm for 5 min. The DNA was stored in aliquots of 1 ml at -20°C.
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2.5 The Polymerase Chain Reaction (PCR)
Thermo-Start Hot-start Taq DNA polymerase (Abgene, UK) was used to generate 
specific PCR products for the DNA sequences of interest. The hot-start enzyme 
remains inactive until it is activated at high temperature. Primers were designed to be 
specific to the appropriate sequence and dissolved at a concentration of 100 pmol/pl in 
Nuclease-Free H2O and stored at -20°C. Each primer set was optimised using control 
DNA samples by performing PCR at different annealing temperatures to determine the 
optimal reaction conditions.
2.5.1 PCR using Thermo-Start DNA Polymerase
A  ready made 2x Thermo-Start PCR Master Mix was used. The final lx  reaction 
mixture contained the following components: 1.5 units Thermo-Start DNA Polymerase, 
lx  Thermo-Start buffer, 1.5 mM MgC12 and 0.2 mM dNTP mix.
1. A PCR master mix was prepared for each primer set for the required number of 
samples plus a negative control. The volumes of reagents for one sample were as 
follows:
2x Thermo-Start PCR Master Mix 25 pi 
Forward primer 1.25 pi
Reverse primer 1.25 pi
Nuclease-Free H2O 21.5 pi
2. 49 pi aliquots of the PCR master mix were added to individual wells of a 96 well
PCR plate and 1 pi of DNA template was added to the appropriate wells.
3. The plate was centrifuged briefly.
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4. The PCR amplification was performed using the 9700 PE GeneAmp PCR 
System (Applied Biosystems, UK) using the thermal cycling profile detailed in Table 
2.1
Table 2.1 Thermal cycling profile for Thermostart DNA polymerase
Temperature Time Number of cycles
Enzyme activation 95°C 15 min 1 cycle
Denaturation 95°C 10 sec
Annealing 50-65°C 30 sec 35 cycles
Extension 72°C 0.5-1 min
Final extension 72°C 5 min 1 cycle
Hold temperature 4°C 00 1 cycle
2.5.2 Agarose Gel Electrophoresis o f PCR Products
Agarose gel electrophoresis was used to resolve and visualise PCR products. 1% (w/v) 
agarose gels were typically used.
1. The required amount of agarose was added to lx  TBE (130 mM Tris, 45 mM
Boric Acid, 2.5 mM EDTA) and heated in a microwave to dissolve the agarose.
2. The gel solution was allowed to cool at room temperature for approximately 5 
min and ethidium bromide was added at a dilution of 1 in 10,000.
3. The gel solution was poured into a gel tray and combs were inserted. The gel
was left to set at room temperature.
4. 5 pi of each PCR product was mixed with 1 pi of loading buffer (0.25% 
bromophenol blue, 0.25% xylene cyanol, 30% Glycerol).
5. The set gel was placed in a gel tank and submerged in 1 x TBE. 5 pi of
Hyperladder IV (Bioline, UK) was added to the first well.
37
6. The PCR products were added to subsequent wells and the gel was run at 5 
V/cm for approximately 40 min.
7. The bands were visualised by placing the gel in a UV transiluminator.
8. The remaining PCR products were stored at -20°C in the 96 well plate until 
required for further analysis.
2.5.3 PCR Product Quantitation using the Agilent Bioanalyzer
The Agilent Bioanalyser and the DNA 1000 kit were used to obtain accurate size and 
quantitative data of multiplex PCR products. It is a microfluidics based system that 
allows high resolution fragment analysis as low as 5 bp. Traditional gel electrophoresis 
principles have been transferred to a chip format and samples run along glass micro 
channels. The samples are mixed with an intercalating dye and detected by laser 
induced fluorescence. A DNA ladder of known size is run at the same time as the PCR 
products and each sample is run with two internal standard markers to align the PCR 
product data with the DNA ladder. The data can be plotted as a gel like image or an 
electropherogram plot of fluorescence intensity versus size.
1. The DNA dye concentrate and DNA gel matrix were equilibrated to room 
temperature for 30 min.
2. The DNA dye concentrate was vortexed and briefly centrifuged then 25 pi was 
added to the DNA gel matrix vial.
3. The gel dye mix was vortexed and transferred to a spin filter and centrifuged for 
15 min at 6000 rpm.
4. The spin filter was discarded and 9 pi of gel dye mix was added to the well 
marked with a circled letter G on a new DNA chip in the chip priming station.
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5. The chip was pressurised by depressing the plunger of the syringe attached to 
the chip priming station and the plunger was secured for 1 min.
6. After 5 sec the plunger was pulled up.
7. 9 pi of gel dye mix was added to the wells marked G.
8. 5 pi of DNA marker was added to the remaining wells.
9. 1 pi of DNA ladder was added to the well marked with the ladder symbol.
10. 1 pi of each sample to be analysed was added to the appropriate sample wells.
11. The chip was vortexed for 1 min at 2400rpm in the IKA vortex mixer.
12. The chip was loaded into the Bioanalyser instrument and the Agilent 2100
expert software was used to start the run for a DNA chip.
13. Electropherograms were viewed using the Agilent 2100 expert software and a
run was considered successful when all 13 peaks of the DNA ladder were well resolved 
and both markers were correctly identified in each sample.
2.6 Cycle Sequencing
Cycle sequencing for mutation analysis of candidate genes was carried out using the 
ABI PRISM 3100 Genetic Analyser. Dye terminator chemistry was used and a 50cm 
ABI Genetic Analyser 16 Capillary Array and Performance Optimized Polymer 6 (POP- 
6) were required to run the samples.
2.6.1 Purification of PCR Products using ExoSAP-IT
The ExoSAP-IT reagent (USB) was used to purify PCR products prior to sequencing to 
remove contaminating primer dimers and unincorporated dNTPs that could interfere
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with the sequencing reactions. ExoSAP-IT consists of the enzymes Exonuclease I and 
Shrimp Alkaline Phosphatase and cleans up PCR products without the loss of sample.
1. 5 pi aliquots of each of the PCR products to be purified were added to a separate 
labelled 0.5 ml microcentrifuge tube.
2. 2 pi of ExoSAP-IT was added to each tube on ice and tubes were mixed and
centrifuged briefly.
3. The samples were incubated on a thermal cycler for 15 min at 37°C.
4. The samples were then incubated for 15 min at 80°C to deactivate the ExoSAP- 
IT.
5. The contents of the tubes were centrifuged briefly and lp l aliquots were added 
immediately to prepared sequence reaction tubes.
2.6.2 Preparation of Sequencing Reactions
The BigDye Terminator v l.l  Cycle Sequencing Kit (Applied Biosystems UK, 
Warrington, Cheshire) was used to prepare the sequencing reactions. This kit used dye 
terminator chemistry in which a different coloured fluorescent dye is attached to each of 
the four ddNTPs. Two sequencing reactions were prepared for each template, one each 
for the forward and reverse primers.
1. A master mix was prepared for each primer for the appropriate number of
samples. The volume of components was as follows:
Terminator Ready Reaction Mix 4 pi
5x Sequencing Buffer 2 pi
Primer (3.2 pmol/pl) 1 pi
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Nuclease-Free H2O 12 pi
2. The master mix was vortexed and centrifuged briefly.
3. 19 jliI aliquots of master mix were added to labelled 0.2 ml microfuge tubes and 
lp.1 of the corresponding purified PCR product was added.
4. The tubes were mixed and centrifuged briefly.
5. The tubes were then placed on the GeneAmp 9700 Thermal Cycler (Applied 
Biosystems) and subjected 25 cycles of 96°C for 30 sec, 50°C for 15 sec and 60°C for 4 
min followed by a hold at 4°C until ready for purification.
6. The sequence reaction products were stored at -20°C at this point if necessary.
2.6.3 Sodium Acetate Precipitation of Sequencing Reactions
1. 2 pi each of 3M sodium acetate (pH 4.6) and 500 mM EDTA were added to 
each sequencing reaction tube with 70 pi of 100% ethanol.
2. The tubes were vortexed briefly and incubated on ice for at least 30 min or up to 
24 hr to precipitate.
3. The tubes were centrifuged at 16,000g for 30 min.
4. The supernatant was carefully removed taking care not to dislodge the pellet.
5. 100 pi of 70% ethanol was added to each pellet and the tubes were vortexed 
briefly then centrifuged for 5 min at 16,000g.
6. The supernatant was removed and the tubes were centrifuged for a further 5 min.
7. Any remaining supernatant was carefully removed.
8. The pellets were left to air dry for 20 min.
9. Each pellet was resuspended in 20 pi of Hi-Di Formamide (Applied Biosystems) 
then vortexed to resuspend the pellets before centrifuging briefly. The samples can be 
stored at -20°C at this stage if necessary.
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11. The samples were denatured at 95°C for 2 min and placed on ice.
12. 10 pi aliquots of the precipitated sequence reaction products were added to the 
96 well sequencing plate and the plate was loaded on the 3100 Genetic Analyser.
2.6.4 Sequence Data Analysis
The sequence data was collected using the ABI PRISM Data collection software version 
1.0.1 and was processed using the ABI PRISM DNA Sequencing Analysis Software 
version 3.7 NT. Sequences were compared to that of the NCBI database by pairwise 
analysis using Sequence Analysis software (Informagen).
2.7 Cloning o f PCR Products
The pGEM-T Easy Vector System II was used to clone PCR products where required. 
The vector in this system has been linearised with a single 3’ terminal thymidine at both 
ends to allow insertion of PCR products with single base adenine overhangs. Colonies 
containing vectors where the PCR product has been inserted successfully are identified 
using blue/white screening of transformants on IPTG/X-Gal indicator plates. When a 
PCR product has been inserted in the vector it will disrupt the coding region of the (3- 
galactosidase enzyme and colonies will appear white. If no insert is present then the 
gene will not be disrupted and colonies will appear blue.
2.7.1 Ligation
1. Ligation reactions were set up in 0.5 ml tubes as described in table 2.2. Before 
each use the 2x rapid ligation buffer was vortexed vigorously.
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2. The reactions were mixed by pipetting and incubated overnight at 4°C.
Table 2.2 Components of ligation reactions using the pGEM-T Easy Vector System 
II
Reaction Component Standard
Reaction
Positive
Control
Background
Control
2 x Rapid Ligation Buffer, T4 DNA Ligase 5 pi 5 pi 5 pi
pGEM-T Easy Vector (50 ng) 1 pi 1 pi 1 pi
PCR product 1 pi - -
Control Insert DNA - 2 pi -
T4 DNA Ligase (3 Weiss units/pl) 1 pi 1 pi 1 pi
nuclease-free H2O to a final volume of 10 pi 10 pi 10 pi
2.7.2 Transformation
1. The tubes containing the ligation reactions were centrifuged briefly.
2. 2 pi of each ligation reaction was added to a 1.5 ml microcentrifuge tube on ice.
3. One tube of frozen JM109 High Efficiency Competent Cells per ligation was 
placed in an ice bath until just thawed then cells were mixed by gently flicking the tube.
4. 50 pi of cells were added to each ligation reaction tube.
5. Reactions were flicked to mix and incubated on ice for 20 min.
6. The cells were heat-shocked for 50 sec in a water bath at 42°C then immediately 
returned to ice for 2 min.
7. 950 pi room temperature SOC medium (2% Tryptone (pancreatic digest of 
casein) (w/v), 0.5% Yeast extract (w/v), 8.6 mM NaCl, 2.5 mM KC1, 20 mM MgS04, 
20 mM Glucose) was added to the tubes.
8. The samples were incubated for 1.5 hr at 37°C with shaking at 150 rpm.
9. 100 pi of each transformation culture was plated onto LB/ampicillin/IPTG/ X- 
Gal plates.
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10. The plates were incubated overnight at 37°C.
11. White colonies containing inserts were identified by eye before proceeding with
purification.
2.7.3 Purification of Plasmid DNA using the Wizard Plus Minipreps DNA 
Purification System
The Wizard Plus Minipreps DNA Purification System (Promega) allows for small scale 
purification of plasmid DNA using the Vac-Man Laboratory Vacuum Manifold.
1. Each colony to be selected was transferred into 5 ml of LB/ampicillin in a 
separate 50 ml centrifuge tube.
2. The tubes were incubated overnight at 37°C with shaking at 150 rpm.
3. The cells were pelleted by centrifugation at 10,000 g for 10 min and the
supernatant was removed before blotting the tube upside-down on a paper towel to 
remove excess media.
4. The cell pellets were resuspended in 300 pi of Cell Resuspension Solution and 
transferred to a 1.5 ml microcentrifuge tube.
5. 300 pi of Cell Lysis Solution was added to each sample and mixed by inverting 
the tube 4 times.
6. 300 pi of Neutralization Solution was added to each sample and mixed by 
inverting the tube several times.
7. The tubes were centrifuged at 10,000 g in a microcentrifuge for 5 min to pellet 
the cell debris.
8. For each miniprep one Wizard Miniprep Column was prepared by attaching a 
Syringe Barrel to the Luer-Lok extension of each Minicolumn. The tip of the
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Minicolumn/Syringe Barrel assembly was inserted into the vacuum manifold and all of 
the stopcocks closed.
9. 1 ml of resuspended Wizard Minipreps DNA Purification Resin was added to
each barrel of the Minicolumn/syringe assembly.
10. The cleared lysate from each miniprep (supernatant from Step 7) was transferred 
to the barrel of the Minicolumn/syringe assembly containing the resin.
11. The stopcocks were opened and a vacuum was applied until all of the 
resin/lysate mix had been pulled into the Minicolumn.
12. 2 ml of Column Wash Solution was added to each Syringe Barrel and the
vacuum applied.
13. The resin was dried by continuing to draw a vacuum for 30 seconds after the 
solution had been pulled through the column.
14. The Syringe Barrels were removed and the Minicolumns were transferred to 
1.5ml microcentrifuge tubes.
15. The Minicolumns were centrifuged at 10,000 g in a microcentrifuge for 2 min to
remove any residual Column Wash Solution.
16. The Minicolumns were transferred to a new microcentrifuge tube and 50 pi of 
nuclease-free H2O was added to each Minicolumn and incubated for 1 min.
17. The tubes were centrifuged at 10,000 g in a microcentrifuge for 20 sec to elute 
the DNA.
18. The minicolumns were discarded and purified plasmids were stored at -20°C.
19. Plasmid sequences were confirmed by Cycle Sequencing.
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2.8 Bisulfite Modification o f  DNA for Methylation Specific PCR (MSP)
The CpGenome DNA modification kit was used to bisulfite modify purified genomic 
DNA from patient and control samples. Using this process any unmethylated cytosines 
are deaminated and sulfonated which will convert them to Uracil. Any methylated 
cytosines are protected from bisulfite modification and remain unchanged.
2.8.1 Preparation of Solutions
1. 3 M NaOH stock was freshly prepared prior to each modification.
2. 20 mM NaOH/90% ethanol was freshly prepared prior to each modification.
3. For each sample to be modified 0.227 g of DNA Modification Reagent I was 
added to 0.571 ml of H2O and mixed by vortexing.
4. The pH of reagent I was adjusted to 5.0 with approximately 20 pi of 3M NaOH.
5. 1 pi of p-mercaptoethanol was added to 20 ml of deionized H2O and for each 
sample to be modified 750 pi of this solution was added to 1.35 g of DNA Modification 
Reagent II and mixed well.
2.8.2 DNA Modification Procedure
1. For each DNA sample to be modified 7 pi of 3M NaOH was added to 1 pg of 
DNA in 100 pi of water in a 2 ml screwcap microcentrifuge tube.
2. The DNA was incubated for 10 min at 50°C in a water bath.
3. 550 pi of DNA Modification Reagent I was added to each sample and vortexed.
4. The samples were incubated at 50°C for 16 hr in a water bath protected from 
light.
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5. DNA Modification Reagent III was resuspended by vortexing and drawn into 
and out of a 1 ml pipette tip to disperse any remaining clumps.
6. 5 pi of DNA Modification Reagent III was added to the DNA samples in the 
tubes.
7. 750 pi of DNA Modification Reagent II was added to each sample and mixed 
briefly.
8. The samples were incubated at room temperature for 5-10 min.
9. The samples were centrifuged for 10 sec at 5,000 g to pellet the DNA Reagent 
III and supernatant was discarded.
10. 1 ml of 70% ethanol was added to each sample then samples were vortexed and 
centrifuged for 10 sec at 5,000 g and supernatant was discarded.
11. Step 10 was repeated two more times.
12. The samples were centrifuged at 13,000 g for 2 min the remaining supernatant 
was removed.
13. 50 pi of the 20 mM NaOH/90% ethanol solution was added to the samples.
14. The samples were vortexed briefly to resuspend the pellet then incubated at 
room temperature for 5 min.
15. The samples were centrifuged for 10 sec at 5,000 g.
16. 1 ml of 90% ethanol was added and tubes were vortexed to wash the pellet. The 
samples were centrifuged for 10 sec at 5,000 g and the supernatant was removed.
17. Step 16 was repeated.
18. The tubes were centrifuged at 13,000 g for 3 min.
19. The pellets were allowed to air dry for 10-20 min at room temperature.
20. 20 pi of TE Buffer was added to each sample and the tubes were vortexed.
21. The samples were incubated for 15 min at 56°C to elute the DNA.
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22. The samples were centrifuged at 13,000 g for 3 min and the supernatant 
containing the modified DNA was transferred to a new tube.
23. The samples were stored at -20°C if required before proceeding to MSP.
2.9 Real-Time Quantitative PCR (TaqMan)
For TaqMan analysis cDNA was prepared from 2 pg of patient and control RNA that 
was first DNase I treated to eliminate contamination of genomic DNA. TaqMan probe 
based assay chemistry was used to determine gene expression levels of candidate genes 
in patient and control samples. TaqMan chemistry uses an oligonucleotide flourogenic 
probe to detect amplification of specific PCR products during the amplification reaction. 
The probe has a fluorescent reporter dye attached to the 5’ end and a quencher dye on 
the 3’ end. During PCR amplification the probe is cleaved by the 5’ nuclease activity of 
the Taq DNA polymerase. This separates the reporter dye from the quencher dye to 
increase the signal of the reporter dye. With each cycle of PCR more reporter dye is 
released in proportion to the amount of PCR product generated. The TaqMan reactions 
were performed on the 5700 Applied Biosystems Sequence Detection System.
2.9.1 DNase I  Treatment of RNA
The DNA-free reagent from Ambion (Austin, Texas, USA) was used to DNase treat all 
samples to remove contaminating DNA from RNA preparations. Additionally, divalent 
cations are removed which may otherwise degrade RNA when heated.
1. 2 pg of each RNA sample was added to a 1.5 ml microcentrifuge tube
2. 0.1 volume 10 x DNase I Buffer and 1 pi rDNase I were added to the RNA 
samples and mixed gently.
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3. The samples were incubated at 37°C for 30 min.
4. The DNase Inactivation Reagent was resuspended and 0.1 volume or 2 pi,
whichever was greater, was added to each sample and mixed well.
5. The samples were incubated at room temperature for 2 min with occasional 
mixing.
6. The samples were centrifuged at 10,000 g for 1.5 min and the RNA was
transferred to a fresh microcentrifuge tube.
2.9.2 First Strand cDNA Preparation
Reverse transcription of cDNA from patient and control RNA templates was carried out 
using the RETROscript kit (Ambion).
1. For each sample 2 pg of DNase I treated total RNA was added to 2 pi of
Random Decamers in a 1.5 ml microcentrifuge tube then nuclease free H2O was added 
to a final volume of 12 pi.
2. The samples were mixed, centrifuged briefly and heated at 75°C for 3 min to
denture the RNA.
3. The tubes were placed on ice, centrifuged briefly and returned to ice.
4. The following RT components were then added to each tube:
10 x RT Buffer 2 pi
dNTP mix 4 pi
RNase Inhibitor 1 pi
MMLV Reverse Transcriptase 1 pi
5. The samples were mixed gently, centrifuged briefly and incubated at 42°C for 1 
hr.
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6. The samples were incubated at 95°C for 10 min to inactivate the Reverse
Transcriptase and stored at -20°C until required.
2.9.3 Real-Time Quantitative PCR (TaqMan) Analysis
The 2 x TaqMan Universal PCR Master Mix (Applied Biosystems) was used for all 5’ 
nuclease assays. For the majority of genes studied ready made TaqMan Gene 
Expression Assays (Applied Biosystems) were used. These contained primers and 
probe and were supplied as 20 x solutions. Where individual primer and probe sets 
were used primers and probes were diluted to 5 pmol/pl.
1. A PCR master mix was prepared for each assay for the required number of
samples plus a negative control. The volumes of reagents for one sample using a ready 
made assay were as follows:
TaqMan Universal PCR Master Mix 12.5 pi 
Gene Expression Assay 1.25 pi
Nuclease-free H2O 6.25 pi
The volumes of reagents for one sample using individual primers and probes were as 
follows:
TaqMan Universal PCR Master Mix 12.5 pi
Forward Primer 1.5 pi
Reverse Primer 1.5 pi
Probe 0.5 pi
Nuclease-free H2O 4 pi
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2. 20 jil of the reaction mix was transferred to the required number of wells in a 
MicroAmp Optical 96-well Reaction Plate (Applied Biosystems).
3. 5pi of cDNA (diluted 1:20) was added to the appropriate well of the plate and 
each sample was run in triplicate.
4. The plate was sealed with MicroAmp Optical caps (Applied Biosystems) and 
was centrifuged briefly.
5. The plate was transferred to the 5700 Sequence Detection System and PCR was 
carried out under the following conditions: Enzyme Activation at 95°C for 10 min 
followed by 45 cycles of 15 sec denaturation at 95°C and 1 min annealing/extension at 
60°C.
6. The samples were analysed using the Sequence Detection System Software 
(Applied Biosystems).
7. To determine the relative gene expression ratio for each sample the 2'AACt 
method was used (Livak and Schmittgen 2001) which compares the average Ct of each 
sample to the average Ct of the normal controls to give a gene expression ratio.
2.10 cDNA Microarray Experiments
cDNA microarray slides were sourced from the Sanger Institute (Cambridge, UK). Each 
slide has 9,932 spotted cDNAs representing approximately 6,000 known genes and 
ESTs. Of these 8,817 cDNAs are derived from the IMAGE collection (HGMP), 647 
cDNAs are derived from the IMAGE collection (Research Genetics) and 468 cDNAs 
from chromosome 22 gene-specific PCR products (Sanger Institute). The microarray 
slides are also spotted with heterologous cDNAs for five bacterial genes (trp, lysA, thrB, 
dapB, pheB) that are not present in mammalian RNA samples. Plasmids with inserts 
corresponding to each of the five bacterial genes were used as a template for in vitro
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transcription and then mixed to produce a bacterial cocktail. The bacterial cocktail was 
added to each sample as a positive control and indicator of sensitivity on the array.
For each experiment total RNA extracted from one patient or control sample was 
compared with a pool of total RNA from normal control samples. The RNA samples 
were amplified and fluorescently labelled then hybridised together on the same 
microarray slide.
2.10.1 Generation o f  a Bacterial mRNA Cocktail
Plasmids with inserts corresponding to each of the five Bacillus subtilis cDNA clones 
were kindly provided by Jiangting Hu (Oxford). 5 pg of each plasmid was digested with 
the restriction endonuclease Notl (Promega) then in vitro transcribed using the T3 
MEGAscript kit from Ambion.
1. A digestion mix was prepared for a total of 8 reactions:
Buffer D 10 x 16 pi
BSAlOOx 1.6 pi
Notl (80 U/pl) 1 pi
2. A digestion reaction was set up for each plasmid in a 0.5 ml microcentrifuge
tube with the following components:
Plasmid DNA volume for 5 pg
Digestion Mix 2.3 pi
H20  to 20 pi
3. The tubes were incubated at 37°C for 2.5 hr.
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4. The reactions were precipitated by addition of the following components:
0.5 M EDTA 1 pi
3 M Sodium Acetate 2 pi
100% Ethanol 40 pi
5. The samples were vortexed and incubated at -20°C for 30 min.
6. The tubes were centrifuged at 13,000 rpm for 15 min in a microcentrifuge.
7. The supernatant was removed and the pellets were air-dried and resuspended in 
10 pi of nuclease-free H2O.
8. An in vitro transcription reaction was set up for each plasmid in a 0.5 ml
microcentrifuge tube with the following reaction components:
Nuclease-free H2O 5 pi
ATP solution (75 mM) 2 pi
CTP solution (75 mM) 2 pi
GTP solution (75 mM) 2 pi
UTP solution (75 mM) 2 pi
10 x Reaction Buffer 2 pi
T3 Enzyme Mix 2 pi
Linear plasmid DNA (~1 pg) 3 pi
9. The samples were incubated at 37°C for 5 hr.
10. The reactions were terminated by addition of 115 pi of nuclease-free H2O and
15 pi of ammonium acetate stop solution.
11. The samples were extracted with 150 pi of phenol/chloroform and then with 150 
pi of chloroform.
12. Each aqueous phase was transferred to a new microcentrifuge tube.
13. 150 pi of isopropanol was added to each tube to precipitate the RNA and
samples were incubated for 30 min at -20°C.
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14. The samples were centrifuged at 13,000 rpm for 15 min at 4°C.
15. The supernatant was removed and the RNA pellets were air-dried and
resuspended in 20 pi of nuclease-free H2O.
16. The purified RNA samples were quantified using a spectrophotometer and 
visualised using agarose gel electrophoresis.
17. 3 volumes of 100% ethanol were added to the RNA samples.
18. 250 pi of a 10 x bacterial mRNA cocktail was prepared with the five mRNAs at
the following concentrations:
0.3 ng/pl lysA
1.5 ng/\i\pheB 
3 ng/pl thrB 
15 ng/pl dapB 
30 ng/pl trp
19. The cocktail was then diluted 10-fold to obtain a 1 x working solution.
2.10.2 Generation of Fluorescently-Labelled aRNA targets
The Amino Ally MessageAmp aRNA Kit (Ambion) was used to amplify input RNA 
from patient and normal control samples. This kit reliably amplifies starting material 
using a T7 based linear amplification method. It also allows for incorporation of the 
fluorescent Cy3 or Cy5 dyes.
2.10.2.1 cDNA Synthesis
1. 2 pg of RNA from each sample to be amplified was placed into a 0.5 ml 
microcentrifuge tube.
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2. 1 ja.1 of T7 Oligo(dT) Primer and 2 jul of bacterial cocktail were added to the 
samples and the volume was made up to 12 pi with nuclease free H2O.
3. The samples were incubated for 10 min at 70°C then centrifuged briefly and 
placed on ice.
4. A reverse transcription master mix was assembled using the following 
components for one reaction:
10 x First Strand Buffer 2 pi
RNase Inhibitor 1 pi
dNTP Mix 4 pi
5. 7 pi of the reverse transcription master mix was added to each sample and the 
samples were placed in an incubator at 42°C.
6. 1 pi of reverse transcriptase was added to each sample in the incubator and the 
samples were incubated for 2 hr.
7. The tubes were placed on ice and the second strand cDNA synthesis components
were added as follows: 
cDNA from step 6 20 pi
Nuclease free H2O 63 pi
10 x Second Strand Buffer 10 pi
dNTP Mix 4 pi
DNA Polymerase 2 pi
RNase H 1 pi
8. The samples were mixed gently and centrifuged briefly before incubating at 
16°Cfor2hr.
9. For each sample one cDNA Filter cartridge was equilibrated by adding 50 pi of 
cDNA binding buffer and incubating for 5 min.
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10. 250 pi of cDNA Binding Buffer was added to each sample and vortexed then the 
samples were added to the cDNA filter cartridges in 2 ml collection tubes.
11. The samples were centrifuged at 10,000 g for 1 min and the flow through was 
discarded.
12. 650 pi of cDNA wash Buffer was added to each cDNA Filter Cartridge and 
centrifuged for 1 min at 10,000 g.
13. The flow through was discarded and the cDNA Filter Cartridges were 
centrifuged for 1 min to remove any residual ethanol.
14. Each cDNA Filter Cartridge was transferred to a fresh 1.5 ml tube.
15. 9 pi of nuclease free H2O heated to 50°C was added to each filter and incubated 
for 2 min. The tubes were then centrifuged for 1.5 min at 10,000 g.
16. Step 15 was repeated and the cDNA filter cartridges were discarded.
17. If required the volume of each cDNA sample was increased to 14 pi with 
nuclease free H2O and stored at -20°C until required.
2.10.2.2 In Vitro Transcription to Synthesise aRNA
1. The in vitro transcription reaction components were assembled at room
temperature. The volume of reagents for one sample was as follows:
double stranded cDNA 14 pi
aaUTP Solution 3 pi
ATP, CTP, GTP Mix 12 pi
UTP Solution 3 pi
T7 10 x Reaction Buffer 4 pi
T7 Enzyme Mix 4 pi
2. The reactions were incubated at 37°C for 14 hr in an air incubator.
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3. 2 |a,l of DNase I was added to each sample and mixed gently then centrifuged 
briefly.
4. The samples were incubated at 37°C for 30 min.
5. One aRNA Filter Cartridge for each sample was equilibrated by adding 100 pi
of aRNA binding buffer and incubating for 5 min.
6. Nuclease free H2O was added to each sample to bring the total volume to 100 pi 
and the samples were mixed gently.
7. 350 pi of aRNA Binding Buffer was added to each sample and mixed gently.
8. 250 pi of 100% Ethanol was added to each sample and mixed gently.
9. The samples were added to the equilibrated aRNA Filter Cartridges in 2 ml 
collection tubes and centrifuged for 1 min at 10,000 g and the flow through was 
discarded.
10. 650 pi of aRNA Wash Buffer was added to each filter and centrifuged for 1 min
at 10,000 g and the flow through was discarded.
11. Each aRNA Filter Cartridge was transferred to a fresh 1.5 ml tube.
12. 50 pi of nuclease free H2O heated to 50°C was added to each filter and incubated
for 2 min. The tubes were then centrifuged for 1.5 min at 10,000 g.
13. Step 12 was repeated and the cDNA filter cartridges were discarded.
2.10.2.3 aRNA Dye Coupling and Clean up
1. The concentration of each aRNA sample was determined by spectrophotometer.
2. 15 pg of each sample was transferred to a fresh tube and vacuum dried to 7 pi.
3. 9 pi of Coupling Buffer was added to each sample and mixed.
4. 4 pi of FluoroLink Cy3 (normal pool) or Cy5 (individual sample) NHS ester dye 
(GE Healthcare, Bucks, UK) was added to each sample and mixed.
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5. The samples were incubated for 30 min at room temperature in the dark.
6. 4.5 pi of 4 M Hydroxylamine was added to each sample to quench the reaction
and incubated for 15 min at room temperature in the dark.
7. The dye labelled aRNA samples were purified as described in section 2.10.2.2 
starting at step 5.
2.10.3 Competitive Hybridisation of Labelled Targets onto Microarrays
1. The two labelled targets were combined as follows:
Labelled target 1 (Cy3-labelled) 33 pi
Labelled target 2 (Cy5-labelled) 33 pi
PolyA DNA (2 pg/pl) 3 pi
Human Cotl DNA (2 pg/pl) 3 pi
3 M Sodium Acetate pH 5.2 7 pi
100% Ethanol 237 pi
2. The nucleic acids were precipitated at -70°C for 30 min.
3. The samples were centrifuged at 13,000 rpm for 10 min to pellet the precipitate.
4. The pellets were washed in 200 pi of 70% ethanol and centrifuged for 1 min
then air dried.
5. The pellets were resuspended in 30 pi of hybridisation buffer (5X SSC, 6X 
Denhardt’s solution, 60 mM Tris HC1 pH 7.6, 0.12% sarkosyl, 48% formamide) and 6 
pi of nuclease free H2O.
6. The hybridisation mixture incubated in a dry block at 100°C for 5 min then
cooled for 10 min at room temperature and centrifuged briefly.
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7. For each hybridisation one coverslip and one microarray slide were cooled to 
4°C in a cold room to reduce non specific binding of the labelled targets to the surface 
of the slide.
8. In the cold room, the hybridisation mixture was applied to the centre of the 
coverslip and the microarray slide was inverted and lowered onto the coverslip to allow 
the hybridisation mixture to spread evenly across the microarray.
9. The microarray slide was placed in a sealed humid chamber to prevent buffer 
evaporation and incubated at 47°C overnight in the dark.
10. The microarrays were removed from the humid chambers and placed 2 x SSC 
until the coverslip slid off.
11. The microarrays were washed with gentle shaking in 2 x SSC for 5 min at room 
temperature.
12. The microarrays were transferred to 0.1 x SSC, 0.1% SDS and washed for 30 
min at room temperature.
13. Step 12 was repeated.
14. The microarrays were transferred to 0.1 x SSC and washed for 5 min at room 
temperature.
15. Step 14 was repeated.
16. The microarrays were centrifuged at 1,000 rpm for 1 min to dry the slides.
2.10.4 Scanning and Image Quantitation
The microarray slides were scanned using the ScanArray 4000 microarray scanner 
(PerkinElmer, Boston, MA) with a 10 pm resolution. This generated one image for the 
Cy3 channel scanning at wavelength 532 nm, and one image for the Cy5 channel 
scanning at wavelength 635 nm. The images were saved as TIFF files and imported into
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the image quantitation software QuantArray 3.0 (PerkinElmer). Using QuantArray the 
Cy-3 image was given a red colour and the Cy5 image was given a green colour then 
the two images were overlaid. The top left spot of the array was located manually to 
allow the software to display a grid of circles organised to locate each spot on the array. 
If required, the grid was adjusted manually to accurately match the location of the spots 
on the array. The QuantArray software then calculated the signal intensity for each spot 
in the Cy3 and Cy5 channels. This was calculated from the 60th-95th percentile 
interval to reduce background signal by the exclusion of low intensity pixels and give 
lower weight to saturated pixels. The intensities of the Cy3 and Cy5 signals were then 
normalised to the median value of the array as a whole and the ratio for each spot was 
obtained. The data was exported to the GeneSpring software as a tab delimited text file 
for data analysis.
2.10.5 Data Analysis
Tab delimited text files were imported into the GeneSpring software package (Silicon 
Genetics, Redwood City, CA) and data analysis was performed. The data were firstly 
log transformed to give an approximately normal distribution. Lists of genes with 
increased or decreased expression were generated by filtering by expression level. 
Typically an expression ratio cut off of >0.2 was selected for genes with increased 
expression and a cut off of <0.5 was selected for genes with decreased expression. In 
order to compare groups of samples the t-test or ANOVA based on a parametric 
Welch’s t-test without assumption of equality of variances was used. The false 
discovery rate was controlled by either the Benjamini-Hochberg multiple testing 
correction or the more conservative Bonferroni multiple testing correction. Hierarchical 
clustering was performed using standard correlation.
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2.11 Affymetrix GeneChip Experiments
The Affymetrix Human GeneChip U133 Plus 2.0 whole genome expression array 
(Affymetrix, Santa Clara, CA) was used for this study. The probe sets on these arrays 
were identified from the GenBank dbEST and RefSeq databases and the sequence 
clusters were created from the UniGene database build 133 (April 2001). These 
sequence clusters were then refined by analysis and comparison with public databases 
such as the University of California Santa Cruz Golden-Path human database (April 
2001). There are an additional 9,921 probe sets representing a further 6,500 genes from 
the GenBank dbEST and RefSeq databases and the sequence clusters were created from 
the UniGene database build 159 (January 2003). These sequence clusters were then 
refined by analysis and comparison with public databases such as NCBI human genome 
assembly (Build 31). This results in an array that can provide an analysis of over 
47,000 transcripts representing 39,000 human genes. The complimentary 
oligonucleotide probes are synthesised directly on the array. These comprise of eleven 
pairs of oligonucleotide probes corresponding to each sequence represented on the 
array. Total RNA samples from patients or normal controls were amplified and biotin 
labelled using the Two-Cycle Target Labelling and Control Reagent kit (Affymetrix) 
and one sample was hybridised to one array. Poly-A controls were added to the starting 
RNA as internal controls for amplification, labelling, assay sensitivity, and data 
consistency. These controls hybridise to the internal control probe sets for the B. 
subtilis genes lys, phe, thr, and dap that are contained on the array. The arrays were 
washed and stained before being scanned with an Affymetrix Gene Chip Scanner 3000.
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2.11.1 Target Amplification and Labelling
2.11.1.1 cDNA Synthesis, Cycle 1
1. A mix of the T7-oligo(dT) primer and poly-A controls was prepared for ten 
reactions as detailed below:
T7-oligo(dT) primer (50 pM) 2 pi
Diluted poly-A controls 2 pi
RNase-free H2O 16 pi
2. Each total RNA sample was mixed with the T7-oligo(dT) primer/poly-A 
controls mix in the following quantities:
Total RNA 50 ng
T7-oligo(dT) primer/poly-A controls mix 2 pi 
RNase-free H2O to 5 pi
3. The samples were incubated at 70°C for 6 min then snap-chilled on ice for 2 
min.
4. The following First-strand Master-Mix components were added to each sample:
5 x 1st Strand Reaction Mix 2 pi
0.1M DTT lp l
RNase Inhibitor 0.5 pi
lOmMdNTPs 0.5 pi
Superscript II 1 pi
5. The samples were incubated at 42°C for 1 hr.
6. The samples were heated at 70°C for 10 min to inactivate the RT enzyme then 
cooled at 4°C for 2 min.
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7. The following Second-strand Master-Mix components were added to each
sample
RNase-free H2O 4.8 pi
17.5 mM MgC12, 4.0 pi
lOmMdNTPs 0.4 pi
E. coli DNA Polymerase I 0.6 pi
RNase H 0.2 pi
8. The samples were incubated at 16°C for 2 hr.
9. The samples were heated at 70°C for 10 min then cooled at 4°C for 2 min.
2.11.1.2 In  Vitro Transcription, Cycle 1
The MEGAScript T7 kit (Ambion) was used for in vitro transcription (TVT) 
amplification of the samples.
1. The following IVT components were added to each of the double-stranded
cDNA samples:
10 x Reaction Buffer 5 pi
ATP Solution 5 pi
CTP Solution 5 pi
UTP Solution 5 pi
GTP Solution 5 pi
Enzyme Mix 5 pi
2. The samples were incubated at 37°C for 16 hr in an air incubator.
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2.11.1.3 cRNA Clean Up, Cycle 1
1. 50 pi of RNase-free H2O was added to each IVT reaction and the samples were 
mixed by vortexing.
2. 350 pi of IVT cRNA Binding Buffer was added to each sample and the tubes 
were mixed by vortexing.
3. 250 pi of 100% ethanol was added to the samples and the tubes were mixed well 
by pipetting.
4. Each sample was applied to an IVT cRNA Cleanup Spin Column in a 2 ml 
collection tube and centrifuged for 15 sec at 12,000 rpm. The flow-through and 
collection tube were discarded and the spin columns were transferred to new 2 ml 
collection tubes.
5. 500 pi of IVT cRNA Wash Buffer was added to the spin columns. The columns 
were centrifuged for 15 sec at 12,000 rpm and the flow-through was discarded.
6. 500 pi of 80% ethanol was added to the spin columns. The columns were 
centrifuged for 15 sec at 12,000 rpm and the flow-through was discarded.
7. The columns were centrifuged for 5 min at 13,000 rpm with the caps open to dry 
the membrane. The flow-through and collection tube were discarded and the spin 
columns were transferred to new 1.5 ml collection tubes.
8. 13 pi of RNase-free H2O was pipetted onto the membrane of each spin column 
and the columns were centrifuged for 1 min at 13,000 rpm to elute the cRNA.
9. cRNA yield was determined by spectrophotometry and 600 ng of cRNA was 
used for the second round of amplification.
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2.11.1.4 cDNA Synthesis, Cycle 2
1. 2 pi of diluted random primers (0.2 pg/pl) were added to 600 ng of cRNA and
H2O was added to a final volume of 11 pi.
2. The samples were incubated at 70°C for 10 min then snap-chilled on ice for 2 
min.
3. The following First-strand Master-Mix components were added to each sample
5 x 1 st Strand Reaction Mix 4 pi
0.1M DTT 2 pi
RNase Inhibitor 1 pi
lOmMdNTPs 1 pi
Superscript II 1 pi
4. The samples were incubated at 42°C for 1 hr then cooled at 4°C for 2 min.
5. 1 pi of RNase H was added to each sample and the tubes were incubated at 37°C 
for 20 min.
6. The samples were heated at 95°C for 5 min then cooled at 4°C for 2 min.
7. 4 pi of diluted T7-oligo(dT) primer (5 pM) was added to each sample and the
tubes were incubated at 70°C for 6 min then cooled at 4°C for 2 min.
8. The following Second-strand Master-Mix components were added to each
sample:
RNase-free H20  88 pi
5 x 2nd Strand Reaction Mix 30 pi
lOmMdNTPs 3 pi
E.coli DNA Polymerase I 4 pi
9. The samples were incubated at 16°C for 2 hr.
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10. 2 pi of T4 DNA Polymerase was added to each sample and the tubes were
incubated at 16°C for 10 min then cooled at 4°C for 2 min.
2.11.1.5 Double-Stranded cDNA Cleanup, Cycle 2
1. 600 pi of cDNA Binding Buffer was added to each sample and mixed by
vortexing.
2. 500 pi of each sample was added to a cDNA Cleanup Spin Column in a 2 ml
collection tube. The columns were centrifuged for 1 min at 12,000 rpm and the flow­
through was discarded.
3. The remainder of the sample was added to the spin column and centrifuged for 1 
min at 12,000 rpm. The flow-through and collection tube were discarded and the spin 
columns were transferred to new 2 ml collection tubes.
4. 750 pi of cDNA Wash Buffer was added to the spin columns. The columns 
were centrifuged for 1 min at 12,000 rpm and the flow-through was discarded.
5. The columns were centrifuged for 5 min at 13,000 rpm with the caps open to dry 
the membrane. The flow-through and collection tube were discarded and the spin 
columns were transferred to new 1.5 ml collection tubes.
6. 14 pi of cDNA Elution Buffer was pipetted onto the membrane of each spin 
column and the columns were incubated for 1 min at room temperature then centrifuged 
for 1 min at 13,000 rpm to elute the cDNA.
2.11.1.6 Synthesis o f Biotin-labelled cRNA
1. The following IVT components were added to 12 pi of double-stranded cDNA:
RNase-free H2O 8 pi
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10 x IVT Labelling Buffer 4 JLll
IVT Labelling NTP Mix 12 jjlI
IVT Labelling Enzyme Mix 4 |xl
2. The samples were incubated at 37°C for 16 hr in an air incubator.
2.11.1.7 Cleanup and Quantification o f Biotin-Labelled cRNA
1. 60 pi of RNase-free H2O was added to each IVT reaction and the samples were 
mixed by vortexing.
2. 350 pi of IVT cRNA Binding Buffer was added and the samples were mixed by 
vortexing.
3. 250 pi of 100% ethanol was added to the samples and mixed well by pipetting.
4. Each sample was added to an IVT cRNA Cleanup Spin Column in a 2 ml 
collection tube and centrifuged for 15 sec at 12,000 rpm. The flow-through and 
collection tube were discarded and the spin columns were transferred to new 2 ml 
collection tubes.
5. 500 pi of IVT cRNA Wash Buffer was added to the spin columns. The columns 
were centrifuged for 15 sec at 12,000 rpm and the flow-through was discarded.
6. 500 pi of 80% ethanol was added to the spin columns. The columns were 
centrifuged for 15 sec at 12,000 rpm and the flow-through was discarded.
7. The columns were centrifuged for 5 min at 13,000 rpm with the caps open to dry 
the membrane. The flow-through and collection tube were discarded and the spin 
columns were transferred to new 1.5 ml collection tubes.
8. 11 pi of RNase-free H2O was pipetted onto the membrane of each spin column 
and the columns were centrifuged for 1 min at 13,000 rpm to elute the cRNA.
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9. 10 (xl of RNase-free H2O was pipetted onto the membrane of each spin column 
and the columns were centrifuged for 1 min at 13,000 rpm to elute the cRNA.
10. cRNA yield was determined by spectrophotometry.
2.11.2 Fragmentation of Biotin-Labelled cRNA
The Fragmentation Buffer used for this step allows the break down of full length cRNA 
to 35-200 base fragments by metal induced hydrolysis.
1. The following components were added to 20 pg of biotin-labelled cRNA:
5 x Fragmentation Buffer 8 pi
RNase-free H2O to 40 pi
2. The samples were incubated at 94°C for 35 minutes and then cooled on ice.
2.11.3 Target Hybridisation
1. Each sample was mixed in a hybridisation cocktail as follows:
Fragmented cRNA (0.5 pg/pl) 30 pi (15 pg)
Control Oligonucleotide B2 (3 nM) 5 pi
20 x Eukaryotic Hybridisation Controls 15 pi
(bioB, bioC, bioD, ere)
Herring Sperm DNA (10 mg/ml) 3 pi
Bovine Serum Albumin (50 mg/ml) 3 pi
2 x Hybridisation Mix 150 pi
DMSO 30 pi
H20  64 pi
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2. The hybridisation cocktail was incubated at 99°C for 5 min and then at 45°C for 
5 min.
3. The samples were centrifuged at 13,000 rpm for 5 min to remove any insoluble 
material from the hybridisation mixture.
4. The Affymetrix arrays were equilibrated to room temperature to prevent 
cracking of the rubber septa.
5. Each array was filled through one of the septa with 200 pi of 1 x Hybridisation 
Buffer.
3. The arrays were incubated at 45°C for 10 min with rotation at 60 rpm in an 
Affymetrix Hybridisation Oven.
4. The 1 x Hybridisation Buffer was removed and the array cartridge was filled
with 200 pi of the hybridisation cocktail.
5. The arrays were incubated in the hybridisation oven at 45°C for 16 hr with 
rotation at 60 rpm.
2.11.4 Washing and Staining
The washing and staining protocol uses the following solutions:
Wash Buffer A: Non-Stringent Wash Buffer (6 x SSPE, 0.01% Tween-20)
Wash Buffer B: Stringent Wash Buffer (100 mM MES, 0.1 M [Na+], 0.01% Tween-20) 
Stain Buffer (100 mM MES, 1 M [Na+], 0.05% Tween-20)
SAPE Solution Mix (1 x Stain Buffer, 2 mg/ml BSA, 10 pg/ml Streptavidin
Phycoerythrin-SAPE)
Antibody Solution Mix (1 x Stain Buffer, 2 mg/ml BSA, 0.1 mg/ml Goat IgG, 3 pg/ml 
Anti-streptavidin biotinylated antibody)
69
1. After the 16 hr hybridisation, the hybridisation cocktail was removed from the 
array and 250 pi of Wash Buffer A was added to completely fill the array.
2. The arrays were washed and stained in the Affymetrix Fluidics Station 450, 
using the EukGE-WS2v5 fluidics script as follows:
Post Hyb Wash #1 10 cycles of 2 mixes/cycle with Wash Buffer A at 30°C
Post Hyb Wash #2 6 cycles of 15 mixes/cycle with Wash Buffer B at 50°C
1st Stain Stain the array for 5 min in SAPE solution at 35°C
Post Stain Wash 10 cycles of 4 mixes/cycle with Wash Buffer A at 30°C
2nd Stain Stain the array for 5 min in antibody solution at 35°C
3rd Stain Stain the array for 5 min in SAPE solution at 35°C
Final Wash 15 cycles of 4 mixes/cycle with Wash Buffer A at 35°C.
The holding temperature was 25°C.
2.11.5 Scanning and experiment quality control
The Affymetrix chips were immediately scanned using the Affymetrix GeneChip 
Scanner 3000 with a 3 pm pixel resolution at 570 nm wavelength. When the scan was 
completed the GCOS automatically aligned a grid on the image for probe cell 
identification and calculated the probe cell intensity data using the Cell Analysis 
algorithm. All chips were scaled to a target intensity of 100 to control image brightness 
and to render all chips comparable. To achieve this the intensity values were multiplied 
by a scaling factor to reach the target level of 100. The scaling factor should be 
comparable for all samples and less than 3. The Average Background values were 
typically around 50-70, and the acceptable range is 20-100. The number of probe sets 
identified as “present” by the GCOS was expressed as a percentage of the total number 
of probe sets on the array and was approximately 40% for all samples. The
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Hybridisation Controls added to the hybridisation cocktail were identified as “present” 
by the GCOS. The signal values of the 3’ and 5’ probe sets for the GAPDH gene were 
used to assess RNA integrity and amplification. The ratio of the 3’ to the 5’ probe set 
was calculated for all samples and although the expected ratio would be 1 the acceptable 
level is a value less than 3. The amplification method used in these experiments has a 
3’ bias due to the T7 promoter resulting in transcription of cRNA from the sense strand 
of the cDNA. The data was exported to the GeneSpring software as a tab delimited text 
file or .CEL file for data analysis.
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Chapter 3
Gene expression analysis of
telomerase related genes in Chronic
Myeloid Leukaemia
Associated Publication: hTERT, the catalytic component of telomerase, is
downregulated in the haematopoietic stem cells of patients with chronic myeloid 
leukaemia.
L J Campbell, C Fidler, H Eagleton, A Peniket, R Kusec, S Gal, T J Littlewood, J 
S Wainscoat and J Boultwood. Leukemia (2006) 20, 671-679
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3.1 Introduction
3.1.1 Chronic Myeloid Leukaemia
Chronic Myeloid Leukaemia (CML) is a clonal myeloproliferative disorder that 
originates in a pluripotent haematopoietic stem cell (HSC) (Shet et al. 2002). The 
disease is characterised by an excessive proliferation of granulocytes (Hehlmann et al. 
2007). Disease incidence is rare with 1 or 2 cases per 100,000 head of population per 
year and median age of onset is 65 years (Hehlmann et al. 2007). CML is consistently 
associated with an acquired genetic abnormality: the Philadelphia (Ph) chromosome 
(Nowell and Hungerford 1960; Rowley 1973). This is a rearrangement between the 
major breakpoint cluster region (BCR) on chromosome 22 and the c-ABL proto­
oncogene on chromosome 9 (Shet et al. 2002). This results in a t(9;22) translocation 
encoding the BCR/ABL oncogenic fusion gene. This gene encodes the p210 
BCR/ABL, an oncogenic fusion protein with increased tyrosine kinase activity that can 
induce cytoskeletal abnormalities which may increase cell motility (Salgia et al. 1997). 
The fusion protein enhances cell survival by conferring resistance to apoptosis (Bedi et 
al. 1994). The translocation is the hallmark of CML and is found in up to 95% of 
patients (Groffen et a l 1984). The translocation has been demonstrated to be sufficient 
and necessary for malignant transformation (Daley et a l 1990; Lugo et a l  1990). 
Transplantation of BCR/ABL transduced cells into animal models induces CML like 
syndromes and the mouse model is a very accurate model of the human disease (Van 
Etten 2002).
In patients the disease inevitably progresses through a series of stages beginning with a 
chronic phase (CP) lasting 3-4 years where myeloid progenitors and mature cells
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accumulate in the blood (Shet et a l  2002). After this time the disease can transform to 
accelerated phase (AP) and terminates in blast crisis (BC), in which transformation to an 
acute leukaemia with myeloid, B-lymphoid, or occasionally T-lymphoid features occurs 
(Martin et al. 1980; Allouche et a l 1985; Kantaijian et al. 1987; Calabretta and Perrotti 
2004). The Ph chromosome is typically the only cytogenetic abnormality reported in CP 
patients, but cells with additional chromosomal abnormalities are commonly present at 
BC. Approximately 80% of patients show additional chromosome changes in BC, the 
most common of which are extra copies of the Philadelphia chromosome, trisomy 8, 
isochromosome 17, trisomy 19 and complex karyotypes (Hehlmann and Saussele 2008). 
Mutations are also relatively common with 25% of myeloid BC patients having p53 
mutation and 50% of lymphoid BC having pi6/AKT mutation (Ahuja et al. 1989; 
Hehlmann and Saussele 2008). Additionally, expression of the BCR/ABL fusion protein 
results in an unstable genome in the haematopoietic stem cell. Increasing levels of 
BCR/ABL lead to inhibition of DNA repair allowing the accumulation of genetic 
defects and disease progression (Kharbanda et al. 1997; Deutsch et a l 2001).
For many years the only curative treatment of CML was an allogeneic bone marrow 
transplant, however many patients were excluded from this due to age or donor 
availability (Mughal and Goldman 2004). Treatment of patients with CML was 
revolutionised with the first clinical use of imatinib mesylate (Gleevec;STI571) (Druker 
et a l 2001; Druker et a l 2001). This is a highly specific tyrosine kinase inhibitor of the 
BCR/ABL fusion protein (Druker et a l 1996). Imatinib blocks the kinase activity of 
BCR/ABL by competing with ATP for the enzymatic binding site and significantly 
reduces the number of leukaemic cells (Druker et a l 1996). Many newly diagnosed 
patients are now being successfully treated with this drug (Mughal and Goldman 2004).
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3.1.2 Telomeres and Telomerase in CML
A reduction in telomere length has been demonstrated to associate with disease 
evolution in CML. It has been demonstrated that telomere length in AP and BC is 
reduced compared with serial samples taken at CP in patients with CML (Boultwood et 
al. 1999). Furthermore telomere shortening observed at the time of diagnosis in CML 
significantly influences the time of progression to AP suggesting that the measurement 
of diagnostic telomere length may be clinically important in the selection of patients at 
high risk of disease transformation in CML (Boultwood et al. 2000). Similarly, 
Brummendorf and colleagues have shown that patients with CML, in whom the blast 
phase subsequently developed within 2 years, had significantly shorter telomeres than 
those in whom the blast phase did not develop for at least 2 years (Brummendorf et al. 
2000). Telomerase activity has been investigated in the bone marrow cells of patients 
with CML during disease progression (Tatematsu et al. 1996; Ohyashiki et al. 1997; 
Verstovsek et a l 2003; Bock et al. 2004). These studies measured telomerase activity 
rather than expression of hTERT in peripheral blood or bone marrow mononuclear cells 
of CML patients and reported an increase in telomerase activity. It was reported that 
telomerase activity increased with disease progression of CML. An increase in 
telomerase activity has been correlated with a decrease in telomere length in these 
studies. This apparent paradox has been explained by the suggestion that a critical point 
of telomere length is reached and only those cells with increased telomerase activity can 
survive (Ohyashiki et al. 1997).
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3,1.3 hTERT expression as a marker for telomerase activity
There is a strong correlation between the presence of hTERT mRNA and telomerase 
activity and it is recognized that hTERT is the rate-limiting determinant of the 
enzymatic activity of human telomerase (Weinrich et al. 1997; Counter et al. 1998; 
Nakayama et al. 1998). Although various steps at post-transcriptional and post- 
translational level can modulate hTERT function the transcriptional control of the gene 
is a major contributor to the regulation of telomerase activity in human cells (Poole et 
al. 2001; Aisner et al. 2002). Nakayama et al. demonstrated that ectopic hTERT 
expression is sufficient to confer enzymatic activity to telomerase negative cells and 
showed that hTERT expression is the primary determinant regulating telomerase activity 
(Nakayama et al. 1998). It is widely accepted that hTERT expression levels may be 
used as a surrogate marker for telomerase activity (Dome et al. 1999; Bieche et al. 
2000; de Kok et al. 2000). Indeed, several groups consider that the measurement of 
hTERT levels by quantitative RT-PCR is a more accurate and sensitive means of 
quantitation and detection than the TRAP assay (Dome et al. 1999; Bieche et al. 2000; 
de Kok et al. 2000).
3.1.4 Telomerase splice variants
Posttranscriptional mechanisms play a role in the regulation of telomerase. Several 
splice variants of the hTERT gene have been identified (Fig 3.1) that have different 
activity as a result of truncations in domains with catalytic activity (Ulaner et al. 1998). 
The full length transcript is known as +a+B and is folly functional (Yi et al. 2000). The 
-a+B transcript has a 36bp deletion causing an in frame deletion of the reverse 
transcriptase motif that is a dominant negative inhibitor of hTERT enzyme activity
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(Colgin et al. 2000). The +a-B is a 182bp deletion that causes a nonsense mutation 
before the RT domain causing a non-functional protein to be formed (Ulaner et al. 
1998). When both of the above sites are deleted this results in a -a-B transcript which is 
an inactive truncated protein (Yi et al. 2000). Differences in expression of these splice 
variants can been studied by measuring RT-PCR products on the Agilent Bioanalyser to 
reveal the size and quantity of each band (Keith and Hoare 2004).
36 bp 182 bp
Figure 3.1 Telomerase splice variants. Representation of the coding region of human 
telomerase reverse transcriptase. The reverse transcriptase domains are shown as filled 
boxes and labelled 1, 2 and A-E (Nakamura et al. 1997). Locations of the 36bp a 
deletion and the 182 bp p deletion are shown as open boxes (Ulaner et al. 2000).
3.1.5 Regulation of Telomerase
The proto-oncogene c-Myc, a positive regulator of telomerase, is one of the major 
determinants of hTERT expression. It acts by directly binding the hTERT promoter to 
induce transcription. Kyo et a l have shown that expression of c-Myc and SP1 correlates 
with transcription of hTERT and suggest that c-Myc and SP1 cooperatively function as 
the main regulators of hTERT expression (Kyo et al. 2000). c-Myc binds a site known 
as the E-box (CACGTG) and SP1 binds a GC-box sequence (Takakura et al. 1999). c- 
MYC and hTERT expression are found to be increased in parallel in several 
malignancies such as prostate cancer, cervical cancer and lipomatous tumours and it is
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likely that increased c-MYC expression leads to increased hTERT expression in these 
diseases (Latil et al. 2000; Sagawa et al. 2001; Schneider-Stock et a l 2003).
A potent inhibitor of telomerase protein activity, the TRF1-interacting protein PinXl, 
has been identified. Telomerase activity is inhibited by direct binding of PinXl to the 
catalytic subunit of telomerase, so that the RNA template cannot bind (Zhou and Lu 
2001; Banik and Counter 2004). Increased PinXl expression leads to reduced 
telomerase activity and shortened telomeres (Zhou and Lu 2001). Recently it has been 
demonstrated that PinXl directly interacts with TRF1 and this interaction allows TRF1 
to recruit PinXl to telomeres which is required for PinXl to prevent telomere 
elongation (Soohoo et al. 2011).
3.1.6 Telomerase holoenzyme
Human telomerase is a ribonucleoprotein of which the minimum components are human 
telomerase RNA component (hTR), human telomerase catalytic subunit (hTERT) and 
TEP1, a telomerase associated protein. TEP1 is not the rate limiting factor for 
telomerase activity but it is involved in enzyme activity and is thought to be required for 
full activity of the enzyme (Chang et al. 2002). hTR, is commonly expressed in both 
malignant and normal cells and several studies have shown that hTR is up-regulated 
during tumorigenesis (Avilion et al. 1996; Blasco et al. 1996). Expression of hTR has 
previously been determined in many cancers and it generally does not correlate with 
hTERT expression levels. Unlike hTERT, the expression of hTR does not predict the 
presence or amount of telomerase activity (Avilion et al. 1996; Blasco et al. 1996).
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3.1.7 Telomeric associated proteins
Over recent years a number of telomeric-associated proteins have been identified. The 
interaction between the telomeric-associated proteins telomeric-repeat binding factor 
protein-1 (TRF1), Tin2 and tankyrase is organized to control the access of telomerase to 
TTAGGG telomeric repeats. A Tin2/TRF1 complex binds telomeric DNA and inhibits 
the access of telomerase to the telomeres to prevent the addition of more repeats 
(Smogorzewska and de Lange 2004). Tankyrase is a TRF1-interacting factor and 
tankyrase-mediated ADP-ribosylation of TRF1 leads to the release of TRF1 from 
telomeres, opening up the telomeric complex and permitting access to telomerase 
(Smith et al. 1998; Smith and de Lange 2000; Cook et al. 2002). Since Tankyrase 
inhibits binding of TRF1 to telomeric repeats in vitro it has been suggested that 
tankyrase regulates TRF1 and therefore might control telomere dynamics in vivo (Smith 
and de Lange 2000). Telomeric-repeat binding factor protein-2 (TRF2) mainly 
functions in telomere end-protection and, by restricting telomere elongation, is a 
negative regulator of telomere length (van Steensel et al. 1998). Thus telomerase and 
tankyrase are positive regulators of telomere length, whilst TRF1, TRF2 and PinXl are 
negative regulators. Telomere length in normal and malignant cells is regulated by a 
delicate balance between these factors.
3.1.8 Aims o f  the study
The aim of this study was to investigate the expression levels of the components of 
telomerase, its regulators and several telomeric-associated proteins in the HSCs of CML 
patients during disease progression in order to gain insight into the biology of 
telomerase and its regulation in CML during disease evolution.
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3.2 Materials and Methods
3.2.1 Samples
Patient samples were sourced from either patients attending the John Radcliffe Hospital 
or from Dr. Rajko Kusek (University Hospital Merkur, Croatia). Bone marrow 
aspirates were obtained from patents with CML and in some cases peripheral blood was 
obtained and CD34+ cells were then isolated. The clinical details of these patients are 
detailed in table 3.1. Normal control CD34+ cells were obtained from bone marrow 
samples from patients attending the John Radcliffe Hospital for hip replacement 
surgery.
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Table 3.1 Clinical Details of CML patients.
M=Male, F=Female, STI= treatment with Imatinib, INF= treatment with interferon 
alpha, CP=Chronic Phase, AP=Accelerated Phase, BC=Blast Crisis.
Identifier Sex A ge
(yrs)
T reatm ent at 
tim e o f  
sam pling
Sam pling
tim e
(post
diagnosis)
Rem ission
status
C ytogenetics
Pt 1 F 66 INF 12 yrs CP 46,X X ,t(9;22)(q34;ql 1)
Pt 13 F 36 Hydroxyurea 7 yrs CP 4 6 ,X X ,t(l;2 )(q l l;p l l),t(9;22) 
(q 3 4;q ll),in v (10)(p l3q 22)
Pt 14 F 42 none at diagnosis CP 46,X X ,t(9;22)(q34;ql 1)
Pt 15 M 64 none at diagnosis CP 46,X Y ,t(9;22)(q 34;q ll)
Pt 19 M 26 INF 1 mth CP 46,X Y ,t(9;22)(q34;ql 1)
Pt 26 M 61 none at diagnosis CP 46,XY,?t(9;22; 19)[7]/48,idem , 
+8,+der(22)t(9;22)[3]
Pt 28 M 34 none at diagnosis CP 46,XY,t(9;22; 14)
Pt 29 F 27 none at diagnosis CP 46,X X ,t(9;22)(q34;ql 1)
Pt 31 M 58 none at diagnosis CP 46,X Y ,t(9;22)(q34;ql 1)
Pt 20 F 68 Hydroxyurea and 
INF
4 yrs AP 46,XX,t(9;22)[4]/46,idem ,
I(17)[61
Pt 27 M 79 Hydroxyurea 4 yrs AP 46,X Y ,t(9;22)(q34;ql 1)
Pt 18 M 33 Hydroxyurea 11 yrs BC 46,X Y ,t(9;22)(q34;ql 1)
Pt 32 M 51 Hydroxyurea 8 yrs BC 46,X Y ,t(9;22)(q34;ql 1)
Pt 33 F 18 Hydroxyurea 2 yrs BC 46,X X ,t(9;22)(q34;ql 1)
Pt 34 F 77 Hydroxyurea 9 yrs BC 46,X X ,t(9;22)(q34;ql 1)
Pt 35 M 49 Hydroxyurea 2 yrs BC 46,X Y ,t(9;22)(q 34;q ll)
Pt 36 M 65 Hydroxyurea and 
INF
11 yrs BC 46,X Y ,t(9;22)(q34;ql 1)
Pt 3 M 58 STI 3 mth STI in 
remission
46,XY,der(9),t(9;22)?del(22)
(q l3),der(22)t(9 ;22)(q34;q ll)
0/50
Pt 4 F 54 STI 3 mth STI in 
remission
46,X X ,t(9;22)(q34;ql 1) 0/50
Pt 6 M 30 STI 3 mth STI in 
remission
46,X Y ,t(9;22)(q34;ql 1) 3/50
Pt 9 F 67 STI 3 mth STI in 
remission
46,X X ,t(9;22)(q34;ql 1) 0/50
Pt 11 F 44 STI 3 mth STI in 
remission
46,X X ,t(9;22)(q34;ql 1) 0/100
Pt 17 M 33 none at diagnosis CP 46,X Y ,t(9;22)(q34;ql 1)
STI 3 mth STI in 
remission
46,X Y ,t(9;22)(q34;ql 1) 5/55
Pt 22 F 32 none at diagnosis CP 46,X X ,t(9;22)(q34;ql 1)
STI 3 mth STI in 
remission
46,X X ,t(9;22)(q34;ql 1) 0/50
Pt 21 M 79 none at diagnosis CP 46,X Y ,t(9;22)(q34;ql 1)
Hydroxyurea 11 mth AP
Hydroxyurea 13 mth BC
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3.2.2 Real time PCR
RNA was extracted from normal and control samples with TRIZOL reagent as 
described in chapter 2. RNA was then DNase treated using the DNA-free reagent 
(Ambion) and cDNA synthesis was carried out as detailed in chapter 2 using the 
Ambion RETRO script kit.
To account for differences in input cDNA Beta-2-microglobulin ifi2M) expression was 
examined with a pre-developed assay (Applied Biosystems, Foster City, CA). hTERT 
and c-Myc were also quantified using pre-developed assay reagents (Applied 
Biosystems). For confirmation of hTERT expression data an alternative assay 
amplifying a different region of the gene was used (Assays on Demand, Applied 
Biosystems). TEP1, tankyrase and PinXl expression were also quantified using Assays 
on Demand (Applied Biosystems). Primers and Taq-man probes for hTR and TRF2 
mRNA were designed using Primer Express 2.0 software (Applied Biosystems). 
Primers and probe for TRF1 were as previously described (Yamada et al. 2002). These 
primer and probe sets were synthesized by MWG-Biotech (Milton Keynes, UK). 
Sequences of the oligonucleotides and probe for hTR, TRF1 and TRF2 are detailed 
below:
hTR:
Forward primer, 5'-GCTGTTTTTCTCGCTGACTTTCA-3',
Reverse primer, 5'-GCAGCTGACATTTTTTGTTTGCT-3', and 
Probe, 5'-FAM-TGCCGCCTTCCACCGTTCATTCT-TAMRA-3\
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TRF1:
Forward primer, 5 ’-GCAACAGCGCAGAGGCTATTATT
Reverse primer, 5 ’-AGGGCTGATTCCAAGGGTGTAA
Probe, 5’-FAM-TCCAGTCTAACAGCTTGCCAGTTGAGAACG-TAMRA-3 ’
TRF2:
Forward primer, 5'-ACCAGGGCCTGTGGAAAAG-3',
Reverse primer, 5,-GCACCAGACAGAGTCTTGAAAGC-3, and 
Probe, 5'-FAM-AGAACCCGCAAGGCAGCTACGGAAT-TAMRA-3
A reverse transcriptase negative control was included for each assay to rule out any 
genomic DNA contamination. GAPDH (Applied Biosystems, Assays on Demand) was 
used as an alternative reference gene.
3,2.3 Quantification o f hTERT transcript variants
cDNA from patient and control CD34+ cells was PCR amplified as described in Chapter
2. A single primer set that would generate a product containing the deleted regions of 
the different hTERT transcripts was used (Drummond et a l 2005). The primer 
sequences were as follows: hT2164F: 5,-GCCTGAGCTGTACTTTGTCAA-3' and
hT2620R: 5'-CGCAAACAGCTTGTTCTCCATGTC-3' with an annealing temperature 
of 64°C. The sequence amplified with these primers was confirmed using cycle 
sequencing. The control gene y62M was also amplified from the samples using the 
following primers designed using the Primer3 website (Rozen and Skaletsky 2000): 
P2M- F: 5 ’-GGCATTCCTGAAGCTGACA-3 ’ and j32M-R\
5’TCCCCCAAATTCTAAGCAGA-3’ with an annealing temperature of 62°C. The
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PCR products were then quantified using the Agilent Bioanalyser as described in 
Chapter 2.
3.3 Results
3.3.1 Real Time PCR analysis o f Telomerase subunits
3.3.1.1 hTERT
Following data collection and analysis using Gene Amp 5700 SDS software the 
expression data of each gene was normalized to the endogenous reference fl2M. The 
normalized gene expression (Act) of patients was related to the average Act of controls 
and the relative gene expression was calculated (2 '^ ^ ) . Statistically significant 
differences in gene expression between patient groups were identified using Graph Pad 
Instat 3. This analysis revealed that the expression levels of hTERT were reduced in the 
CD34+ cells of patients with CP CML relative to the CD34+ cells of normal individuals 
in 8 of 12 patients, P=.0387. hTERT was significantly down-regulated in the 
CD34+/blast cell fraction in 2 of 3 patients with AP CML and 7 of 7 patients with BC 
CML (P= 0017). Fig 3.1a shows a progressive decrease of hTERT expression levels 
during CML disease evolution. Median expression levels of the different patient groups 
are shown in Table 3.2
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Fig 3.2 Relative gene expression of telomerase and associated genes. CP= chronic 
phase AP= Accelerated phase B O blast crisis STI= patients treated with imatinib. (a) 
Data from all CML patients. The data is shown on a logarithmic scale. Each box 
represents the expression of one gene, relative to controls, in one of the three groups of 
patients. The dashed line represents the approximate value of controls, (b) Data from a 
single patient during disease progression. Each line represents one gene and each 
symbol represents the expression level for that gene. The dashed line represents the 
approximate level of controls, (c) Data from a single patient following successful 
treatment with imatinib. Each line represents one gene and each symbol represents the 
expression level for that gene. The dashed line represents the approximate level of 
controls.
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Table 3.2 Relative gene expression ratios of telomerase and associated genes in 
CML.
Control n=8, CP n=12, AP n=3, BC n=7, Imatinib n=7
G en e D isea se  S ta tu s R a n g e M ed ia n
hTERT Control 0 .67-1 .31 1.08
Chronic Phase 0 .0 8 -3 .0 0 0 .65
A ccelerated  Phase 0 .1 3 -0 .95 0 .32
B last Crisis 0 .0 1 -0 .28 0 .12
Imatinib 0 .1 -4 .0 0 1.64
hTR Control 0 .7 0 -1 .6 6 0 .95
Chronic Phase 0 .2 4 -3 .5 2 2 .0 2
A ccelerated  Phase 1.13-2.91 1.99
B last Crisis 0 .0 6 -4 .98 2 .0 2
Imatinib 0 .5 0 -1 .2 4 0 .84
TEP1 Control 0 .4 5 -1 .7 7 0 .99
Chronic Phase 0 .7 6 -2 .8 6 1.43
A ccelerated Phase 1 .21-2 .53 1.39
B last Crisis 1 .13 -10 .46 2 .42
Imatinib 0 .8 9 -1 .7 8 1.47
c-Myc Control 0 .5 3 -2 .35 0 .88
Chronic Phase 1.20 -8 .76 3 .34
A ccelerated  Phase 1.13-2 .02 1.42
B last Crisis 0 .0 9 -1 .2 7 0.37
Imatinib 0 .4 8 -1 .4 0 0.98
PinXl Control 0 .7 0 -1 .1 8 0 .99
Chronic Phase 1.55-5 .52 3.31
A ccelerated  Phase 1 .08-3 .44 2 .13
B last Crisis 0 .9 7 -3 .1 4 1.73
Imatinib 0 .5 0 -1 .5 0 1.23
TRF1 Control 0 .65 -1 .53 0 .99
Chronic Phase 0 .7 8 -6 .4 5 2 .69
A ccelerated  Phase 1.12-4 .49 3 .79
B last Crisis 0 .2 0 -1 .2 2 0 .80
Imatinib 0 .6 8 -1 .5 4 1.06
TRF2 Control 0 .82 -1 .43 0 .97
Chronic Phase 0 .8 9 -4 .4 6 1.70
A ccelerated Phase 1 .43-1 .93 1.81
B last Crisis 0 .2 0 -1 .8 0 1.13
Imatinib 0 .7 7 -2 .1 2 1.26
Tankyrase Control 0 .7 4 -1 .3 5 1.01
Chronic Phase 1.13-4 .30 2 .73
A ccelerated Phase 1.40-3 .94 1.85
B last Crisis 0 .6 7 -3 .4 2 1.72
Imatinib 0 .75 -1 .63 1.06
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To further illustrate the decrease of hTERT expression, samples were available from CP, 
AP and BC from one of the patients included in this study (pt21) giving an insight into 
the dynamics of telomerase gene expression in a single case during disease progression. 
In serial samples from this patient it can be seen that expression levels of hTERT in 
decrease with disease progression (Fig 3.2b).
In order to validate the above data results were confirmed using an alternative assay 
amplifying a different region of the hTERT transcript in 18 samples, from which there 
was sufficient material. Results showed a high level of correlation, Spearman r= 
0.9716, P=<0.0001, Fig 3.3a.
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Fig 3.3 Comparison of alternative gene expression assays for determination of 
hTERT  expression. Trend lines were calculated using linear regression statistics, (a) 
Comparison of two applied biosystems gene expression assays for hTERT. Expression 
ratios of hTERT expression are represented by open circles. hTERT= Pre developed 
assay reagent 4319447F. hTERT-2= Assay on Demand Hs00162669_ml. (b)
Comparison of jH2M and GAPDH control genes for determination of hTERT expression. 
Expression ratios of hTERT are represented by open circles.
To further verify the results hTERT expression data was confirmed in 18 samples, using 
GAPDH as a control gene. These results correlated well with the expression of hTERT 
using p2M  as a control (Spearman r=0.855, P=.0004), Fig 3.3b. The same test was
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performed with GAPDH as a control for expression of the other telomerase associated 
genes and results showed high correlation.
3.3.1.2 Splicing o f hTERT RNA
The hTERT transcript has four different splice variants that represent an additional level 
of gene regulation. The +a+B transcript is full length functional hTERT. -a+B is a 
dominant negative inhibitor of hTERT activity while the +a-B and -a-B transcripts are 
inactive truncated proteins. Quantification of hTERT splice variants in CML will give 
insight into the mechanisms of hTERT regulation.
The four hTERT splice variants can be amplified in a single PCR amplification. 
However, it is not possible to resolve all fragments using standard agarose gel 
electrophoresis. Using the Agilent Bioanalyzer DNA 1000 assay it has been possible to 
resolve and quantify hTERT splice variant PCR products in the CD34+ cells of CML 
patients and normal controls. The microfluidics based electrophoresis platform 
produces an electropherogram for each sample and then converts the electropherogram 
into a gel like image. DNA is quantified using an internal standard. Quantities of the 
individual transcript variants are expressed as a percentage of total hTERT expression. 
An example of a case showing all four hTERT splice variants is shown in Fig 3.4.
All samples in this study expressed the +a+p and +a-p hTERT splice variants. The -a+p 
and -a-p variants were expressed at low levels but not in all samples. -a-P was 
expressed in 2 of 8 controls, 9 of 12 CP, 1 of 3 AP and 2 of 7 BC. -a+p was expressed 
in 3 of 8 controls, 7 of 9 CP, 2 of 3 AP and 1 of 7 BC.
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Fig 3.4 Agilent Bioanalyzer gel like image of hTERT  splice variants. The internal 
markers are shown as purple or green bands on the gel and the DNA fragments are 
visualised between these markers. In lane 2 four bands can be seen corresponding to the 
four splice variants. One band is visible in lane 4 representing the j62M control 
amplification.
It can be seen in Figure 3.5 that these results indicate a shift in the splicing patterns of 
hTERT in the CD34+ cells of patients with CML. The proportion of +a-B is decreased 
in CML patients in all stages of disease and the proportion of +a+B transcripts is 
increased. However, these changes do not reach statistical significance. The levels of - 
a+B and -a-B transcripts were not significantly different between patients and normal 
controls.
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Figure 3.5 hTERT  transcript expression. Splice variant levels in each disease stage 
are shown as the percentage that each variant contributes to the total. The figures 
represent the mean for each transcript in each group with the standard error of the mean 
shown below. CP= chronic phase AP= Accelerated phase BC=blast crisis STI= patients 
treated with imatinib.
3.3.1.3 hTR
The hTR gene encodes the telomerase RNA template from a single exon gene. This 
means that any real time PCR assay for hTR will amplify cDNA and any contaminating 
genomic DNA in the sample. All RNA samples included in this study were DNase 
treated before cDNA synthesis. This should remove any contaminating genomic DNA 
from the samples. To ensure that this was the case a reverse transcriptase negative 
control was included and this was always negative.
Real time PCR and data analysis of hTR expression showed that median levels of hTR 
were increased in the CD34+ cells of patients in CP relative to normal controls. 
However, there was a wide range in the expression levels and two patients had 
expression levels below the range of controls (ratio 0.52 and 0.24). With the exception
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of one patient in BC with a marked decrease in hTR levels (ratio 0.06), levels of 
expression were relatively constant during disease progression. These results suggest 
that there is a trend towards increased hTR expression in CML, however, any 
differences in hTR gene expression levels did not reach statistical significance 
(P=.1256).
3.3.1.4 TEP1
TEP1 is the third telomerase holoenzyme subunit included in this study. The expression 
levels of TEP1 were increased relative to normal controls in CP, but not to a statistically 
significant degree. TEP1 expression levels were highest in BC CML and significantly 
higher than normal controls (P= 0037). This is the only telomerase related gene to 
show a significant increase above normal control expression levels in BC CML.
3.3.2 Real time PCR Analysis o f  Telomerase Regulators
3.3.2.1 c-Myc
c-Myc activates expression of telomerase by directly binding the hTERT promoter, c- 
Myc expression levels were high relative to controls in CP CML but, like hTERT, 
decreased with disease progression. In the majority of patients in BC expression levels 
of c-Myc were lower than that of normal CD34+ cells. c-Myc expression in BC was 
significantly lower than CP and AP (P=.0001).
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The action of c-Myc to increase transcription of telomerase indicates that a correlation 
in the expression of these two genes is likely. Using the Spearman rank correlation test 
to compare hTERT and c-Myc expression in all patient samples it can be seen in Figure 
3.6a that c-Myc expression levels correlated positively with hTERT expression in all 
stages of CML (Spearman ^0.744, P= 0007). This result is further enforced by the fact 
that expression of both hTERT and c-Myc decrease in a single patient (pt21) during 
disease progression (Fig 3.2b).
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Figure 3.6 Correlation of gene expression levels in telomerase associated genes.
Trend lines were calculated using linear regression statistics, (a) hTERT and c-Myc 
expression levels correlate in all stages of disease in CML. Spearman t^O.744 P=.0007. 
(b) Correlation between TRF2 and Tankyrase expression levels in CML patients in all 
stages of CML. Spearman r=0.859 P=<.0001.
33.2.2 PinXl
PinXl inhibits telomerase enzyme activity by binding the catalytic subunit to stop 
binding of the RNA template. Expression levels of PinXl were high, relative to 
controls, in the majority of patients in CP and AP. Median levels of PinXl expression 
decrease with disease progression. However, the majority of patients in BC had higher 
PinXl expression levels than controls and these differences were statistically significant 
(P=.0037).
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3.3.4 Real Time PCR analysis o f Telomeric-Associated Genes
33.4.1 TRF1
The telomere repeat binding factor TRF1 restricts access of telomerase to the telomere 
repeats. Expression of TRF1 was increased in the majority of patients in CP, relative to 
normal controls (P= 0015). In contrast, TRF1 expression levels were reduced, relative 
to normal controls, in the majority of patients in BC.
3.3.4.2 TRF2
The main function of TRF2 is telomere end protection. Expression levels of TRF2 were 
increased in the CD34+/blast cells of the majority of CML patients in CP and AP. This 
trend was not maintained during BC and levels were in the range of controls in the 
majority of these patients.
3.3.4.3 Tankyrase
Tankyrase positively regulates telomere length by interacting with TRF1. Expression 
levels of tankyrase were highest in patients with CP and AP CML. Analysis by the 
Kruskal-Wallis test revealed that Tankyrase expression in the three patient groups was 
significantly higher than controls, P=.0028. Although tankyrase has no known effect on 
the transcription of TRF2, or vice versa, it is of interest to note that the expression levels 
of these two factors correlated in all stages of disease in CML patients (Spearman 
r=0.859, P=<.0001). This is illustrated in Figure 3.6b.
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3.3.5 Expression o f  telomerase and telomerase-associated genes in patients treated 
with imatinib
Patients treated with imatinib can reach cytogenetic remission in as little as three 
months. If all cells are of normal karyotype then samples from these patients could be 
considered as haematologically normal, providing an internal control for expression 
data in these patients.
3.3.5.1 hTERT
The expression levels of hTERT were increased in the CD34+ cells of seven CP CML 
patients in remission following successful treatment with imatinib, relative to untreated 
CP patients. Furthermore, hTERT expression was not significantly different from 
normal individuals (P=. 1520). Two of the patients included in this analysis were also 
sampled in CP at diagnosis. In these two patients it can be seen that, after treatment 
with imatinib, hTERT expression is returning to levels similar to those of normal CD34+ 
cells. The data from one of these patients (ptl7) is shown in Figure 3.2c to illustrate 
this point.
3.3.5.2 Splicing o f  hTERT RNA
Expression of the telomerase transcript variants in patients treated with imatinib is 
summarised in Fig 3.5. -a-|3 was expressed in 5 of the 7 patients treated with imatinib 
and -a+p was expressed in 4 of 7. Similar to CP patients the proportion of +a-B is 
decreased and the proportion of +a+6 transcripts is increased when compared to the 
normal control group. Figure 3.5 shows that expression of hTERT splice variants in
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patients treated with imatinib is more similar to CP patients than to normal controls. 
The differences in +a+B and +a-13 splice variants are not statistically different between 
the STI, CP and control groups.
3.3.53 hTR and TEP1
The median expression levels of hTR in these seven patients were reduced as compared 
to untreated CP patients. The same pattern of gene expression was also observed in 
samples taken from two patients pre-and post- treatment with imatinib (Fig 3.2c). 
Overall, TEP1 expression was decreased in patients treated with imatinib and 
furthermore the expression levels of TEP1 fell within the range observed in normal 
controls.
3.3.5.4 Telomerase regulators
Median expression levels of the telomerase regulators c-Myc and PinXl were reduced in 
patients following successful treatment with imatinib when compared to untreated CP 
patients. As illustrated in Figure 3.2c, this pattern is again echoed in patients where 
samples have been obtained pre- and post- treatment with imatinib.
3.3.5.5 Telomerase associated genes
In correlation with the above data median expression levels of TRF1, TRF2 and 
tankyrase were reduced in the group treated with imatinib when compared to untreated 
CP patients. As can be seen in Table 3.2 the levels of expression of TRF1 fell within 
the range of normal controls.
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3.4 Discussion
The expression levels of the components of telomerase, its regulators and several 
telomeric associated proteins have been evaluated in the CD34+/blast cell populations of 
22 CML patient samples as compared to the CD34+ cell population of eight healthy 
individuals. Expression levels of hTR, hTERT and TEP1, (the three major subunits of 
telomerase), TRF1, TRF2 and tankyrase, (telomeric-associated proteins) and c-Myc and 
PinXl, (positive and negative regulators of telomerase, respectively), have been 
determined by real-time quantitative PCR analysis.
The discovery that hTERT is down regulated in the CD34+ cells of patients with CML is 
in contrast to earlier studies investigating telomerase activity and protein levels 
(Broccoli et al. 1995; Tatematsu et al. 1996; Ohyashiki et al. 1997; Bitisik et al. 2000; 
Verstovsek et a l 2003). The finding of the current study is robust given the levels of 
validation of the result: Two different real time PCR assays for telomerase were used 
with two different control genes, each time showing the same result. The previous 
studies detailed above measure telomerase enzyme activity rather than hTERT 
expression in unfractionated bone marrow samples (Verstovsek), bone marrow 
mononuclear cells (Ohyashiki) or peripheral blood mononuclear cells (Ohyashiki, 
Bitisik, Tatematsu) of CML patients. In the study by Ohyashiki et al. (Ohyashiki et a l
1997) bone marrow mononuclear cells or peripheral blood samples from 33 CP patients 
were shown to have telomerase activity above background levels measured in normal 
peripheral blood. It was also noted that telomerase activity in mononuclear cells from 
21 patients in BC had a significant increase in telomerase activity when compared to 
both CP patients and normal control peripheral blood cells. Similar findings were 
presented in the studies by Tatematsu and Bitisik who compared the CML samples to
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peripheral blood mononuclear cells. However, the mononuclear cells of BC CML 
patients will have a higher percentage of blast cells (expressing telomerase) than CP 
patients and the difference in telomerase activity between these patient groups could be 
explained by the increased number of immature cells present in the BC samples. 
Similarly, mononuclear cells from CP CML will have more blast cells present than 
normal control peripheral blood. In the present study hTERT expression in normal 
CD34+ cells has been compared with CML CD34+/blast cells, i.e. comparing like with 
like. Therefore, the differences in telomerase activity between this and previous studies 
may be a reflection of the cell types studied. In fact, this is consistent with a study by Li 
et a l (Li et al. 2000) which shows a linear correlation between telomerase activity and 
the logarithm of bone marrow blast percentages in CML. Additionally, Gene 
expression profiles from peripheral blood and bone marrow samples in CML have 
significantly different gene expression profiles, authors identified 459 genes that were 
differentially expressed between peripheral blood and bone marrow samples from CML 
patients highlighting the importance of analysing the correct cell type (Nowicki et a l 
2003).
A paper by Drummond et a l (Drummond et a l 2005) supports the findings of this 
study. They showed that hTERT expression in CD34+ cells of CP CML patients is not 
significantly different from expression in CD34+ cells of normal controls. It was also 
shown that telomerase activity, when corrected for the decreased number of cells in Go 
in CP, is not significantly increased in CML when compared with controls. This 
suggests that the small differences in telomerase activity between these samples are a 
reflection of cell cycle status rather than a real increase in telomerase activity. A recent 
investigation by Gerber et a l further confirms the result of reduced hTERT expression 
in CML (Gerber et a l 2011). They isolated CML stem cells and compared then with
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stem cells of normal controls and showed that hTERT expression was reduced in the 
patient samples when compared to normal control stem cells and appeared to decrease 
with disease progression.
It may be suggested that this decrease in telomerase is a result of the BCR/ABL fusion 
gene in CML. In fact, it has been shown that antisense inhibition of BCR/ABL or c-Abl 
increases hTERT levels (Bakalova et a l 2004). Therefore, the presence of the BCR/ABL 
fusion in CML may contribute to the down regulation of hTERT observed in the 
CD34+/blast cells of the CML patients in this study.
An additional level of gene regulation of hTERT is the alternative splicing of the gene. 
Investigation of the proportions of the four alternative splice variants of hTERT was 
carried out. Results indicate that the relative proportion of full length active +a+fi 
transcripts is increased in CML while the proportion of inactive +a-13 is decreased, 
although this does not reach statistical significance. This indicates that while the overall 
expression levels of hTERT are decreased in the CD34+ cells of CML patients a shift in 
splicing patterns could allow a higher proportion of +a+!3 transcripts to be active and 
therefore maintain telomere length above the critical level allowing the leukaemic cells 
to proliferate. Drummond et a l similarly noted an increase in the levels of the +a+fi 
transcripts at the expense of the +a-B in CP CML as compared to normal controls 
(Drummond et a l 2005).
The data in the present study shows a trend for increasing hTR levels in the CD34+ cells 
from the majority of CML patients in all phases (however, two CP patients have hTR 
expression levels below the range of normal controls). Levels of hTR were also 
investigated by Drummond et a l (Drummond et a l 2005) and a significant decrease in 
the expression of hTR was noted in some CP CML patients. In the majority of patients
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in the present study the changes in expression levels of hTR did not correlate with the 
changes in expression levels observed for hTERT and any changes in hTR expression 
did not reach statistical significance. Similar observations have been made in other 
malignancies including AML and thyroid cancer (Xu et al. 1998; Hoang-Vu et al. 
2002).
The expression levels of the telomerase enzyme component TEP1 increased with 
disease progression of CML. This is the only telomerase component gene to be 
significantly up regulated in BC CML. TEP1 expression has also been shown to be 
increased in and breast cancer where it has prognostic value. Salhab et al. (Salhab et al. 
2008) showed that expression levels of TEP1 could predict overall survival in breast 
cancer. However, it has been shown that TEP1 is not an essential protein of the 
telomerase complex and that telomerase can function in the absence of TEP1 (Koyanagi 
et al. 2000; Liu et a l 2000). However, TEP1 is required for full enzyme activity and is 
expressed at relatively constant levels in human tissues and cell lines (Chang et al. 
2002). The expression of hTERT is the limiting factor for the function of telomerase 
and TEP1 may be expressed in cells with no effect and only used for assembly of the 
telomerase complex when hTERT is expressed.
Expression levels of c-Myc were increased in CP CML in relation to normal controls 
and significantly decreased with disease progression. Additionally expression levels of 
c-Myc positively correlated with expression of hTERT. An increase in c-Myc has 
previously been demonstrated by microarray analysis in the CD34+ cells of CP CML 
patients and this is in agreement with the current study (Diaz-Bianco et al. 2007). It is 
known that c-Myc positively regulates hTERT expression and a significant association 
between increased c-Myc expression and increased hTERT expression has been
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demonstrated in several cancers such as breast, prostate and cervical cancers (Bieche et 
al. 2000; Latil et al. 2000; Sagawa et al. 2001). Furthermore, telomerase activity is 
inhibited in leukaemia cells treated with anti-sense oligonucleotides targeting c-Myc 
(Fujimoto and Takahashi 1997). It could therefore be concluded that the decrease in 
hTERT expression in the CD34+/blast cells of BC CML patients may be directly caused 
by the reduction in expression of c-Myc in these patients.
Expression of the telomerase inhibitor PinXl was significantly increased in the majority 
of CML patients. In addition to its role in telomerase enzyme inhibition it has recently 
been shown that PinXl may act through c-Myc to control expression of hTERT. Wang 
et al. demonstrated that transfection of PinXl into PinXl negative gastric cancer cells 
reduced expression of c-Myc and telomerase activity (Wang et al. 2010). Furthermore, 
PinXl RNAi experiments resulted in increased expression of c-Myc. Therefore, it can 
be suggested that in the CML patients included in this study the presence of elevated 
PinXl expression above normal control levels could contribute to the resulting decrease 
in c-Myc expression which in turn leads to decreasing hTERT expression.
TRF1 and TRF2 expression levels were increased in the CD34+/blast cells of CP 
patients and expression of both genes decreased with disease progression. TRF1 
inhibits the action of telomerase at the telomeric region to control telomere length (van 
Steensel and de Lange 1997). Increased TRF1 leads to telomere shortening. The 
increased expression levels of TRF1 in CP and AP may contribute to the telomere 
shortening observed in CML. Both TRF1 and TRF2 restrict elongation of telomeres so 
a decrease in expression of these genes with disease progression suggests that in BC 
telomerase would be able to access the telomeres and the low levels of telomerase 
would be able to maintain telomere length above the critical level. High expression
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levels of TRF2 in human primary cells have been shown to prevent or delay the 
signalling of critically shortened telomeres to induce senescence (Karlseder et al. 2002). 
The presence of TRF2 expression in CML could be preventing the signalling of short 
telomeres in the patients allowing the leukaemic cells to continue to proliferate with 
critically short telomeres.
Tankyrase expression levels were significantly increased in the CD34+ cells of CML 
patients in all stages of disease. This is in agreement with previous findings in breast 
cancer where expression of Tankyrase is increased in cancerous tissue when compared 
to the adjacent normal tissue (Poonepalli et al. 2008). Overexpression of Tankyrase in 
telomerase-positive human cells inhibits the action of TRF1 and results in elongation of 
telomeres (Smith and de Lange 2000). If this is the case in CML then it could be 
concluded that increased Tankyrase expression in patients allows optimal telomerase 
elongation of telomeres by the low levels of telomerase present in the patient samples. 
The correlation noted in the expression levels of the telomere binding proteins TRF2 
and Tankyrase suggests that the parallel up-regulation of these genes could contribute to 
telomere maintenance in CML.
Seven patients successfully treated with imatinib were included in this study. 
Expression levels of hTERT were increased in the CD34+/blast cells of these patients 
compared with untreated CP patients. If hTERT expression is increased then it would 
be expected that telomere length would also increase. Indeed, it has been reported that 
peripheral blood leukocyte telomere length increases in CML patients after long term 
treatment with imatinib (Brummendorf et al. 2003).
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The expression levels of hTR, c-Myc, TRF1, TRF2, PinXl and Tankyrase in the seven 
patients included in the present study were markedly reduced as compared to untreated 
CP CML patients and were not significantly different from normal controls. 
Furthermore, the expression levels of TEP1 and TRF1 fell within the range observed in 
normal controls. These changes were also observed in serial samples taken from two 
patients pre- and post- treatment with imatinib. These results reflect the restoration of 
haematopoiesis towards normality as the leukaemic cells are depleted during treatment. 
Expression levels of the telomerase associated genes are returning to the normal range 
in the patients that have undergone successful treatment with imatinib. This is in 
agreement with a gene expression profiling study of CD34+ cells by Neumann et al. 
(Neumann et al. 2005) investigating patients in remission following treatment with 
imatinib. Neumann et al. demonstrate that most genes have unchanged expression in 
patients in cytogenetic remission after treatment when compared to normal controls. 
The patients in the present study were treated for three months, while in the 
investigation by Neumann et al. patients had undergone treatment for at least eleven 
months. It is possible that with longer periods of treatment expression of all genes 
investigated in the present study will fall within the normal range in these patients.
This data challenges the view that hTERT is always increased in cancer. The reduced 
expression of hTERT in the CD34+ cells of CML patients suggests that levels of the 
enzyme in these cells would be reduced with disease progression. Disease progression 
of CML is associated with a decrease in telomere length. It could therefore be 
suggested that decreased expression of hTERT is contributing to the shortened telomeres 
observed in CML. Expression of hTERT is likely to be reduced by the reduction of c- 
Myc expression, increased PinXl expression and by the presence of the BCR/ABL 
fusion gene. The presence of TRF2 may prevent shortened telomeres being recognised
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as double strand breaks and allow the leukaemic cells to keep dividing with critically 
short telomeres which will promote genetic instability and which can in turn lead to 
further genomic aberrations that are associated with disease progression.
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Chapter 4 
Causes of deregulated hTERT 
expression in Chronic Myeloid 
Leukaemia
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4.1 Introduction
4.1.1 Control o f hTERT gene expression by methylation
DNA methylation refers to the modification of a cytosine residue at CpG dinucleotide 
sites in the genome (Ehrlich and Wang 1981). The cytosine is methylated at position 
C5 of the CpG site and is referred to as 5-methylcytosine (Ehrlich and Wang 1981). 
Methylation is carried out by DNA methyltrasferase enzymes (Hsu et al. 1999). CpG 
sites occur in clusters along the mammalian genome and are named CpG islands (Bird 
1986). These CpG islands are estimated to be associated with the promoter regions of 
50-60% of human genes (Cross and Bird 1995; Ewing and Green 2000). Methylation of 
CpG sites is associated with lack of expression of a gene. Methylation inhibits 
transcription factor binding in the promoter region of a gene leading to repression of 
transcription (Robertson 2005). The majority of CpG sites are not methylated and CpG 
islands of normal mammalian cells are in general not methylated (Wamecke and Bestor 
2000). The primary role of methylation in the genome is to protect against 
transcriptional activation of transposon promoters by methylating these regions (Bestor
1998). Additionally, DNA methylation is essential for normal development and is 
involved in X-chromosome inactivation and imprinting (Li et al. 1993; Panning and 
Jaenisch 1998). Imprinting is the phenomenon of differential expression of the maternal 
and paternal alleles of a gene and is controlled by DNA methylation (Bartolomei and 
Tilghman 1997). A well characterised example of an imprinted gene is H I9 which 
expresses a non-coding RNA with tumour suppressor functions (Yoshimizu et al. 2008). 
Methylation of the promoter region of the paternal allele of H I9 ensures that expression 
is exclusively controlled through the maternal allele (Zhang and Tycko 1992; Jinno et
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a l 1996). This means that the paternal allele of H19 is always methylated and not 
expressed whereas the maternal allele is always unmethylated and fully active.
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Figure 4.1 DNA methylation and Modification. Biochemical changes in the structure 
of Cytosine are shown when the base undergoes methylation and subsequent 
deamination or bisulfite modification. Figure adapted from Singal and Ginder 1999.
Aberrant methylation has been proposed to contribute to carcinogenesis (Wamecke and 
Bestor 2000). Increased hypomethylation of primary human cancer cells compared to 
normal tissues was first demonstrated by Feinberg and Vogelstein (Feinberg and 
Vogelstein 1983). This loss of methylation is thought to be a result of demethylation of 
repetitive transposon elements of the genome and subsequent activation of these 
elements may contribute to genetic instability in tumour cells (Yoder et al. 1997). 
Although cancer cells undergo general hypomethylation there is also hypermethylation 
of the CpG islands of specific genes resulting in gene silencing (Issa 2004). Genome 
wide methylation analysis has revealed that CpG island methylation is present in both 
low and high grade tumours and it appears that the patterns of methylation are not
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random with some CpG islands being preferentially methylated (Costello et a l 2000). 
Indeed, CpG island methylation has been associated with reduced expression of several 
tumour suppressor genes. Methylation of the promoter CpG island of the Cyclin 
Dependant Kinase inhibitor CDKN2A has been identified in many cancers including 
lung carcinoma and gastric carcinoma and this methylation is known to lead to 
decreased expression of the gene (Oue et a l 2003; Nakata et a l 2006). CDKN2A is a 
known tumour suppressor gene that controls cell cycle progression and methylation in 
T-cell leukaemia suppresses expression and is associated with disease progression in 
these patients (Nosaka et a l 2000). The retinoic acid receptor RARB is a ligand 
activated transcription factor that limits cell growth by regulating gene expression and 
decreased RARB is associated with carcinogenesis (Xu et a l 1994; Widschwendter et 
a l 1997; Xu et a l 1997). Methylation resulting in decreased expression of RARB has 
been identified in several malignancies including cervical cancer and acute 
promyelocytic leukaemia (Chim et a l 2003; Narayan et a l 2003).
The presence of methylation at a CpG site is associated with an increase in the rate of 
mutation. The cytosine residue of a CpG dinucleotide is vulnerable to deamination, 
which when not methylated, produces uracil and is repaired by the mismatch repair 
machinery of the cell (Holliday and Grigg 1993). However, deamination of 5- 
methylcytosine produces thymine which is a normal DNA base and therefore not 
recognised by the cell as an error and so is not repaired by the cells mismatch repair 
machinery (Holliday and Grigg 1993). As a result of this the CpG dinucleotide is under 
represented in the genome and the mutation rate of the 5-methylcytosines at these sites 
is at least 12 times higher than the normal transition rate (Sved and Bird 1990).
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The hTERT CpG island has been identified and has been shown to be controlled by 
methylation. Devereux et al. assessed the hTERT promoter methylation status in normal 
tissue, immortal cells and cancer cell lines (Devereux et al. 1999). They identified 
methylation of the hTERT promoter in these samples. Although they did not identify a 
pattern of specific methylation that correlated with hTERT expression they 
demonstrated that demethylation of an hTERT negative cell line induced the cells to 
express hTERT. Interestingly, it has been shown that methylation of the hTERT 
promoter can be correlated with gene expression rather than gene silencing (Guilleret et 
al. 2002). In normal and tumour tissues hTERT expression was observed in those 
samples with hypermethylation of the hTERT promoter (Guilleret et al. 2002). 
However, it was later discovered that the hTERT CpG island can be extensively 
methylated and produce hTERT transcripts as long as levels of methylation around the 
transcription start site are low or absent (Zinn et al. 2007).
The status of methylation of the hTERT gene has been assessed in human cancers 
including gastric cancer, cervical cancer and B-cell lymphocytic leukaemia (Bechter et 
al. 2002; Gigek et al. 2009; Iliopoulos et al. 2009). Hypermethylation was shown to be 
associated with low telomerase activity in B-cell lymphocytic leukaemia and in cervical 
cancer hypermethylation was associated with cervical oncogenesis progression (Bechter 
et al. 2002; Iliopoulos et al. 2009). However, in gastric carcinomas the hTERT 
promoter was more methylated in cancer than in normal gastric mucosa and this 
correlated with an increase in hTERT protein levels (Gigek et al. 2009). Additionally, 
in colorectal cancers and cell lines increased hTERT expression correlates with 
hypermethylation of the hTERT promoter. This indicates that the role of promoter 
methylation in controlling gene expression of hTERT is complex and is unlikely to be 
the only factor contributing to control of gene expression.
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4.1.2 Control o f hTERT expression: Promoter mutation
As discussed in chapter 3 expression of hTERT is controlled by the binding of c-Myc 
and SP1 to the promoter of the gene. The hTERT core promoter is thought to be 
responsible for the transcriptional activity of the hTERT gene (Takakura et a l  1999). 
The promoter contains two E-boxes where c-Myc will bind and an SP-1 consensus 
motif where the general transcription factor SP-1 binds and these sites are required for 
activation of hTERT (Takakura et al. 1999). Mutations in these sites can significantly 
decrease activation of hTERT transcription indicating that mutation stops transcription 
factor binding (Kyo et al. 2000). The promoter also contains an Ets2 binding site. Ets 
binds the hTERT promoter at this site to transduce a signal from Epidermal Growth 
factor (EGF) to activate telomerase (Maida et al. 2002). Polymorphism of the Ets2 
binding site has been correlated with a decrease in hTERT expression in non-small cell 
lung cancer (Hsu et a l 2006). The SNP is a T to C substitution at -245 bp from the 
transcription start site and those patients with the genotype C/C or T/C at this locus 
were shown to have lower telomerase activity than T/T homozygotes.
The hTERT promoter can be methylated and given the increased rate of mutation in 
methylated CpG sites it will be of interest to investigate the mutation status of the 
hTERT promoter in CML.
4.1.3 BCR/ABL detection in CML
The BCR/ABL t(9;22) reciprocal translocation is the hallmark genetic abnormality and 
diagnostic standard of CML. The breakpoints of both BCR and ABL vary between 
patients as shown in Fig 4.2. The majority of breakpoints of BCR occur in a 5.8kb
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region termed the major breakpoint cluster region (M-BCR) (Groffen et al. 1984). M- 
BCR contains exons 12 to 16 of the BCR gene which historically were named b l to b5 
(Melo 1996). The ABL gene has two alternative first exons known as la  and lb  and 
breakpoints in this gene occur either between exons la  and lb, downstream of exon la  
or upstream of exon lb (Melo 1996). Most commonly BCR exon b2 or b3 is fused to 
ABL exon a2 upstream of ABL exon lb  giving rise to the p210 fusion protein seen in the 
majority of CML patients (Deininger et al. 2000). Sporadically BCR can also break 
within the minor breakpoint cluster region (m-BCR) between the two alternative exons 
e2’ and e2 which gives rise to an ela2 pl90 fusion product (Chan et al. 1987). This 
fusion product can be observed in patients with acute lymphoblastic leukaemia and only 
in sporadic cases of CML (Verma et al. 2009). In rare cases of CML a third type of 
transcript is observed which is a product of a fusion between BCR exon 19 and ABL a2 
(Saglio et al. 1990). This gives rise to a larger p230 fusion protein (Wilson et al. 1997).
Initial diagnosis of CML is based on the characteristic blood count showing 
overproduction of granulocytes (Hehlmann et al. 2007). Presence of the BCR/ABL 
fusion transcript is then confirmed by fluorescent in situ hybridisation and can also be 
detected by real time PCR (Hehlmann et al. 2007). Real time PCR has been used 
extensively for research purposes to monitor BCR/ABL transcripts in patients with CML 
(Hughes et al. 2006). Monitoring of BCR/ABL transcript levels by real time PCR in 
CML shows that BCR/ABL levels are significantly increased with disease progression 
(Elmaagacli et al. 2000). It has been shown that high levels in CP can predict a 
progression of disease to AP and BC (Gaiger et al. 1995). Additionally, the increase in 
BCR/ABL transcripts is an actual increase in mRNA in malignant cells and does not 
reflect an increase in levels of leukaemic cells (Gaiger et a l 1995). Measurement of 
BCR/ABL expression by Real time PCR has been introduced to routine testing for CML
110
e1 e 1 ‘ e 2 ’
BCR
e2 b1 b5 e 1 9
I I  ■II IIII I I HIIII l l l l l l l
m -BCR
ABL
M -BCR
a 2  a3
b2a2
b3a2
e1a2
e19a2
BCR/ABL
Figure 4.2 BCR/ABL breakpoint variants. Exons are represented by coloured boxes. 
The alternative first and second exons of BCR are labelled el, e l ’, e2 and e2’ and the 
breakpoint regions are indicated with double headed arrows. The common breakpoints 
of ABL are indicated by arrows. The resulting fusions transcripts are shown with the 
molecular weight of the proteins.
patients treated with imatinib. Imatinib specifically inhibits the tyrosine kinase activity 
of BCR/ABL by competitively inhibiting the ATP binding site of the enzyme (Druker et 
al. 1996; Druker and Lydon 2000). Imatinib specifically targets cells expressing 
BCR/ABL and does not affect normal cells (Druker et al. 1996; Deininger et al. 1997). 
This results in inhibition of downstream tyrosine phosphorylation by BCR/ABL 
(Druker and Lydon 2000). It is well tolerated in patients with CML and has significant 
anti-leukaemic activity (Druker et al. 2001). Treatment with imatinib results in a 
significant decrease in the levels of BCR/ABL transcripts (Muller et al. 2003).
I l l
Detection of BCR/ABL positive cells by real time PCR in patients undergoing treatment 
with imatinib is used to measure levels of residual disease during and after treatment. 
After three months of treatment this method can predict complete cytogenetic response 
within the first year (Muller et a l 2003). There has been some discussion about 
standardised procedures for monitoring BCR/ABL levels particularly with regard to an 
appropriate control gene. Initial guidelines suggested comparing expression of 
BCR/ABL to that of the untranslocated ABL allele (Gabert et a l 2003). However, using 
this approach primers designed to amplify normal ABL would also amplify BCR/ABL 
making interpretation of results problematic. It has now been suggested that more 
appropriate control genes should be considered such as p-glucuronidase or y62M 
(Hughes et a l 2006).
The constitutive activation of the BCR/ABL fusion is known to result in activation of 
numerous signalling pathways. BCR/ABL promotes cell proliferation and survival by 
activating the RAS, SHP2 and PDC-AKT pathways and downregulating ICSBP and 
JUNB (Ren 2005). It also plays a role in regulating telomere maintenance pathways, for 
example, inhibition of BCR/ABL in cell lines expressing the fusion gene results in an 
increase in telomerase activation and tankyrase expression (Bakalova et a l  2004). 
BCR/ABL can stimulate reactive oxygen species that can cause DNA damage including 
mutations and double strand breaks (Nowicki et a l 2004). These are not repaired 
faithfully as BCR/ABL can promote unfaithful double strand break repair resulting in 
cytogenetic abnormalities and genomic instability which are thought to be required for 
progression of carcinogenesis (Skorski 2002; Nowicki et a l  2004).
Other proteins activated by BCR/ABL include RAS and JAK transducers and activators 
of transcription. BCR/ABL has been shown to phosphorylate the signal transducer and
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activator of transcription STAT5 and this leads to constitutive activation of STAT5 
(Ilaria and Van Etten 1996). STAT5 regulates cell proliferation, differentiation and 
apoptosis and it’s activation by BCR/ABL is thought to contribute to cell proliferation 
(Ilaria and Van Etten 1996; Nosaka et al. 1999). When STAT5 is activated by 
BCR/ABL it can induce expression of BCL-xL which has anti-apoptotic functions and 
may contribute to apoptosis resistance in CML cells (Horita et a l 2000). Additionally, 
BCR/ABL phosphorylates JAK2 to induce tyrosine kinase activation and this has been 
detected in peripheral blood of BC CML patients and may be a contributing factor in 
disease transformation in CML (Xie et a l  2001).
4.1.4 Aims o f  the study
The aims of this study were to gain further insight into the mechanisms leading to the 
deregulated gene expression of telomerase associated genes identified in Chapter 3. 
The investigation of the methylation and mutation status of the hTERT promoter will 
further understanding of these processes in CML and investigate any involvement in 
levels of hTERT gene expression. Investigation into levels of the BCR/ABL fusion 
product will identify correlations with deregulated gene expression and disease 
progression.
4.2 Materials and methods
4.2.1 Methylation specific PCR (MSP)
Genomic DNA from patient and control samples as detailed in chapter 3 were bisulfite 
modified along with universally methylated and unmethylated DNA controls by means
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of the CpGenome DNA modification kit (Chemicon/Millipore, Billerica, MA, USA). 
PCR was then carried out according the protocol in Chapter 2 using the primer sets 
detailed in Table 4.1 specific for methylated and unmethylated DNA in the 5’region and 
3’ region (including the transcription start site) of the hTERT promoter. Control primers 
were also included to identify any unmodified DNA. A touchdown PCR protocol was 
used where the annealing temperature is initially 70°C and decreases by 1 °C each cycle 
for 10 cycles. A further 30 cycles were then performed with an annealing temperature 
of 60°C.
Table 4.1 Methylation Specific PCR primers for hTERT  promoter regions
Prim er Name Sequence 5’-3’
hTERT 5U F GTGGGTATAGATGTTTAGGATTGT
hTERT 5U R CCACATACACAACAAAACACAACA
hTERT 5M F GGGTATAGACGTTTAGGATCGC
hTERT 5M R CGTACGCAACAAAACGCAACG
hTERT 3U F AGTTTTGGTTTTGGTTATTTTTGT
hTERT 3U R AAACACTAAACCACCAACACA
hTERT 3M F AGTTTTGGTTTCGGTTATTTTCGC
hTERT 3M R CAAACACTAAACCACCAACGCG
hTERT NmodF GGCCGATTCGACCTCTCT
hTERT NmodR AAGGTGAAGGGGCAGGAC
4.2.2 Cycle sequencing o f  hTERT promoter regions
The hTERT promoter regions were identified and primers were designed to amplify the 
appropriate regions using the primer 3 software. Primer sets 2 and 3 both include the 
known Ets2 site polymorphism. Genomic DNA from CD34+ patient and control DNA 
samples was then amplified and subjected to cycle sequencing as detailed in Chapter 2. 
Primer sequences are detailed in Table 4.2 and annotated on the sequence in Fig 4.3
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Table 4.2 hTERT  promoter PCR and sequencing primers
Prim er Name Sequence 5’-3’
hTERT IF AACAGATTTGGGGTGGTTTG
hTERT 1R GCCTAGGCTGTGGGGTAAC
hTERT 2F CGTCCTCCCCTTCACGTC
hTERT 2R CAGCGCTGCCTGAAACTC
hTERT 3F GGCCGATTCGACCTCTCT
hTERT 3R AGCACCTCGCGGTAGTGG
t c c a t t t c c c  a c c c t t t c t c  g a c g g g a c c g  c c c c g g t g g g  t q a t t a a c a q  a t t t q q q q t q
q t t t g c t c a t  g g t g g g g a c c  c c t c g c c g c c  t g a g a a c c t g  c a a a g a g a a a  t g a c g g g c c t
g t g t c a a g g a  g c c c a a g t c g  c g g g g a a g t g  t t g c a g g g a g  g c a c t c c g g g  a g g t c c c g c g
t g c c c g t c c a  g g g a g c a a t g  c g t c c t c g g g  t t c g t c c c c a  g c c g c g t c t a  c g c g c c t c c g
t c c t c c c c t t  c a c q t c c q q c  a t t c g t g g t g  c c c g g a g c c c  g a c g c c c c g c  g t c c g g a c c t
g g a g g c a g c c  c t g g g t c t c c  g g a t c a g g c c  a g c g g c c a a a  g g g t c g c c g c  a c g c a c c t g t
t c c c a g g g c c  t c c a c a t c a t  g g c c c c t c c c  t c q q q t t a c c  c c a c a q c c t a  q q c c q a t t c q
a c c t c t c t c c  g c t g g g g c c c  t c g c t g g c g t  c c c t g c a c c c  t g g g a g c g c g  a g c g g c g c g c
g g g c g g g g a a  g c g c g g c c c a  g a c c c c c g g g  t c c g c c c g g a  g c a g c t g c g c  t g t c g g g g c c
a g g c c g g g c t  c c c a g t g g a t  t c g c g g g c a c  a g a c g c c c a g  g a c c g c g c t c  c c c a c g t g g c
g g a g g g a c t g  g g g a c c c g g g  c a c c c g t c c t  g c c c c t t c a c  c t t c c a g c t c  c g c c t c c t c c
g c g c g g a c c c  c g c c c c g t c c  c g a c c c c t c c  c g g g t c c c c g  g c c c a g c c c c  c t c c g g g c c c
t c c c a g c c c c  t c c c c t t c c t  t t c c g c g g c c  c c g c c c t c t c  c t c g c g g c g c  q a q t t t c a q q
c a q c q c t g c q  t c c t g c t g c g  c a c g t g g g a a  g c c c t g g c c c  c g g c c a c c c c  c g c g a t g c c g
c g c g c t c c c c  g c t g c c g a g c  c g t g c g c t c c  c t g c t g c g c a  q c c a c t a c c q  c q a q q t q c t q
Figure 4.3 hTERT  promoter sequence. The start codon is highlighted in red. The 
SNP at -245 bp is the C nucleotide highlighted in red. The E box sequences where c- 
Myc binds are highlighted in blue and Spl consensus motifs are highlighted in green. 
Ets2 binding sites are highlighted in grey and underlined. Primer sequences are 
underlined and detailed in Table 4.2.
4.2.3 Measurement o f  BCR/ABL transcripts by real time PCR
Multiplex PCR to identify BCR/ABL breakpoint was carried out on cDNA from all 
patient samples as detailed in chapter 2. Primer sequences were modified from those 
described by Cross et a l (Cross et a l 1994) to amplify BCR/ABL fusion transcripts as 
follows: Normal BCR 808bp, pl90 BCR/ABL 481bp, p210 b3a2 BCR/ABL 385bp and 
p210 b2a2 BCR/ABL 310bp. The following primers were used in a multiplex PCR with 
an annealing temperature of 64°C:
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C5e: 5’-CAGCTCTCCTTTGCAACCGGGTCTGAA-3’
CA3: 5’-TGTTGACTGGCGTGATGTAGTTGCTTGG-3’
BCR-C: 5 ’ -ACCGCATGTTCCGGGACAAAAG-3 ’
B2B: 5 ’-ACAGCATTCCGGTGACCATCAATAAG-3 ’
Absolute expression levels of BCR/ABL were calculated in relation to p2M  against a 
plasmid standard curve of known cDNA copy number. For the B2M  standard curve 
plasmid pLJCB2M.5 PCR products were generated from control cDNA using primers 
described in section 3.2.3 and cloned into the pGEM-T Easy vector system (Promega, 
Madison, WI). Positive clones were selected, extracted using Wizard plus minipreps 
(Promega) and then sequenced for confirmation of their insert using M l3 sequencing 
primers (Big Dye Terminator cycle Sequencing Kit, Version 1.1, and ABI 3100 
Genomic Analyser, Applied Biosystems). For quantification of p210 BCR/ABL the 
plasmid pNC210/G was used, kindly provided by Dr J Kaeda (Hammersmith Hospital, 
London, UK).
Plasmids were quantified spectrophotometrically and the mass of a single plasmid was 
calculated from the size of the vector and insert. This value was used to calculate the 
concentration of plasmid DNA needed to achieve the copy numbers of interest. 
Plasmids were linearised and serially diluted in nuclease free H2O with 50pg/ml E.coli 
16s and 23s rRNA (Roche, Manheim Germany) as a background nucleic acid to mimic 
the unknown samples. Successive dilutions were prepared in the range 107 - 103 copies 
for pNC210/G and 109 - 104 for pLJCB2M.5, with steps at every half order of 
magnitude on a logarithmic scale. Correlation coefficients (r2) for calibration curves 
were always greater than 0.99 and mean slopes of the curves were -3.47 for B2M and - 
3.31 forp210.
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The standard curve method was used to extrapolate the exact copy number present in 
the patient samples. A standard curve of plasmid DNA calibrators was derived by 
plotting the Ct values for each plasmid dilution against the log copy number of the 
plasmid. B2M was used as the control gene to compensate for any differences in input 
RNA and efficiency of the reverse-transcriptase reaction. BCR/ABL primers and probe 
were as described by Gabert (Gabert et al. 2003). Normalised copy number of 
BCR/ABL transcripts was expressed as a percentage of B2M  transcript copy number.
4.3 Results
4.3.1 hTERT promoter methylation status in CML
The hTERT promoter region CpG island was identified from the genbank file 
AF097365 corresponding to the hTERT promoter region and partial coding sequence 
using MethPrimer online software (Li and Dahiya 2002). Genomic DNA from CD34+ 
cells of CML patients and normal controls was first subjected to bisulfite treatment, 
which will convert all unmethylated cytosines to uracil. PCR using primers specific for 
methylated or unmethylated DNA was then used to distinguish the methylation status of 
the DNA. Two promoter regions of hTERT representative of the 5’ and 3’ ends of the 
hTERT CpG island were amplified using primer pairs specific for methylated or 
unmethylated DNA. All patients and controls described in Chapter 3 were used for this 
part of the study. Amplified DNA fragments were visualized by means of agarose gel 
electrophoresis.
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4.3.1.1 hTERT promoter methylation in CD34+ cells
Methylation specific PCR (MSP) shows that both the 3’ and 5’ promoter regions of the 
hTERT promoter are not methylated in the CD34+ cells of CML patients and of normal 
controls. In Fig 4.4a it can be seen that only the primers specific for unmethylated DNA 
yield a PCR product in these samples. There was, however, one exception: The 5’ 
promoter region of the sample from patient 21 taken in accelerated phase of disease. A 
PCR product was produced using primers specific for both methylated and 
unmethylated DNA in this region. However, this result was not reproducible (Fig 4.4b). 
Two separate PCR amplifications give product for methylated and unmethylated DNA 
and two additional separate PCR amplifications give product for unmethylated DNA 
only. Methylated DNA in the 3’ promoter region of this sample was not amplified by 
the primers specific for methylation in this region.
To further investigate this result the methylation specific PCR products were sequenced 
in a selection of cases including pt 21. Cycle sequencing was carried out using the ABI 
3100 machine with the MSP primers. Analysis of the sequencing data shows that all 
CpG sites amplified by the primers specific for unmethylated DNA are not methylated. 
Sequencing of PCR products specific for methylated DNA shows that 12 out of 13 CpG 
sites in this region are methylated in patient 21. Fig 4.5
Since all but the sample from pt 21 do not yield any PCR product using primers specific 
for methylated DNA it is important to include a positive control for these primers. 
Universally methylated DNA was used as a positive control for methylated primers to 
confirm successful PCR amplification, as shown in Fig 4.4a.
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Figure 4.4 Methylation Specific PCR of the hTERT  promoter region. U= PCR with 
primers specific for unmethylated DNA, M= PCR with primers specific for methylated 
DNA. (a) MSP of CD34+ cell DNA from one patient sample and from universally 
methylated (+) DNA controls, (b) MSP of DNA from patient 21 showing amplification 
of methylated and unmethylated DNA in the left hand panel and only unmethylated 
DNA in the right hand panel, (c) MSP of H I9 in a patient sample showing 
amplification of methylated and unmethylated DNA.
4.3.1.2 hTERT promoter methylation in Neutrophils
To investigate methylation between different cell types and disease bisulfite modified 
DNA from peripheral blood neutrophils of 10 CML patients, four cases of Acute 
Myeloid Leukaemia and 6 normal controls was tested. This DNA was amplified using 
the primers specific for methylated or unmethylated hTERT promoter DNA. This 
Methylation specific PCR shows that the hTERT promoter is not methylated in the 5’ 
and 3’ CpG sites in neutrophils of CML and AML patients or in normal control 
neutrophils. A neutrophil DNA sample from pt 21 in AP was included in this analysis 
and this was also negative for methylation of both hTERT promoter regions.
Figure 4.5 Cycle sequencing of Methylation specific PCR products. CpG islands are 
highlighted by black boxes and underlined, (a) Unmethylated C has been converted to 
T by bisulfite modification, (b) Sample from pt 21. Methylated C has been protected 
from bisulfite modification by methylation.
4.3.13 Specificity o f  Methylation Specific PCR
To ensure that any results obtained from methylation specific PCR of patient samples 
were that from genuine DNA of defined methylation status a control gene of known 
methylation status was amplified for all patient and control samples. The imprinted 
HI 9 gene gives a positive control for the detection of methylation status in these cells, 
one copy is always methylated and one copy is always unmethylated. Therefore, PCR 
specific for methylated or unmethylated H19 DNA should always be positive in patient 
and control samples. This was the case for all samples analysed, see Fig 4.4c.
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4.3.2 hTERTpromoter mutation status
Cycle sequencing of the hTERT promoter using three overlapping primer sets was used 
to analyse the hTERT promoter in genomic DNA from the CD34+ cells of CML patients 
and normal controls. DNA was not available for three of the patients. Differences 
between the known hTERT promoter sequence and sequences obtained from the 
samples studied were identified using pairwise analysis of sequences using Sequence 
Analysis software.
Mutation analysis of the hTERT promoter has confirmed the presence of a SNP at -245 
bp from the hTERT transcription start codon in the Ets2 binding site, as reported by 
(Hsu et al. 2006) (Fig 4.6a,b,c). This SNP was found to have the genotype C/C, T/C or 
T/T. The most common genotype in patient and control groups was T/T, 12 patients 
and 8 of 11 normal controls had this genotype. Five patients and one control had the 
C/C genotype and four patients and two controls were T/C heterozygotes. Where serial 
DNA samples were available from a single patient (Pt 17, Pt 21, Pt 22) the hTERT 
promoter SNP genotype did not change between samples. It has been previously 
reported that the C/C and T/C genotypes correlated with lower telomerase activity (Hsu 
et al. 2006). The genotype of the SNP was correlated with hTERT expression in patients 
and controls but there was no significant difference in the levels of hTERT expression 
between the samples with T/T genotype versus the C/C and C/T groups. Similarly there 
was no difference in expression observed when comparing the C/C genotype to the C/T 
genotype. Therefore, no correlation was identified between T/T, T/C or C/C genotype 
at the Ets2 binding site and reduced expression of hTERT. In fact, one of the samples 
with highest hTERT expression levels (ratio 1.64) was P tll who was homozygous for 
the C/C genotype.
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Additional base changes were found in three patients and two normal controls. One 
patient and one control had a heterozygous C to T mutation at position -613 (Fig 4.6f). 
A further control sample had a homozygous C to T change of this nucleotide (Fig 4.6e). 
This control also had a homozygous A to G mutation at position -699 (Fig 4.6d). These 
mutations did not correlate with hTERT expression. Two further patient samples 
showed a heterozygous C to A base change at position -578 (Fig 4.6g). This mutation 
was not seen in any of the normal control samples. Comparing hTERT expression in 
these two patients ptl4 and pt20 ratio 0.08 and 0.95 respectively it appears that this 
change does not correlate with hTERT expression.
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Figure 4.6 hTERT  promoter sequence variation in CML. Variation is indicated by a 
black arrow, (a) C/C genotype at -245 bp. (b) T/C genotype at -245 bp. (c) T/T 
genotype at -245 bp. (d) A to G substitution at -699 bp. (e) C to T substitution at -613 
bp. (f) A heterozygous C to T substitution at -613 bp. (g) A heterozygous C to A 
substitution at -578 bp.
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4.3.3 BCR/ABL transcript levels in CML
4.3.3.1 Identification o f transcript variant in patient samples
The Philadelphia chromosome has two common breakpoints. BCR exon b2 or b3 is 
fused to ABL exon a2 giving rise to the p210 fusion protein seen in the majority of CML 
patients. In sporadic cases of CML BCR exon el is fused to ABL exon a2, encoding the 
p i90 fusion protein. It was therefore necessary to establish the transcript variant that 
each patient expressed in order to use the appropriate real time PCR assay. cDNA of 
CML patients was typed for transcript variant using multiplex PCR primers designed to 
produce PCR products of different sizes corresponding to the three possible breakpoints 
in BCR. This method uses four primers designed to give different bands depending on 
the fusion transcript: Normal BCR 808bp, p i90 BCR/ABL 481bp, p210 b3a2 BCR/ABL 
385bp and p210 b2a2 BCR/ABL 3 lObp. Visualisation of these PCR products by agarose 
gel electrophoresis reveals that all patients studied express the most common p210 
BCR/ABL transcript variant, Fig 4.7. In patients treated with imatinib only the normal 
BCR gene and not the BCR/ABL fusion transcript was detected by PCR. Only one type 
of fusion transcript was detected in each patient. The cell line K562 was included as a 
positive control for BCR/ABL amplification and normal control neutrophils as a control 
for normal BCR amplification.
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Figure 4.7 Agarose gel electrophoresis of BCR/ABL transcript variant PCR. PCR
products were resolved on a 1.8% agarose gel. K562: cDNA from the K562 cell line, 
BCR/ABL -ve: normal control neutrophil cDNA. P tl l  is normal BCR, Ptl3 is P210 
b2a2 and ptl4  is P210 b3a2.
4.3.3.2 Real time PCR monitoring of BCR/ABL transcript levels
Absolute expression levels of BCR/ABL were calculated in relation to p2M  against a 
plasmid standard curve of known cDNA copy number. Levels of BCR/ABL transcripts 
are expressed as a percentage of f32M transcripts. Statistically significant differences in 
expression levels between the patient groups were investigated using Mann-Whitney or 
Kruskal-Wallis non parametric tests where appropriate. Results are summarised in table 
4.3. Expression levels of BCR/ABL in chronic phase were variable ranging from 0.07 to 
109.6 with a median of 23.5. Excluding samples from patients treated with imatinib, 
three out of the twelve samples from chronic phase were receiving treatment. These 
three patients had BCR/ABL expression levels below the median for CP and p tl, who 
had been in CP for twelve years and was being treated with interferon, had the lowest 
expression level in this group at 0.07. Median BCR/ABL expression for untreated CP 
patients is 27.7 and for the three patients treated with interferon or hydroxyurea median 
BCR/ABL is 0.17. These differences are not quite significant (p=0.063). BCR/ABL
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Levels in AP and BC patients appear more constant than the CP group and median 
expression is slightly lower than CP at 20.3 and 20.93, respectively. These differences 
do not reach statistical significance (p=0.19). All patients in AP and BC were receiving 
some kind of treatment, see table 3.1. In a single patient (pt21) where serial samples are 
available BCR/ABL levels decrease with disease progression from 39.09 at diagnosis in 
CP to 20.27 in AP and 20.93 in BC following treatment with hydroxyurea.
Table 4.3 BCR/ABL expression levels in CML patients.
Disease Status Range Median
CP 0.07-109.6 23.5
AP 12.8-25.2 20.3
BC 10.4-51.9 20.93
STI 5.6 x 10° - 0.38 0.002
4.3.3.3 Real time PCR for BCR/ABL transcript levels in patients treated with imatinib
Samples were available from seven patients following three months of treatment with 
imatinib. The action of this drug reduces the number of BCR/ABL positive cells and 
therefore reduces BCR/ABL transcript levels. All patients showed partial or complete 
cytogenetic response to treatment after three months. Levels of BCR/ABL in patients 
treated with imatinib were very low with expression levels ranging from 5.6 x 10'5 to 
0.38 and a median of 0.002. Moreover, expression was significantly reduced as 
compared to CP patients, P=.0008. Median expression of BCR/ABL in the patients 
treated with imatinib is lower than the CP patients undergoing other treatments, 
however these differences are not statistically significant. In serial samples from two 
patients treated with imatinib BCR/ABL levels were greatly reduced after three months
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of treatment. In pt 17 BCR/ABL levels decrease from 109.6 in untreated CP to 0.38 
after treatment and in pt 22 levels decrease from 27.7 to 0.001 after treatment.
4.4 Discussion
Investigation of the methylation status of the hTERT promoter region in both CD34+ 
cells and neutrophils reveals that the promoter region is not methylated in CML or 
normal control samples. In general, methylation of the promoter region of a gene 
results in reduced expression of that gene and there is evidence to suggest that this is the 
case for hTERT. Investigation of methylation in the bone marrow of patients with B- 
cell lymphocytic leukaemia reveals that those'patients that have low telomerase activity 
also exhibit more hTERT promoter methylation than those patients with high telomerase 
activity (Bechter et al. 2002). In contrast to this it has been demonstrated that HL-60 
leukaemia cells treated with a demethylating agent exhibit reduced hTERT expression 
(Hajek et al. 2008). It has been shown in cancer cells lines that hTERT is expressed 
despite promoter methylation (Guilleret et al. 2002). It has been suggested high levels 
of promoter methylation of hTERT can be present as long as levels of methylation 
around the transcription start site are low or absent (Zinn et al. 2007). In the current 
study this region was amplified by the primers specific for the 3’ region of the promoter 
and no methylation was found. Absence of promoter methylation of hTERT can 
decrease transcription by allowing the binding of negative regulators of transcription. 
For example, the ubiquitously expressed CCCTC-binding factor (CTCF) which binds to 
GC-rich sequences to inhibit transcription in the absence of DNA methylation 
(Lobanenkov et al. 1990; Renaud et al. 2007). CTCF has been shown to inhibit hTERT 
transcription in this way (Renaud et al. 2005). CTCF binds the first exon of the hTERT 
gene, the majority of which was amplified by the primers used in this study to amplify
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the 3’ region of the hTERT CpG island (Renaud et a l 2007 122). This region was 
shown to be unmethylated in patient and control samples. It can be speculated that the 
absence of methylation around this site and the other promoter regions studied is not 
directly effecting the expression of hTERT in the CML patients. Therefore, methylation 
of the hTERT promoter region does not appear to cause the reduction in hTERT 
expression in patients with CML. However the absence of methylation in these cells 
could lead to repression of hTERT transcription by allowing the binding of CTCF which 
would lead to the observed reduction in transcription. This reveals another potential 
mechanism underlying the reduced hTERT expression seen in the CML patients and it 
would be of interest to investigate if aberrant expression of CTCF is involved in disease 
progression of CML.
The one exception to this is a sample from pt 21 in AP where a positive result for 
methylation was seen using primers amplifying the 5’ promoter region. However, this 
was not reproducible. It is unlikely that this result was due to contamination as there 
was never product seen in the negative control and the result was restricted to this 
sample. It may be the case that a small number of clones were present in this sample 
which did have methylation of the hTERT promoter. However, as there are serial 
samples available from this patient which were all negative for methylation it may be 
the case that this result was an artefact. Additionally, methylation is this region will not 
necessarily have an effect on hTERT expression as it has been demonstrated that the 
hTERT promoter can be methylated and still express hTERT as long as the region 
around the start site (amplified by the 3’ primers) is not methylated (Zinn et a l 2007).
Sequencing of the hTERT promoter region was carried out to investigate the presence of 
a SNP in the Ets2 binding site at -245 bp from the start codon that results in decreased 
expression of hTERT (Hsu et a l 2006). The region sequenced also contains two E-
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boxes where c-Myc will bind and an SP-1 consensus motif where the general 
transcription factor SP-1 binds. In agreement with the study by Hsu et al. the most 
frequent genotype detected for the SNP at -245 was T/T homozygote. In the samples 
with either C/T or C/C genotype it was not possible to confirm the relationship between 
this genotype and reduced hTERT expression. This suggests that in the CD34+ cells of 
the CML patients in the current study the SNP at -245 bp is not regulating hTERT 
expression. A total of twelve samples were shown to have either C/T or C/C whereas in 
the study by Hsu et al. 57 samples had either of these two genotypes. It may be the case 
that a higher sample number in the present study would increase the statistical power 
allowing a relationship to be observed.
ETS2 has been shown to directly interact with c-MYC in breast cancer cell lines (Xu et 
al. 2008). When c-MYC is reduced ETS2 binding at its site in the hTERT promoter is 
inhibited and the authors suggest that these two proteins form a complex when binding 
the promoter and together regulate hTERT transcription. Additionally, ETS2 expression 
is required for expression of c-MYC and in the absence of these two proteins hTERT 
transcription is switched off. In the present study c-MYC expression is reduced and this 
may lead to reduced binding of ETS2 at the hTERT promoter which could contribute to 
the reduced hTERT expression. It can also be suggested that ETS2 may itself be 
reduced and this could be a cause of a reduction in c-Myc expression. However, reports 
of gene expression analysis in CML suggest that ETS2 expression is increased in CML 
(Nowicki et al. 2003).
The other mutations observed in the hTERT promoter region were not in the region of 
known binding sites of transcriptional activators or repressors of hTERT. The base 
changes seen here may be infrequent SNPs that do not influence transcription levels of 
hTERT. Therefore, it could be concluded that the base pair changes observed in the
128
hTERT promoter are not a direct cause of the reduced hTERT expression observed in 
CML.
Expression levels of BCR/ABL were measured in the CD34+ cells of CML patients by 
real time PCR. Analysis of patients in CP that were sampled at diagnosis and before 
treatment had higher BCR/ABL levels than the patients who were undergoing treatment. 
This includes patients that were treated with interferon (Pt 1 and Pt 19) or hydroxyurea 
(Pt 13). Treatment with these agents can control CML and patients do have a 
cytogenetic response, although this is rare with hydroxyurea. This suggests that a 
decrease in the numbers of BCR/ABL positive cells would be expected after treatment. 
Therefore the reduced expression in the three patients treated with interferon or 
hydroxyurea could be a reflection of the choice of treatment. In fact, in a CML cell line 
KT-1, treatment with interferon reduced the expression of the BCR/ABL fusion gene 
(Yanagisawa et al. 1998). Additionally, using real time PCR monitoring it has been 
shown that BCR/ABL transcript levels are reduced in patients after treatment with 
interferon and some patients achieve a complete cytogenetic response (Muller et al. 
2003). This is likely to be the case for Pt 1, who had been in CP for twelve years and 
was being treated with interferon and had the lowest BCR/ABL expression level in this 
group at 0.07. This suggests that the number of leukaemic CD34+ cells in this patient 
have been greatly reduced by treatment.
Serial samples were available for pt 21 in disease progression from CP, AP and BC. It 
may be expected that as the disease is progressing expression of BCR/ABL would 
increase. However, this was not the case and expression of BCR/ABL in AP and BC 
was lower than the CP sample at diagnosis from this patient. This patient was being 
treated with hydroxyurea in AP and BC which inhibits ribonucleotide reductase to stop
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cells dividing and is thought to increase survival in CML patients by slowing 
proliferation rates of granulocytes (Hehlmann et a l 1993). This could mean that CD34+ 
cell proliferation rates in this patient may be regulated in part by treatment with 
hydroxyurea resulting in steady levels of BCR/ABL transcripts after treatment.
In the patients treated with imatinib BCR/ABL transcript levels are greatly reduced 
compared to untreated CP patients. Imatinib directly inhibits the BCR/ABL fusion 
protein to reduce the number of leukaemic cells. This results in a decrease in levels of 
BCR/ABL transcripts as seen in the current study. This result is in agreement with 
several other studies that also show reduced BCR/ABL expression after treatment with 
imatinib (Wang et a l 2002; Kantaijian et a l 2003; Muller et a l 2003; Press et a l 
2006). This reflects the return of normal haematopoiesis as cells expressing BCR/ABL 
are eliminated. As described in chapter 3 it has been shown in the current study that 
levels of hTERT transcription in the patients treated with imatinib are increased when 
compared with untreated CP patients. In the treated patients a decrease in BCR/ABL 
expression correlates with an increase in hTERT expression. It could be suggested that 
this decrease in BCR/ABL expression could lead to the increase in hTERT expression as 
the cells expressing BCR/ABL are eliminated. This is in agreement with a study 
showing that inhibition of BCR/ABL in human cell lines promotes hTERT expression 
and this appears to be happening in the patients in this study that were treated with 
imatinib (Bakalova et a l  2004). Interestingly, it has been shown that in patients that 
have undergone long term treatment with imatinib telomeres are extended 
(Brummendorf et a l 2003). This suggests a link between the decrease in BCR/ABL 
after treatment with imatinib and increased hTERT expression leading to an increase in 
telomere length as the leukaemic cells are eliminated.
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The reduction of hTERT expression in observed in the CD34+ cells of CML patients 
may be partly caused by the BCR/ABL fusion protein inhibiting hTERT expression. 
This effect could be enhanced by the absence of methylation of the hTERT promoter 
which would allow binding of negative regulators of transcription such as CTCF. 
Mutation of promoter regions of hTERT do not appear to play a role in reducing 
expression, however, a reduction in c-MYC expression could reduce binding of the 
positive transcriptional activator ETS2 to its promoter binding site contributing to the 
reduction of hTERT expression.
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Chapter 5 
Gene Expression Profiling of 
Platelets and Neutrophils of Patients 
with Essential Thrombocythaemia
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5.1 Introduction
5.1.1 Clinical characteristics o f ET
The myeloproliferative neoplasms are clonal disorders resulting in an overexpansion of 
cells of the myeloid lineage and include Chronic Myeloid Leukaemia (CML), Essential 
Thrombocythaemia (ET) and Polycythaemia Vera (PV). PV typically has increased 
erythrocytosis but it is common for patients to have proliferation of the erythroid, 
megakaryocyte and granulocyte lineages (Levine and Gilliland 2008). Where CML 
exhibits an over proliferation of granulocytes ET displays increased megakaryocyte 
proliferation (Tefferi and Vardiman 2008). ET is characterised by dysmorphic 
megakaryocyte production leading to excessive platelet production resulting in a 
significant risk of thrombohaemorrhagic complications. (Wolanskyj et a l 2005) 
However, the median survival of patients is more than 20 years and up to 10% will 
transform into an acute leukaemia. (Wolanskyj et al. 2005) Karyotypic abnormalities in 
ET are rare and it is estimated that only 5% of patients have cytogenetic abnormalities 
at diagnosis and these do not appear to be prognostically useful (Beer et al. 2011). 
Trisomy 8 and 9 have been observed in multiple cases of ET pre transformation (Elis et 
al. 1996). Duplication of the long arm of chromosome 1, deletion of 20q and 13q are 
also observed in numerous cases (Bench et al. 2001; Steensma and Tefferi 2002). 
Approximately 3% of patients carry the mutation MPL W515L/K which does not appear 
to represent a distinct disease phenotype but can be of diagnostic importance 
(Vannucchi et al. 2008). The most common molecular abnormality in these patients is 
the JAK2V6\1¥ mutation (Beer et a l 2011).
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5.1,2 TheJAK2 V617F mutation
JAK2 is a member of the Janus kinase family and is a ubiquitously expressed protein 
tyrosine kinase that functions to mediate cytokine signalling. (Kisseleva et al. 2002) 
Cytokines bind haematopoietic cytokine receptors and use JAK kinases to initiate signal 
transduction which regulates the proliferation and differentiation of haematopoietic 
cells. (Murray 2007)
The JAK2 V617F mutation was first described in 2005 by several groups and was 
reported to be present in the majority (approximately 95%) of patients with PV and 
approximately 50-60% of ET patients (Baxter et al. 2005; James et al. 2005; Kralovics 
et al. 2005; Levine et al. 2005; Zhao et al. 2005). The mutation, in exon 14 of the JAK2 
gene on chromosome 9p24 is a G to T point mutation that results in valine at amino acid 
617 being substituted with phenylalanine. In those patients where the mutation was 
homozygous it has been shown that this homozygosity was a result of mitotic 
recombination (Baxter et al. 2005; Kralovics et al. 2005).
The mutation affects the pseudokinase domain of JAK2 which is thought to have a 
function in inhibiting kinase domain activity (Saharinen et al. 2000). The mutation 
results in a conformational change of the pseudokinase domain leading to constitutive 
activation of the kinase activity (Zhao et al. 2005). Similar to the activated kinase 
BCR/ABL being sufficient to cause CML, JAK2 V617F has been shown to be sufficient 
for development of PV in mice receiving a bone marrow transplant which was 
transduced with JAK2 V617F (Lacout et al. 2006; Wemig et al. 2006).
Several groups have investigated the differences between JAK2 V617F positive and 
negative patients with ET and PV. These studies are in agreement that ET patients with
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the mutation have higher haemoglobin concentrations, neutrophil counts and total white 
cell counts than those without (Antonioli et a l 2005; Campbell et a l 2005; Wolanskyj 
et a l 2005; Zhang et a l 2008). These characteristics are phenotypically similar to PV 
and it has been suggested that the mutation divides ET patients into two subtypes: One 
type JAK2 V617F positive with similar characteristics to PV; and the other JAK2 
V617F negative exhibiting classical clinical features of ET (Campbell et a l 2005). 
Although the JAK2 mutation is diagnostically important it cannot be used to distinguish 
between ET and PV, therefore histological analysis is still essential for diagnosis of 
these patient samples. The factors responsible for ET and its transformation to acute 
leukaemia remain largely unknown.
5.1.3 Platelets and markers
Platelets are cytoplasmic fragments produced from megakaryocytes and contain no 
genomic DNA (Newman et a l 1988). However, they do retain some RNA (estimated 
to be 0.002 fg per cell) derived from megakaryocytes and the translational machinery 
required for protein production (Newman et a l 1988; Schedel and Rolf 2009). Platelets 
are activated by the coagulation cascade and have a role in maintaining vascular 
integrity (Ho-Tin-Noe et a l 2011).
There have been limited studies characterising the RNA from platelets by microarray. 
These studies have shown that the most abundant transcripts in platelets are those 
encoding well characterised platelet genes such as Platelet factor 4 (PF4), glycoprotein 
lib and glycoprotein Iba (GP1BA). Genes involved in cytoskeletal organisation and 
immune response were also present. Interestingly, several genes with unknown 
function in platelets were also expressed: neurogranin which is a PKC substrate and
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Clusterin which inhibits complement lysis. Given the limited amount of RNA in 
platelet samples it is important to achieve high purity of the sample before analysis.
5.1.4 cDNA Microarray analysisc
DNA microarrays are an important tool for the analysis of relative abundance of mRNA 
transcripts in a cell population. The arrays allow the analysis of global gene expression 
in many different scenarios such as disease versus normal, changes is expression during 
the cell cycle or development (Gershon 2002). cDNA arrays consist of cDNA or 
oligonucleotide sequences that are spotted onto a glass microscope slide by high 
precision robots (Holloway et al. 2002). The cDNAs are typically PCR products from 
cDNA clone sets such as the IMAGE consortium clones or oligonucleotides ranging in 
size from 50 -70 bases that are specific to known genes (Holloway et al. 2002). To 
compare the gene expression patterns in two different samples by cDNA microarray 
analysis the samples are first labelled with either Cy3 or Cy5 fluorescent dyes. The 
labelled samples are then competitively hybridised to the same microarray slide where 
the labelled nucleic acids will hybridise specifically to their corresponding cDNA on the 
array. The fluorescence intensity of each dye on each spot on the microarray is then 
measured by a specialised scanner and the measurements are overlaid to provide a gene 
expression ratio for each gene. The experimental process is summarised in Fig 5.1. The 
arrays used in this study were provided by the Sanger Institute (Cambridge, UK) and 
contain 9,932 cDNA spots representative of 6,000 known human genes and ESTs which 
can all be analysed simultaneously.
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Figure 5.1 Overview of a cDNA m icroarray experiment. Image adapted from 
Duggan et al. 1999.
5.1.5 Aims o f  the study
The aims of this section of the study are to investigate the feasibility of separating a 
pure population of platelets from peripheral blood and to analyse these samples by gene 
expression profiling. Neutrophil samples will also be collected to investigate 
differences in gene expression of JAK2 V617F positive neutrophils in ET and PV. It is 
hoped that microarray analysis will identify differentially expressed genes to aid with 
diagnosis of these disorders where currently the only widely used molecular marker is 
the JAK2 V617F mutation. These samples will also be compared with neutrophils from 
CML patients expressing the activated tyrosine kinase of the BCR/ABL fusion transcript 
which is the definitive molecular marker for CML.
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5.2 Materials and Methods
5.2.1 Samples
Neutrophil fractions were separated using the Histopaque reagent from peripheral blood 
of twelve ET, three PV and five normal controls as described in chapter 2. Patient 
details are shown in table 5.1. RNA and genomic DNA were extracted from these 
samples using TRIzol reagent. A normal pool of healthy control RNA was created by 
mixing equal amounts of RNA from each of the normal control samples.
Table 5.1 Details of ET and PV patients.
Patient Identifier Disease Status
M1352 ET
M1353 ET
M1354 ET
M1357 ET
M1358 PV
M1360 PV
M1372 ET
M1377 ET
M1378 ET
M1379 ET
M1381 PV
M1391 ET
M1395 ET
M1415 ET
M1421 ET
5.2.2 Separation ofplatelets from peripheral blood
Platelets were separated from peripheral blood of patient and control samples by 
centrifugation and removal of platelet rich plasma as detailed in Chapter 2. Levels of 
contaminating cells were assessed by flow cytometry by labelling aliquots of
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fractionated cells with FITC-Conjugated anti-CD41 to detect platelets, PE-conjugated 
anti-glycophorin A to label red blood cells and PerCP-conjugated anti-CD45 to label all 
leukocytes. Levels of individual cell types were analysed by flow cytometry using the 
FACSCalibur flow cytometer (BD Biosciences, Oxford, UK).
5.2.3 Cycle sequencing of JAK2
Cycle sequencing was carried out as described in Chapter 2. Primers to amplify JAK2 
were used as described by James et al. (James et al. 2005). Forward Primer 5’- 
GGGTTTCCTCAGAACGTTGA-3 ’ and Reverse Primer 5’ 
TTGCTTTCCTTTTTCACAAGA-3 ’. The primers used for PCR were subsequently 
used to sequence the resulting PCR product.
5.2.4 cDNA microarray analysis
For every cDNA microarray experiment, neutrophil RNA from one patient or control 
sample was compared to the normal RNA pool. The Amino Allyl MessageAmp aRNA 
kit (Ambion) was used to for cDNA synthesis, antisense RNA (aRNA) synthesis and 
amplification and dye incorporation. For each patient and control pool sample 2 pg of 
total RNA was used. The normal control pool was labelled with Cy3 NHS ester dye 
and each patient sample was labelled with Cy5 NHS ester dye. The two labelled 
samples were then mixed and competitively hybridised to the cDNA microarray. 
Hybridisation was carried out at 47°C overnight and slides were washed. All 
experiments were performed in duplicate.
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Slides were scanned using the ScanArray 4000 machine (PerkinElmer) with a 10-pm 
resolution. This generated TIFF images which were imported in Quant Array 3.0 
(PE/Packard BioScience). Grid alignment and spot location were carried out and the 
Cy5 and Cy3 intensities were normalised to the median value of the entire array and the 
ratio for every spot was obtained. Analysis files were imported into GeneSpring 7.2 
(Silicon Genetics, Redwood City, CA) and gene filtering and clustering performed.
5.2.5 Real Time PCR
RNA was extracted from patient and control neutrophil samples with TRIZOL reagent 
as described in chapter 2. RNA was then DNase treated using the DNA-free reagent 
(Ambion) and cDNA synthesis was carried out as detailed in chapter 2 using the 
Ambion RETROscript kit.
To account for differences in input cDNA Beta-2-microglobulin (J32M) expression was 
examined with a pre-developed assay (Applied Biosystems). The primer and probe sets 
used for the genes of interest were supplied from the assays on demand resource from 
Applied Biosystems. The assay numbers are as follows:
SNCA: Hs00240906 
EGR3: Hs00231780 
CCR5: Hs00152917 
FCER1G: Hs00175408
Reactions were set up to run on the ABI prism 5700 Sequence Detection system and 
expression ratios were obtained using the 2'AAct method.
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5.5 Results
5.3.1 Platelet separation from whole peripheral blood
Using a method described by Wang et al. (Wang et al. 2003) 55 ml of whole peripheral 
blood was used to determine if a highly pure population of platelets could be isolated 
from a normal control. At each step of the protocol aliquots of the sample were labelled 
with fluorescent antibodies for detection of cell types by flow cytometry: FITC-
Conjugated anti-CD41 will detect platelets, PE-conjugated anti-glycophorin A will label 
red blood cells and PerCP-conjugated anti-CD45 will label all leukocytes. Flow 
cytometry of whole blood shows that all cells are labelled as expected and clearly 
visible, see fig 5.2a. After spinning the blood at 150g and removing the Platelet Rich 
Plasma (PRP) a decrease in contaminating leukocytes and erythrocytes is seen, as 
shown in Fig 5.2b. A further centrifugation at the same speed shows an increase in the 
platelet concentration and a notable reduction in red blood cells (Fig 5.2c). A final 
centrifugation step at 880g yields a purified platelet pellet with minimal detection of 
other contaminating cell types (Fig 5.2d).
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Figure 5.2 Platelet Purification from Peripheral Blood. Flow cytometry data: Gate 
R3 shows CD41 labelled platelets, Gate R1 shows red blood cells, Gate R4 shows 
leukocytes and Gate R2 shows background levels, (a) Whole Blood, (b) PRP spin 1, 
gate R2 shows high background likely to be from red blood cell lysis, (c) PRP spin 2. 
(d) Pelleted platelets.
5.3.2 cDNA microarray analysis of platelet samples
Total RNA was extracted from the purified platelets of 2 ET patients and one normal 
control. The purity of the platelet samples to be analysed and the amount of information 
that can be extracted from this type of experiment was first investigated in a self vs. self 
microarray experiment using the normal control platelets. This is particularly important 
given the small amount of RNA and therefore transcripts present in platelets.
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53.2.1 Self v self Platelet cDNA microarray analysis
A self vs self microarray experiment uses the same sample and labels it once with Cy5 
and once with Cy3. The two labelled samples are then hybridized to the same 
microarray slide and analysed as for a patient vs normal control experiment. Normal 
control platelets isolated from 55ml of peripheral blood were used for this analysis. As 
shown in Fig 5.3 it can be seen that expression of all genes in the normal control is 
within the 1:1 ratio. This indicates that there is no differential gene expression between 
the two labelled samples from the normal control. Markers for platelets and other cell 
types are present on the array and it is therefore possible to gain some insight into the 
levels of contaminating cells. p2 integrin, a leukocyte marker, is spotted on the array 
three times. One spot has a signal intensity value of 300, consistent with background 
levels, however the remaining two spots show signal levels of 1000. Signal intensity 
levels of Glycophorin A, a red blood cell marker spotted twice on the array, are around 
200-300, again consistent with background fluorescence levels.
The gene with highest expression level in the normal control platelet sample was 
MASP1 (mannan-binding lectin serine protease 1), which is an activating component of 
Ra-reactive factor (RARF). RARF is a complement-dependent bactericidal factor. 
There are no previous reports of this gene being expressed in human platelets. The 
highest expressing genes in normal platelets (signal intensity over 25,000) are shown in 
Table 5.2 This list includes some genes which are also expressed in neutrophil 
populations, such as WNT2B and INSR, and also FCN1 which is expressed in 
leukocytes. Also included are several ribosomal proteins: L37, S24 and L10
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Figure 5.3 Self v Self Platelet M icroarray. Scatterplot of self v self normal control 
platelet data. Each spot is the expression ratio of a single gene. The green lines 
represent expression ratios in the normal range. The middle green line shows the value 
where points would lie if both samples have identical expression ratios.
Platelet specific genes are represented on the array and expression of these is high, 
although they are not among the highest expressing genes. Platelet factor 4 (PF4) 
intensity 15,570, glycoprotein Iba (GP1BA) intensity 2000. To identify the total 
number of genes expressed in the sample any genes with a signal intensity of less than 
500, which is consistent with background signal levels, were excluded. This leaves 
5,271 genes present on the array that are expressed in platelets. The total number of 
cDNAs spotted on the array is 9,932, indicating that 53% of total transcripts on the 
array are expressed in platelets.
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Table 5.2 Genes with highest expression levels in normal platelets
Gene Symbol Full name function
MYBPC3 myosin binding protein C cardiac muscle contraction, 
protein binding
TROAP trophinin associated protein (tastin) cell adhesion, centrosomes, 
cytoskeleton
SFTPD surfactant protein D Cell proliferation
TRIM2 7 tripartite motif-containing 27 Cell proliferation
WNT2B wingless-type MMTV integration site 
family, member 2B
Cell proliferation
MASP1 mannan-binding lectin serine peptidase 1 
(C4/C2 activating component of Ra- 
reactive factor)
Complement Activation
PTPRO protein tyrosine phosphatase, receptor 
type, 0
Integral membrane protein
MYL12B myosin, light chain 12B, regulatory Motor activity
PPBP pro-platelet basic protein (chemokine 
(C-X-C motif) ligand 7
Platelet derived growth 
factor, chemokine, immune 
response, cell division
INSR insulin receptor Regulatory
TRAF4 tumour necrosis factor receptor- 
associated factor 4
signal transduction
FCN1 ficolin (collagen/fibrinogen domain 
containing)
signal transduction
RPL10 Human ribosomal protein L10 Translational elongation
RPL37 ribosomal protein L37 Translational elongation
RPS24 ribosomal protein S24 Translational elongation
S.3.2.2 cDNA microarray analysis ofplatelets from patients with ET
Platelet RNA samples from two ET patients (M1372 and M1377) were used for cDNA 
microarray analysis and compared against the normal platelet sample used above. 
Given the large volumes of normal peripheral blood that would be required to generate 
sufficient RNA to create a normal platelet pool it was not possible to analyse the patient 
samples against pooled normal control platelets.
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When comparing the two patient platelet samples against the normal platelet sample it 
was possible to identify genes that were differentially expressed in the patients. 
Excluding any genes specifically expressed in males and females, or duplicated genes, 
35 genes were identified as down-regulated by greater than 0.35 fold in both patients. 
The analysis also identified 37 genes that were up-regulated by greater than 2 fold in 
both patients. The most up-regulated genes include Ras suppressor protein 1 (RSU1), 
the general transcription factor GTF2A2, the anti-apoptotic DAD-1 (defender against 
cell death 1), pro-apoptotic DAP (Death-associated protein), the non-protein coding 
gene DLEU1 (deleted in lymphocytic leukaemia 1), CCPG1 (cell cycle progression 1), 
which is involved in cell cycle regulation and EIF1B (eukaryotic translation initiation 
factor IB) which regulates translation. The most down-regulated genes include NELL2 
(NEL-like 2) which is expressed in haematopoietic cells, ZNF266 (zinc finger protein 
266) which is involved in erythroid and megakaryocyte differentiation, and several 
ribosomal proteins: S7, L30, L28, P2, L6, L34 and L37.
5.3.3 Mutation analysis o f JAK2 in neutrophils o f ETandPRVpatients
The JAK2 V617F mutation was studied in all patients detailed in Table 5.1. Exon 14 of 
JAK2 was PCR amplified from neutrophil genomic DNA. PCR products were then 
subjected to cycle sequencing using the same primer set. Differences between the 
normal JAK2 sequence and sequences obtained from the samples studied were 
identified using pairwise analysis of sequences using Sequence Analysis software 
(Informagen).
Cycle sequencing of genomic DNA confirmed the presence of a G to T point mutation 
in exon 14 of JAK2 at nucleotide 1849 in all patients. All patients were heterozygous
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for the mutation and it can be seen in fig 5.4 that there appeared to be varying degrees 
of heterozygosity between the patients, ranging from approximately 62% mutated cells 
in case M1415 to less than 10% in case M1360. This was calculated from the relative 
peak heights and can be seen in Fig 5.4. Sequence analysis revealed no further 
nucleotide changes in these patients.
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Figure 5.4 JAK2 V617F mutation analysis. Sequencing electropherograms from 
JAK2 exon 12 sequencing. The reverse sequencing read is shown and the position of 
the G to T mutation is indicated with an arrow, (a) Patient M1415 showing 
approximately 62% mutated cells, (b) Patient M l360 showing less than 10% mutated 
cells, (c) Normal control neutrophils showing only the wild type sequence.
5.3.4 cDNA Microarray analysis o f neutrophils
5.3.4.1 Gene expression analysis of ET and PV
Neutrophils from JAK2 V617F positive ET and PV patients were compared with a pool 
of normal control neutrophils by cDNA microarray. Five individual normal control 
neutrophil samples were also compared against the normal neutrophil pool. Analysis of 
these samples using the genespring software identified 8 genes that were up-regulated 
by greater than 1.6 fold in 5 of 12 ET patients and 13 genes that were down-regulated
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by at least 0.6 in 5 of 12 patients. Using this gene set for hierarchical clustering analysis 
it can be seen in Fig 5.5 that the normal controls cluster in two separate branches and 
that one PV and three ET samples also cluster in these branches. The remaining patient 
samples cluster separately and there appears to be no separation between ET and PV. 
This indicates that the gene expression profile of neutrophils from ET patients showed a 
low level of heterogeneity as compared to normal controls. However, it was possible to 
identify some differentially expressed genes between the ET patient and normal control 
samples. The most up-regulated genes in ET include SNCA (Synuclein, alpha) and 
FCER1G (Fc fragment of IgE). The most down-regulated genes include EGR3 (Early 
growth response 3) and CCR-5 (chemokine receptor 5).
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Figure 5.5 Hierarchical clustering of 21 genes differentially expressed in 
neutrophils of ET patients. Each column represents a single patient or control sample 
on the microarray and each row represents a separate gene. Samples are numbered as in 
Table 5.1 and C3- samples are normal controls.
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5.3.4.2 Gene expression analysis o f ET, PV and CML
Neutrophils were collected from 6 CML CP patients (14, 15, 17, 21, 22 and 23 in Table 
3.1) and RNA was extracted for cDNA microarray analysis. When CML, ET, PV and 
normal controls are analysed with the set of genes identified as differentially expressed 
in ET the ET, PV and control groups do not separate into distinct branches (Fig 5.6). In 
contrast the CML patients cluster in a single branch with one patient with ET: M l391. 
Interestingly, this patient was later to progress to AML.
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Figure 5.6 Hierarchical clustering of 21 genes differentially expressed in 
neutrophils of ET and CML patients. Each column represents a single patient or 
control sample on the microarray and each row represents a separate gene. Samples are 
numbered as in Table 5.1 and C-3 samples are normal controls. Samples from CML 
patients are numbered pt 14 -  pt 23.
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Analysis with the CML patient group identified a set of 59 genes that were either up- 
regulated by greater than 2 fold in 5 of 6 patients or down regulated by less than 0.5 fold 
in 5 of 6 cases. Genes up-regulated in CML included eosinophil granule major basic 
protein (MBP), Neutrophil gelatinase-associated lipocalin precursor (.NGAL), helix- 
loop-helix protein (Id-2) and myeloid-related sequence (DEFA1). Down regulated 
genes in CML included IL-7, hsp70, E-type ATPase (HB6) and secreted and 
transmembrane 1 (SECTM1). Using this gene set for hierarchical clustering the CML 
patients again cluster together as a distinct group (Fig 5.7). With the exception of ET 
patient M l391, the ET, PV and normal control samples are branched separately from 
the CML patients. This patient also clustered with the CML patients when the ET gene 
set was used for analysis.
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Figure 5.7 Hierarchical clustering of 59 genes differentially expressed in 
neutrophils of CML patients. Each column represents a single patient or control 
sample on the microarray and each row represents a separate gene. Samples are 
numbered as in Table 5.1 and C-3 samples are normal controls. Samples from CML 
patients are numbered pt 14 -  pt 23.
5.3.5 Confirmation o f  Gene expression data by Real Time PCR
The expression levels of four differentially expressed genes were measured using real­
time PCR to validate the results obtained using the microarray platform. Four genes 
that were differentially expressed the neutrophils of patients with ET (SNCA, EGR3, 
CCR5, FCER1G) were used for confirmation and the expression data of each gene was
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normalized to the endogenous reference y62M. Expression levels obtained by real time 
PCR were compared with the microarray data and as can be seen in Fig 5.8 the results 
correlate well. This confirms that the genes identified as deregulated by the microarray 
platform have been identified correctly. Statistical analysis performed on results 
obtained with real-time quantitative PCR in the group of ET patients and controls 
showed that expression levels of EGR3 and FCER1G were significantly different 
between patients and normal controls (P=.01 for both genes). However, the changes in 
gene expression for SNCA and CCR5 were not statistically significant between the 
patient and control groups.
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Figure 5.8 Confirmation of Gene Expression Data by Real Time PCR. Gene 
expression ratios from the microarray data are shown as white bars and ratios from real 
time PCR are shown as black bars. The data shown is from the patient neutrophil 
samples detailed in Table 5.1.
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5.4 Discussion
A pure population of platelets has been isolated from the peripheral blood of patients 
with ET and from normal controls. Analysis by flow cytometry indicates that 
contaminating levels of other blood cell types is low. When the platelet samples are 
analysed by cDNA microarray it was noted that the expression of Glycophorin A was 
extremely low, indicating that there is minimal red cell contamination in the samples. 
In addition to this it is worth noting that less than 1% of circulating red blood cells 
contain residual RNA so this is unlikely to affect the results in the present study. 
However, levels of two of the three spots of (32 integrin, a leukocyte marker are above 
background levels. It is possible that some contaminating leukocytes may be present in 
the sample. However it has been shown that activated platelets also express 02 integrin 
and resting platelets express it at low levels (Philippeaux et al. 1996). It may therefore 
be the case that the expression of 02 integrin detected by microarray is from the 
platelets and not contaminating leukocytes. This is in agreement with the flow 
cytometry data. Therefore, it may be concluded that a pure population of platelets has 
been isolated from the samples included in this study.
Previous studies investigating gene expression in platelet samples estimate that between 
13 and 31% of genes are expressed in platelets. These studies show that some of the 
most abundant transcripts are platelet associated genes such as Platelet factor 4 (PF4) 
and glycoprotein Iba (GP1BA). These genes were also expressed at high levels in the 
current study. The gene with highest expression in the normal platelet sample was 
MASP1 (Mannose-binding lectin-associated serine protease), a serine protease that has a 
role in complement activation (Dobo et al. 2009). It has also been identified as being 
involved in coagulation as it can cleave the thrombin substrates fibrinogen and factor
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XTTT (Hajela et al. 2002). It is thought that expression of MASP1 plays an important 
role in the defense against pathogens (Krarup et al. 2008). Platelets become stimulated 
when pathogens are identified and can accumulate at sites of infection so expression of 
MASP1 may be important for this function (Yeaman 2010). There were also genes 
involved in cytoskeletal organisation such as TROAP which has been identified in the 
current study. Cytoskeletal organisation is important for platelet activation and function 
with reorganisation of the cytoskeleton taking place to allow cell spreading at wound 
sites (Hartwig et al. 1999). Additionally, ribosomal proteins L37, S24 and L10 were 
highly expressed. This correlates with the fact that platelets can perform protein 
synthesis and would require an active ribosome to catalyse protein synthesis.
Gene expression profiling of platelet samples from ET patients revealed that compared 
to a normal control both patient samples had common genes that were differentially 
expressed. This was the first study to examine ET patient platelet samples by cDNA 
microarray analysis. Genes with low expression in both patient samples include 
ribosomal proteins S7, L30, L28, P2, L6, L34 and L37 which are involved in protein 
production suggesting that in these patients protein production may be reduced. Adding 
to the sample number would increase the amount of information and allow identification 
of transcripts that are consistently differentially expressed in platelets of patients with 
ET. It shows that this type of study would be feasible and that the advent of new 
platelet specific arrays is likely to reveal insights into the importance of gene expression 
profiling in platelets. Recently, Gnatenko et al. have developed a platelet specific gene 
chip and have carried out gene expression analysis of ET patients (Gnatenko et al. 
2010). They reveal a set of 11 transcripts that can identify patients with ET and just 4 
of these can predict JAK2 wild type ET demonstrating the value of platelet RNA 
profiling.
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Presence of the JAK2 V617F mutation was confirmed by cycle sequencing in all 
patients included in this study. Gene expression profiling of JAK2 V617F positive 
neutrophils in ET and PV reveals that these patients do not have a heterogeneous 
expression profile when compared to normal control neutrophils. The genes identified 
as differentially expressed in these patients were seen as deregulated in less than half of 
the patient samples (5 of 12). This suggests that the regardless of the presence of the 
JAK2 V617F mutation the neutrophils of these patients exhibit a near normal gene 
expression profile. Despite this it was possible to identify some differentially expressed 
genes in the patient and control samples.
Genes with increased expression in the neutrophils of ET patients included SCNA 
(Synuclein Alpha). This gene is associated with Parkinson disease and dementia and the 
protein product accumulates in the nervous systems of patients with the disease 
(Goedert 2001). Expression of the gene has been detected in platelets, lymphocytes and 
erythrocytes suggesting some as yet unknown function in the haematopoietic system 
(Nakai et al. 2007). Over expression of SCNA in cell lines can result in increased 
proliferation (Lee et al. 2003). Increased expression of this gene in ET may contribute 
to an increase in proliferation of neutrophils.
FCER1G (Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide) 
expression was increased in the neutrophils of ET patients in the current study. 
FCER1G is an FC receptor chain that, in cooperation with other protein kinases, 
mediates intracellular signaling (Nambiar et al. 2003). It is also involved in allergic 
reaction (Pawankar 2001). Increased expression of this gene has previously been 
reported in patients with PV (Pellagatti et al. 2003).
155
Expression of EGR3 was significantly decreased in the neutrophils of JAK2 mutated ET 
patients. EGR3 (Early Growth Response 3) is a transcription factor that increases 
transcription of the Fas ligand (Mittelstadt and Ashwell 1998). If expression of EGR3 is 
decreased this may then result in decreased expression of the Fas ligand (Yasunaga et 
al. 2004). When Fas ligand expression is reduced in inflammatory neutrophils the 
viability of these neutrophils is increased (Jonsson et a l 2005). It could therefore be 
suggested that a decrease in EGR3 expression in neutrophils of patients with ET could 
act through a decrease in Fas ligand expression to increase neutrophil viability in these 
patients.
CC Chemokine Receptor 5 (CCR5) expression was reduced in ET patients in the current 
study. CCR5 is a G protein coupled receptor that is involved in inflammation and 
autoimmunity (Ariel et al. 2006). Interestingly, CCR5 is an upstream activator of JAK2 
(Wong et al. 2001; Mueller and Strange 2004). Given that the JAK2 V617F mutation 
results in a constitutively active JAK2 kinase a decrease in CCR5 expression in ET 
patients with the mutation is unlikely to have an effect on activation of JAK2.
A study by Puigdecanet et al. used whole genome oligonucleotide microarrays to 
analyse gene expression profiles of neutrophils of 21 JAK2 mutated and 19 JAK2 wild 
type ET patients (Puigdecanet et al. 2008). They demonstrated that expression of genes 
involved in the immune response was increased in the neutrophils of all ET patients. 
These include genes involved in neutrophil chemotaxis such as PPBP, which was also 
increased in the ET neutrophils analysed in the current study. CCL20 expression was 
also increased in the study by Puigdecanet but was decreased in patients in the current 
study. This may be due to platform variation and also to the increased sample size used 
by Puigdecanet. They identified genes that were differentially expressed between
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patients with and without the JAK2 V617F mutation but noted that expression of these 
genes were not significantly different to normal controls. They identified the genes 
FOSB and CISH as predictors of JAK2 mutation status in neutrophils. CISH expression 
is decreased in JAK2 wild type patients and FOSB is increased in these patients. 
Expression levels of FOSB in the patients in the current study were within the range 
observed for the normal controls. CISH is not present on the microarrays used so it is 
not possible to comment on expression of this gene.
A further study investigating gene expression in the CD34+ cells of ET patients showed 
that the gene expression profile of these cells could not distinguish between patients 
with mutated or wild type JAK2 (Catani et al. 2009). It was also demonstrated that gene 
expression was not significantly altered between patients and normal controls. These 
results suggest that secondary molecular aberrations could be responsible for the 
pathogenesis of ET.
Gene expression profiling of CML neutrophils revealed that these cells were clearly 
highly heterogeneous when compared to normal and JAK2 V617F positive samples. 
Although the JAK2 mutation is detected in the neutrophils of the patents included in this 
study it does not appear that the resulting activated kinase produces a deregulated gene 
expression profile similar to that which is observed in CML. This provides further 
evidence that the JAK2 V617F neutrophils of ET and PV patients are more similar to 
normal neutrophils despite the presence of the mutation. The patient M l391 that 
clustered with the CML patients clearly showed a distinct gene expression profile from 
the other ET and PV samples. This patient was to progress from ET to AML suggesting 
that the gene expression in this patient was becoming more like an acute leukaemia. 
The difference seen in the expression profile of this patient suggests that a secondary
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genetic change may have occurred to result in this deregulated expression pattern and to 
cause the progression of the disease. Further cytogenetic profiling or SNP array 
analysis of this sample could identify subsequent changes which may have led to 
disease progression. In fact, it has been shown that expression of JAK2 V617F can 
result in an increase in DNA damage and genetic instability and it is believed that this 
results in disease progression (Plo et al. 2008). Gene expression profiling of neutrophils 
could prove be a useful tool to predict disease transformation in patients with ET, 
however a larger sample size would reveal the true power of this prediction.
The data presented here demonstrate the feasibility of platelet gene expression profiling 
and suggests that platelet profiling could reveal some novel insights into the 
pathophysiology of ET. Gene expression profiling of neutrophils of ET patients shows 
that gene expression changes are observed between patients and normal controls but are 
uncommon despite the presence of the JAK2 V617F mutation. Gene expression 
profiling of neutrophils of ET patients may be able to predict transformation to AML 
but a larger sample size is needed to confirm this result.
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Chapter 6 
Gene Expression Profiling of 
Telomerase Related Genes in 
Myelodysplastic Syndromes
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6.1 Introduction
6.1.1 Pathogenesis ofM D S
The Myelodysplastic Syndromes (MDS) are a heterogeneous group of haematopoietic 
malignancies characterised by ineffective haematopoiesis and dysplastic bone marrow 
(Nimer 2008). There is dysplasia in the bone marrow of at least one of the myeloid, 
erythroid or megakaryocyte lineage with peripheral blood cytopaenia (Scott and Deeg 
2010). MDS is one of the most common cancers in patients over 70 years of age and 
onset before age 50 is rare (Rollison et al. 2008). In early MDS dysplastic clones will 
proliferate but this is mediated by an increase in apoptosis resulting in hypercellular 
bone marrow with peripheral blood cytopaenia (Nimer 2008; Davids and Steensma 
2010). In around 30% of patients the disease will progress to Acute Myeloid 
Leukaemia (Mufti et al. 2008). Disease progression is thought to be mediated by 
several different pathways. The anti-apoptotic protein BCL-2 is thought to play a role 
in promoting transformation by preventing apoptosis of the dysplastic clone (Parker et 
al. 2000). Gene expression profiling shows that in advanced stages of disease patients 
have deregulated expression of genes involved in the DNA damage response and cell 
cycle checkpoints which may confer a growth advantage to these cells (Pellagatti et al. 
2010). MDS can occur as a secondary complication after radiotherapy or chemotherapy 
and a high percentage of these patients have deletion of the long arm of chromosomes 5 
or 7 (Le Beau et al. 1986). This therapy related MDS, or tMDS has poor prognosis and 
five year survival has been reported at less than 10% (Smith et a l 2003).
The MDS patients in the current study have been classified according to the FAB 
(French American British) classification (Bennett et al. 1982). According to this
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classification refractory anaemia (RA) and refractory anaemia with ringed sideroblasts 
(RARS) are associated with low risk disease and both have less than 5% blasts in the 
bone marrow with RARS exhibiting >15% ring sideroblasts. Refractory anaemia with 
excess blasts (RAEB) is associated with progression to AML. The patients with RAEB 
were divided into two groups: RAEB-1 with less than 10% blasts in the bone marrow 
and RAEB-2 with 10 to 19% blasts in the bone marrow. Prognosis of MDS is evaluated 
using the International Prognostic Scoring System (IPSS). Using this scoring system 
risk is calculated based on blast percentage, number of cytopaenias and bone marrow 
cytogenetics (Greenberg et a l 1997). Table 6.1 shows how the IPSS score is calculated.
International Prognostic Scoring System in MDS
Prognostic Variable Score Value
0 0.5 1.0 1.5 2.0
BM Blast % <5 5-10 - 11-20 21-30
Karyotype Good Intermediate Poor
Cytopaenias 0/1 2/3
Table 6.1 IPSS in MDS. Good karyotype is normal, -Y, del(5q) and del(20q). Poor 
karyotype is complex with >3 abnormalities. Intermediate karyotype is other 
abnormalities. Low risk is a score of 0, Intermediate-1 0.5-1.0, Intermdiate-2 1.5-2.0 
and High risk is >2.5. (Greenberg et al. 1997)
All MDS patients require supportive care in the form of transfusion of red blood cells 
and platelets (Greenberg 2010). The thalidomide analogue lenalidomide has been used 
to successfully treat low risk MDS patients with del(5q) and it has been reported that up 
to 67% of patients achieve transfusion independence and 73% achieve cytogenetic 
response (List et a l 2006). In low risk patients without del(5q) only 26% of patients 
were transfusion independent after treatment (List et a l 2006). However, the drug has
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not yet been approved for use in Europe due to concerns over increased risk of 
progression to AML (Garcia-Manero and Fenaux 2011). For patients with high risk 
MDS the only curative treatment is by haematopoietic stem cell transplant and up to 
29% of these patients will have 5 year disease free survival. This increases to 41% in 
patients with RA/RARS (Chang et a l 2007).
Between 40-50% of patients with RAEB will transform to AML and only 5-15% of 
RA/RARS patients (Greenberg et a l 2002). Gene expression profiling has shown that 
approximately 23% of MDS patients exhibit an AML-like gene expression profile 
(Mills et a l 2009). This profile carries a high risk of leukaemic transformation to AML. 
The most frequent genetic abnormality in de novo AML is mutation of exon 12 of 
Nucleophosmin (NPM1) (Falini et a l 2005). NPM1 is a ubiquitously expressed 
shuttling protein with nucleolar localisation that acts as a molecular chaperone (Borer et 
a l 1989; Okuwaki et a l 2001). The mutations of NPM1 characterised by Falini et a l 
are in exon 12 of NPM1 the most frequent of which is a duplication of a TCTG 
tetranucleotide that results in a frame shift that replaces the last 7 amino acids of the C- 
terminus of the protein. The other mutations detected by Falini et a l are insertions or 
multiple base substitutions and result in the same mutant C-terminal sequence. The 
mutations are most commonly found in normal karyotype AML with up to 60% of these 
patients having mutation of NPM1 (Falini et a l 2005). Patients with mutation have 
higher rates of complete remission and survival compared to those without the mutation 
(Schnittger et a l 2005). These mutations cause NPM1 to localise to the cytoplasm 
rather than the nucleus. The mutation is thought to contribute to leukaemogenesis by 
increasing protein levels of c-MYC and stabilising the protein (Bonetti et a l  2008). The 
mutant also regulates the ARF-p53 tumour-suppressor pathway and can prevent 
initiation of p53 (Colombo et a l 2006). Additionally, recent findings have shown that
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NPM1 can bind DNA that forms G-quadruplexes (Federici et al. 2010). G- 
quadruplexes are a four stranded helical structure formed from G rich DNA sequences 
(Phan 2010). It has been suggested that NPM1 may be involved in transcriptional 
regulation of genes that have these G-quadruplex sequences at their promoters (Federici 
et al. 2010). Genes with promoters that can form these structures include the hTERT 
activator c-MYC (Siddiqui-Jain et al. 2002). G-quadruplexes can also be found at the 
single strand overhang of telomeres and may play a role in preventing telomerase from 
elongating the telomeres (Maiti 2010). The study by Federici et al. (Federici et al. 
2010) reports that the NPM1 mutations reported in AML patients disrupt the C terminal 
G-quadruplex binding domain of the protein. This implies that any binding activity of 
NPM1 would be reduced by the mutation and authors suggest this may drive disease 
progression by promoting gene deregulation. Given the high percentage of MDS 
patients that transform to AML it will be of interest to investigate the role of NPM1 
mutations in disease progression of patients with MDS.
6.1.2 Karyotypic abnormalities in MDS
In primary MDS karyotypic abnormalities are identified in 45% of patients and occur 
most frequently in patients with RAEB (Pozdnyakova et al. 2008). Translocations are 
rare in MDS and any karyotype abnormalities typically consist of partial or complete 
deletion or addition of chromosome regions (Fenaux 2001). The most commonly 
reported cytogenetic abnormalities in MDS are del(5q), del(7q), trisomy 8, del(20q) and 
-Y  (Haase et al. 2007). A more complex karyotype leads to a worse prognosis for the 
patient. For example, patients with normal karyotype have a median survival of 53 
months, with 1 or 2 abnormalities survival is 35-38 months but with 3 abnormalities this
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decreases to 17 months and with 4 to 6 abnormalities median survival is only 9 months 
(Haase et a l 2007).
Patients with 5q- syndrome have del(5q) as the sole karyotypic abnormality. These 
patients have distinct clinical characteristics including macrocytic anaemia, 
thrombocytosis, dyserythropoiesis and megakaryocytes with nonlobulated nuclei (Sokal 
et a l 1975; Boultwood et al. 2010). The disease is slow to develop, is associated with 
good prognosis, indolent disease phenotype and patients respond well to treatment with 
lenalidomide (Giagounidis et a l 2004; Mohamedali and Mufti 2009). In a recent study 
of 541 patients with a deletion of 5q Mallo et a l demonstrated that there is no 
significant difference in overall survival between those with del(5q) as the sole 
abnormality and those with del(5q) and one additional abnormality (Mallo et a l  2011). 
However, they did demonstrate that one additional abnormality gives a higher risk for 
progression to AML and that with two or more additional abnormalities both overall 
survival and risk of AML transformation are significantly increased.
Approximately 5% of patients who develop de novo MDS have del(7q) as the sole 
karyotypic abnormality. This is associated with poor prognosis (Olney and Le Beau 
2001). Patients with del(7q) tend to have to have better survival than patients with 
monosomy 7 but both abnormalities are still considered to confer poor prognosis (Haase 
et a l 2007). Trisomy 8 in MDS is seen in 8% of patients and is associated with 
intermediate risk disease (Haase et a l 2007). The del(20q) abnormality is observed in 
approximately 5% of MDS cases and when present as the sole abnormality is associated 
with low risk disease, low risk of progression to AML and longer than average survival 
(Wattel et a l 1993). However, when del(20q) is part of a complex karyotype patients 
have decreased survival (Olney and Le Beau 2001).
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Y chromosome loss is considered a normal age related abnormality but in cases where 
every cell is identified as having loss of the Y chromosome there is a significant 
increase in MDS/AML (Wong et a l 2008). However, it is thought to be unlikely that Y 
chromosome loss is causing MDS/AML but instead the MDS/AML occurs after a 
mutation in a -Y  cell that will proliferate to such an extent that any cells with the Y 
chromosome will be eliminated (Wong et al. 2008).
Recently gene expression profiling has been used to show that certain karyotypic 
abnormalities in MDS have been associated with changes in gene expression of distinct 
pathways (Pellagatti et al. 2010). Patients with trisomy 8 exhibit deregulation of 
pathways of the immune response, patients with del(7q) deregulate pathways involved 
in cell survival, and patients with del(5q) show deregulation of integrin signalling and 
cell cycle regulation pathways.
6.1.3 Genetic Abnormalities in MDS
There are several genetic abnormalities that are common amongst MDS patients. Some 
of the most frequent point mutations observed in MDS are in the Runt-related 
transcription factor 1 (RUNX1) gene. Mutations in this gene are found in up to 20% of 
patients and are more common in those patients with tMDS (Harada and Harada 2009). 
Patients with the mutation have a significantly worse prognosis than those without 
mutation (Harada et a l 2004). It is thought that mutation reduces RUNX1 activity and 
initiates MDS by inhibiting differentiation of haematopoietic stem cells (Harada and 
Harada 2011).
Mutations of the p53 tumour suppressor are present in over 20% of high risk MDS 
patients and are more common in advanced disease (Sugimoto et a l 1993; Adamson et
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al 1995; Davids and Steensma 2010). In low and intermediate-1 risk patients with 
del(5q) the mutation has been detected in 18% of patients and is associated with 
progression to AML (Jadersten et al. 2011). The mutation is common in patients with 
tMDS and mutation is strongly associated with complex karyotype, deletion of 5q and 
poor prognosis (Christiansen et al. 2001).
Other common abnormalities in MDS include mutation of the ten-eleven translocation 2 
(TET2) gene, the RAS oncogene and the chromatin binding activator of the retinoic acid 
receptor ASXL1 (Neubauer et a l 1994; Padua et a l  1998; Kosmider et a l 2009; Thol et 
al 2011). The number of molecular and cytogenetic abnormalities that have been 
described in MDS patients indicates the complexity of the disease and further 
investigation of these aspects is warranted to increase understanding of disease 
evolution and prognosis.
6.1.4 Telomeres and Telomerase in MDS
Telomere length in MDS is heterogeneous in bone marrow samples but shortened 
telomeres have been associated with poor prognosis, leukaemic transformation and 
higher risk disease (Ohyashiki et a l 1994; Boultwood et a l 1997; Ohyashiki et a l 
1999; Sieglova et a l 2004). In CD34+ cells telomere length is decreased in patients 
when compared to normal controls particularly in cases with unfavourable IPSS scores 
(Engelhardt et a l  2000; Rigolin et a l 2004). Shortened telomeres are often linked to 
complex karyotypic abnormalities suggesting that reduced telomere length leads to 
genomic instability and poor prognosis (Ohyashiki et a l  1994; Boultwood et a l 1997; 
Ohyashiki et a l 2001). Recently Lange et a l have shown that is possible to measure 
individual telomere lengths in MDS (Lange et a l 2010). They used a novel technique
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known as Telomere/Centromere-Fluorescence In Situ Hybridisation (T/C-FISH). This 
involves a FISH probe against telomere repeats used in conjunction with fluorescence 
R-banding to measure the telomere length of each individual chromosome. This 
identified certain subtypes of MDS that have stabilized or even increased telomere 
length. Patients with monosomy 7 showed significantly longer telomeres than normal 
karyotype patients and this was thought to be directly caused by telomerase activation in 
these patients. In a subsequent study this group also demonstrated that patients with a 
del(5q) being treated with lenalidomide who underwent disease transformation had 
significantly shorter telomeres than those who achieved cytogenetic response (Gohring 
et a l 2011). In patients who responded to treatment telomere length was not 
significantly different from controls and this again suggests that shortened telomeres 
can predict leukaemic transformation.
Accelerated telomere shortening can be predictive of tMDS. This was suggested by 
Fern et a l who analysed telomere length in patients treated for non haematological 
malignancies with conventional chemotherapy (Fern et a l 2004). They showed 
accelerated telomere shortening after chemotherapy and a switch to clonal 
haematopoiesis suggesting a link with tMDS. Autologous haematopoietic stem cell 
transplantation (aHCT) is used as a treatment for Hodgkin’s and non Hodgkin’s 
lymphoma that has the complication of tMDS. Patients who have received aHCT have 
an initial increase in telomere length after transplant but this is quickly reduced as 
telomere shortening accelerates in tMDS patients (Bhatia et a l 2005; Chakraborty et a l 
2009). In these patients tMDS can be predicted by increased telomere shortening and it 
is suggested that this leads to genomic instability that contributes to leukaemic 
transformation (Chakraborty et a l 2009).
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Telomerase activity in bone marrow is variable in MDS but it is generally higher in 
patients than in normal bone marrow (Counter et al. 1995; Li et al. 2000). In agreement 
with this telomerase activity has also been reported as increased in CD34+ cells from 
MDS patients (Engelhardt et al. 2000). A study of telomerase activity in bone marrow 
mononuclear cells showed that those MDS patients with poor prognosis had high 
telomerase activity (Fu and Chen 2002). Gurkan et a l measured telomerase activity in 
peripheral blood mononuclear cells of patients with MDS and showed that there was no 
statistically significant difference in telomerase activity when compared with normal 
controls (Gurkan et al. 2005). However, they did report inferior survival in those 
patients with higher telomerase activity. More recently expression of c-MYC, hTERT 
and telomerase activity has been investigated in the bone marrow of patients with MDS 
and is has been shown that both hTERT and telomerase activity were increased in MDS 
relative to normal controls but that c-MYC was not increased (Briatore et al. 2009). 
Additionally, patients with aggressive disease had significantly higher expression of 
hTERT than those with more favourable disease. This suggests that shortened telomeres 
and an increase in telomerase activity/hTERT expression are associated with disease 
progression in MDS.
Mutations in the coding regions of both hTERT and hTR have been identified in cases of 
familial MDS (Kirwan et al. 2009). These mutations can decrease telomerase activity 
when present and the patients have decreased telomere length. This indicates that 
telomerase can play a role in the development of MDS and further investigation of the 
role of telomerase in de novo MDS is warranted.
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6.1.5 The affymetrbc GeneChip platform
The Affymetrix GeneChip platform provides a powerful tool to analyse global gene 
expression patterns in biological samples. These are synthetic oligonucleotide 
microarrays. The arrays are constructed on quartz wafers and oligos are constructed on 
the arrays by photolithography which is the process of light-activated coupling of a 
nucleotide to a growing chain anchored on the wafer (Dalma-Weiszhausz et al. 2006). 
The expression level of every gene represented on the array is measured by 11 pairs of 
oligonucleotide probes. The probes are selected from the 3’ end of the consensus 
transcript for each sequence. Each pair of oligos consists of a perfect match (PM) oligo 
and a mismatch (MM) oligo that differs at nucleotide 13 of 25 and acts as a 
hybridisation control. The PM oligo directly measures expression of the gene of interest 
whereas the MM oligo detects any background non-specific hybridisation. The specific 
intensity of the probe sets are then calculated by subtracting the value of the MM probe 
from the PM probe. Total RNA is extracted from patient and control samples then 
amplified using a T7 based linear amplification. Biotin labelled cRNA is produced by 
in vitro transcription and one sample is hybridised to a single chip. Each chip is washed 
and stained then scanned to measure fluorescence intensity. An overview of the 
experimental process is shown in Fig 6.1. The Affymetrix GeneChip Human Genome 
U133 Plus 2.0 array has been used in the current study and represents over 47,000 
transcripts corresponding to 39,000 human genes.
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Figure 6.1 Overview of an Affymetrix Gene Chip experiment. Image reproduced 
from the Affymetrix website.
6.1.6 Aims o f  the study
The aim of this study was to develop a comprehensive list of telomerase specific genes 
in order to detect genes that are deregulated and may have prognostic value in MDS. 
This would allow investigation of telomerase specific gene expression profiles in MDS 
in the hope of identifying specific gene expression profiles for specific patient groups. 
The NPM1 gene will also be sequenced in MDS patients to reveal if mutation is present 
and if it gives any prognostic clues to progression of the disease to AML.
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6.2 Materials and Methods
6.2.1 Samples
For gene expression analysis bone marrow samples were obtained from patient and 
normal control samples and CD34+ cells were isolated as described in Chapter 2. RNA 
was extracted using the TRIZOL reagent.
For sequence analysis of NPM1 peripheral blood was obtained from patient and normal 
control samples and DNA was extracted using the Qiagen blood maxi kit as described in 
chapter 2. For sequence analysis of TRF2 genomic DNA was isolated from CD34+ 
cells.
6.2.2 Affymetrix Microarray Experiments
Affymetrix experiments were carried out by Andrea Pellagatti. The Two-Cycle cDNA 
Synthesis and the Two-Cycle Target Labelling and Control Reagent packages 
(Affymetrix, Santa Clara, CA) were used to amplify and label 50 ng of total RNA from 
each sample. This produces biotin labelled cRNA and 20 mg of biotin-labelled cRNA 
was fragmented. 10 mg of this fragmented cRNA was hybridised to GeneChip Human 
Genome U133 Plus 2.0 arrays (Affymetrix) at 45°C for 16 hr in the Hybridisation Oven 
640 (Affymetrix). The arrays were then washed and stained in the Fluidics Station 450 
(Affymetrix) and scanned with a GeneChip Scanner 3000 (Affymetrix).
GeneChip Operating Software (GCOS) was used to carry out cell intensity calculation 
and scaling. Data was analysed using GeneSpring 7.2 software (Agilent Technologies). 
Signal intensities of all arrays were scaled to a target of 100 and quality control was
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carried out using GCOS. Scale factors for all samples were comparable and <3.0. 
Background levels, percentage of present calls and intensities of eukaryotic 
hybridisation controls were within the satisfactory range for all samples. The 375’ 
GAPDH ratio was <3.0 for all samples. Affymetrix CEL files were subjected to Robust 
Multi-array Average (RMA) analysis (Irizarry et al. 2003). To calculate expression 
ratios for each gene the raw signal of each gene for every MDS patient was divided by 
the median raw signal of the gene in normal controls. Statistical analysis with 
GeneSpring was performed on log-transformed data using Welch's approximate t-test or 
ANOVA and Benjamini-Hochberg multiple testing correction to control the false 
discovery rate (Benjamini and Hochberg 1995). Hierarchical clustering was calculated 
using standard correlation.
6.2.3 Cycle sequencing
Cycle sequencing was carried out as described in Chapter 2. Primers to amplify TRF2 
were designed by means of the Primer 3 software to amplify the appropriate exons. 
Primers for NPM1 were used as described by Falini et a l (Falini et al. 2005). The 
primers used for PCR were subsequently used to sequence the resulting PCR product. 
Table 6.2 shows details of the primer sets used.
Table 6.2 PCR and Sequencing primers for TRF2 and NPM1
Primer name Sequence 5’-3’ Annealing Temp °C
TRF2 Exon3 Forward TTGCATGCTCCATTTCCATA 62
TRF2 Exon3 Reverse TCAAAGACCCTTGATTTTTGG 62
TRF2 Exon6 Forward TTCTTGGTGAAAGAAGCAGAGA 62
TRF2 Exon6 Reverse CAGCGACCACCCTAGTGTTT 62
NPM1 Exon 12 Forward TTAACTCTCTGGTGGTAGAATGAA 60
NPM1 Exon 12 Reverse CAAGACTATTTGCCATTCCTAAC 60
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6.3 Results
6.3.1 Identification o f a telomerase specific gene list
In order to identify if telomere related genes could be implicated in the pathogenesis of 
MDS a comprehensive set of genes related to telomerase and telomere structure and 
function was compiled. This list was generated by performing a thorough search of the 
current literature and searching the NCBI Gene resource to identify genes with 
functions related to telomerase or telomeres. This resulted in a list of 82 telomere 
related genes shown in table 6.3.
Table 6.3 Telomere related genes used for microarray analysis of MDS patients.
Gene Name Function
ACD TINT1 localised to telomeres via TIN2, functions as a negative 
regulator of telomerase-mediated telomere elongation
AKT associates with HSP90, maintains telomerase activity
BIRC5 survivin enhances telomere activity
BLM recombination mediated telomere lengthening
BRCA1 telomere protection
C15orf20 Pifl may regulate telomere elongation by decreasing telomerase 
processivity
CDKN1B downregulates telomerase activity
CIB1 KIP has a role in telomere length maintenance and regulation
CLK2 hCLK2 has a role in cell cycle progression, apoptosis, and telomere 
length regulation
c-MYC increases hTERT transcription
CRM1 enhances nuclear export of TERT
DCLRE1B protection of telomeres
DKC1 telomerase subunit
EGFR Antisense epidermal growth factor receptor RNA transfection in 
human glioblastoma cells down-regulates telomerase activity and 
telomere length
ERCC1 involvement of ERCC1/XPF NER endonuclease in regulation of 
telomere integrity
ERCC4 involvement of ERCC1/XPF NER endonuclease in regulation of 
telomere integrity
EST1A even shorter telomeres 1
FBXQ4 Fbx4, regulator of Pin2/TRF1 protein abundance, alterations in
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stability can have a dramatic impact on telomere length
FGF2 upregulates telomerase activity
hCLK2 overexpression gradually increases telomere length
HNRPA1 may contribute to maintenance of telomere repeats in cancer cells
HNRPA2B1 telomere maintenance
HSPCB HSP90 is a key for telomerase activation
hTERT Catalytic component of telomerase
hTR Telomerase RNA subunit
IGF1 stimulates telomerase activity
IL15 activates telomerase
IRF1 downregulates telomerase activity
KIP binds telomerase by interacting with human telomerase
LPA VEGF dependant induction of telomerase activity
LSMD1 telomere replication
MAPK8 Calcium signalling in ovarian surface epithelial cells induces 
telomerase activity via JNK
MCRS2 associates with PinXl to reduce telomere length
NBN rescue of a telomere length defect of nijmegen breakage syndrome 
cells requires NBS and telomerase catalytic subunit
NCL interaction of hTERT and nucleolin participates in the dynamic 
intercellular localisation of telomerase complex
NCL nuclear localisation of TERT
NFKappaB regulates hTERT expression via myc
N M inhibits myc induced TERT promoter activity
p23 component of telomerase holoenzyme
PIF1 telomerase regulation
PINX1 binds telomerase so RNA template cannot bind
PKC theta regulates hTERT expression via myc
POT1 Protection of telomeres 1
PRKCA Protein kinase C alpha mediates phosphorylation of TEP1 and 
hTERT to increase telomerase activity
PTGES3 telomerase subunit
RAB9A upregulated by telomerase
RAD50 telomere maintenance
RAD51L3 telomere maintenance requires RAD5ID
RAD54 ALT pathway
RAP1 Telomere binding
RELA NF-kappa-B p65 modulates telomerase nuclear translocation
RFC1 telomere stability
RIF1 telomere maintenance
RTE1 repressor of telomerase expression 1
RTEL1 regulator of telomere elongation helicase 1
SCYL1 telomerase regulation-associated protein; telomerase transcriptional 
elements interacting factor
SMC5 Maintains telomere length in ALT cancer cells
SMC6 Maintains telomere length in ALT cancer cells
SMN1 novel telomerase-associated protein, likely to function in human 
telomerase biogenesis
SMYD3 mediates transcription factor binding to the hTERT promoter
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SNRPN telomere replication
SP1 Spl and Sp3 have roles in regulation of human telomerase reverse 
transcriptase promoter activity
SP3 Spl and Sp3 have roles in regulation of human telomerase reverse 
transcriptase promoter activity
TAK1 represses transcription of telomerase
TELM telomere length, mean leukocyte
TEP1 telomerase associated protein
TERF2IP telomeric repeat binding factor 2 interacting protein
TINF2 TRF1 interacting nuclear factor 2
INKS tankyrase- releases TRF1 from telomeres and allows access to 
telomerase
TNKS1BP1 tankyrase 1 binding protein 1
TNKS2 tankyrase 2
TP53 regulation of telomerase activity in ovarian tumours
TRF1 inhibits access of telomerase to telomeres
TRF2 telomere end protection, negative regulator of telomere length
TSN binds telomere repeats
UBE3A activates hTERT transcription
VEGF upregulates telomerase activity
WRN binding by and stimulation of by telomere binding protein TRF2
WT1 represses transcription of telomerase
XRCC5 Ku70/80 associates with hTERT to regulate access to telomeres
XRCC6 Ku70/80 associates with hTERT to regulate access to telomeres
ZNF146 OZF function may be linked to telomere regulation
6.3.2 Microarray analysis o f MDS with del(5q) with a telomere specific gene set
The telomere specific gene set was used for gene expression profiling of CD34+ cells 
from patients with MDS. The gene set was used to analyse differences between the 
CD34+ cells of patients with and without del(5q). Thirty patients with del(5q) and 87 
patients with normal or other karyotype were analysed. From the original gene list a set 
of 19 genes was identified that could distinguish between these two groups. These 
genes are shown in Table 6.4. Hierarchical clustering was performed with this gene set 
and it can be seen that some segregation of karyotypic groups occurs (fig 6.2). It can be 
seen that the majority of patients with del(5q) cluster together. However, 23 patients 
cluster closely and 8 are distributed throughout on separate branches of the tree.
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Additionally, the gene set was not able to distinguish normal karyotype MDS from any 
other karyotype apart from del(5q).
Genes identified by this analysis include several positive regulators of telomere length 
such as SMYD3. This gene was lower in the del(5q) group (range 0.133 -  2.93 median 
0.89) than the normal karyotype group range (0.67 -  3.40 median 1.26). Also lower in 
the patients with del(5q) were TNKS, hCLK2 and RAD50, all of which are positive 
regulators of telomere length. The genes with higher expression in del(5q) tended to be 
those associated with increased telomerase activity such as PRKCA, FGF2 and SMN1.
Table 6.4 Genes differentially expressed in MDS with and without del(5q)
Gene Name Function
CRM1 enhances nuclear export of TERT
EGFR
Antisense epidermal growth factor receptor RNA transfection in human 
glioblastoma cells down-regulates telomerase activity and telomere 
length
ERCC1
involvement of ERCC1/XPF NER endonuclease in regulation of 
telomere integrity
FGF2 upregulates telomerase activity
hCLK2 overexpression gradually increases telomere length
HSPCB HSP90 is a key for telomerase activation
hTERT Catalytic component of telomerase
PRKCA
Protein kinase C alpha mediates phosphorylation of TEP1 and hTERT 
to increase telomerase activity
RAD50 telomere maintenance
RAD51L3 telomere maintenance requires RAD51D
RFC1 telomere stability
RTEL1 regulator of telomere elongation helicase 1
SMN1
novel telomerase-associated protein, likely to function in human 
telomerase biogenesis
SMYD3 mediates transcription factor binding to the hTERT promoter
TNKS
tankyrase- releases TRF1 from telomeres and allows access to 
telomerase
TRF1 inhibits access of telomerase to telomeres
TRF2 telomere end protection, negative regulator of telomere length
VEGF upregulates telomerase activity
XRCC5 Ku70/80 associates with hTERT to regulate access to telomeres
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Figure 6.2 Hierarchical clustering of 24 telomerase related genes in MDS patients 
with and without del(5q). Each row represents a single gene and each column a 
separate patient. The red bars represent patients with del(5q) and the blue bars represent 
patients without del(5q). The majority of patients with del(5q) cluster together with 8 
distributed on separate branches of the tree.
6.3.3 Identification o f differentially expressed telomere genes in MDS
The telomerase specific gene set was used to analyse gene expression differences in 
patients with distinct disease status. This analysis revealed that the gene set did not give 
rise to a group of genes that could differentiate between RA, RARS, RAEB-1 or RAEB- 
2. The two most extreme disease states were compared alone, 35 patients with RA and 
30 patients with RAEB-2, and this also did not give rise to a gene set that could
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differentiate the two groups. Interestingly, hTERT did not differentiate between the RA 
and RAEB-2 groups. To identify telomerase related genes that may be involved in the 
pathogenesis of MDS ANOVA was used to compile a list of genes from all probe sets 
on the array that could distinguish between RA and RAEB-2 using a p value cut off of 
less than 0.01. This list generated a set of 224 genes that were differentially expressed 
in RA and RAEB-2. From this list genes were identified that have known function 
related to telomerase, and genes that are associated with deregulated telomerase or 
telomere length. Four genes were identified from this list. These are show in Table 6.5 
and expression is detailed in Figure 6.3.
Table 6.5 Telomerase related genes differentially expressed between MDS RA and 
RAEB-2.
Gene Name Function
AURKA c-Myc upregulation
EXO l Yeast homolog involved in telomere maintenance
CASP3 Apoptosis. Correlates with hTERT expression
TRF2 Telomere end protection
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Figure 6.3 Telomere related genes differentially expressed between MDS RA and 
RAEB-2. Each dash or triangle represents one patient sample. The line at 1 represents 
unchanged expression.
6.3.4 TRF2 gene sequencing
The negative regulator of telomere length TRF2 was to be sequenced in patients with 
MDS. Expression of this gene was shown to significantly differentiate between RA and 
RAEB-2 with RAEB-2 patients having lower expression of the gene. Although reduced 
expression of a gene is not always associated with mutation there is known to be 
variation of TRF2 in exons 3 and 6 (Savage et al. 2006). Sequencing of these exons 
was carried out to identify variation between MDS patients of different disease types 
and normal controls. Patients with RA, RARS and RAEB and normal controls were 
sequenced. Genomic DNA was PCR amplified then subjected to cycle sequencing.
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Sequence analysis was carried out using the Sequence Analysis software (Informagen). 
Sequencing data from patients and controls was compared with the known sequence of 
TRF2. In the patient and control samples analysed mutation of TRF2 was not found. 
All sequences generated were homologous to the known TRF2 sequence. An example 
of the sequence data and alignment is shown in Fig. 6.4.
ACTGTTCCTTTGATATGGAGGCTGAGCTCACACCACTGGAATCAGCTATCAATGTGCTGGAGATGATTAAAACGGAATTTACACTGACAGAAGCAGTGGTCGAATCCAGTAGAAAACTGGTCAAGGAAGCT 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
ACTGTTCCTTTGATATGGAGGCTGAGCTCACACCACTGGAATCAGCTATCAATGTGCTGGAGATGATTAAAACGGAATTTACACTGACAGAAGCAGTGGTCGAATCCAGTAGAAAACTGGTCAAGGAAGCT
A TGG  C CAA AA/jG G C T T T G A A A T C T  C A G T C C G C  I G C  C T C \ «  TAG A GGGG- .AGGA AG AT/.  A ACA G C CAGCAC C A G C C  CC T G T G G  AAAAGC CAC C CAG  » G AAC C C GC A* G
Av 70  8 0  90  100  I I . ,  130  H i .  IS*. ) • '
ATGGCCAAAAAGGCTTTGAAATCTGAGTCCGCTGCCTCAAGTACAGGGAAGGAAGATAAACAGCCAGCACCAGGGCCTGTGGAAAAGCCACCCAGAGAACCCGCAAG
ATGGCCAAAAAGGCTTTGAAATCTGAGTCCGCTGCCTCAAGTACAGGGAAGGAAGATAAACAGCCAGCACCAGGGCCTGTGGAAAAGCCACCCAGAGAACCCGCAAG
Figure 6.4 Sequence analysis of TRF2 in MDS patients. The top panel shows the 
sequencing electropherogram from one patient sample of TRF2 exon 3. The alignment 
of the sequence is shown against the NCBI database sequence. The bottom panel shows 
the sequencing electropherogram from one patient sample of TRF2 exon 6. The 
alignment of the sequence is shown against the NCBI database sequence.
6.3.5 NPM1 gene sequencing
NPM1 is known to be mutated in exon 12 in 35% of AML patients and of these the 
majority are normal karyotype. Eighty MDS patients were selected for genomic DNA 
sequencing of NPM1 in order in investigate if mutation was present and if it could 
predict transformation to AML. Initially 19 patients with normal karyotype and RAEB- 
1 or RAEB-2 were selected then patients were added from other disease groups 
including 7 with AML arising from MDS. Genomic DNA was PCR amplified then
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subjected to cycle sequencing. Sequence analysis was carried out using the Sequence 
Analysis software (Informagen). Sequencing data from patients and controls was 
compared with the known sequence of NPM1. Sequence analysis revealed that cases of 
MDS included in the present study did not have mutations in exon 12 of NPM1 and all 
sequences corresponded to the database sequence. An example of the sequence data 
and alignment is shown in Fig 6.5.
T T A AAG A G AC T T C C T C C A C T G C C  AG AG AT C T T GAATAGC
290  400 410 420
T TAAAGAGAC T T C CT C CAC T G CCAGAGAT C T T GAATAGC
I  I  I  I  I  I  I I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I I  I  I  I  I I  I  I  I  I  I  I  I
T TAAAGAGAC TTCCTCCACT G CCAGAGAT C T T GAATAGC
Figure 6.5 Sequence analysis of NPM1 in MDS patients. Sequencing 
electropherogram from one patient sample of NPM1 exon 12. The alignment of the 
sequence is shown against the NCBI database sequence.
6.4 Discussion
Gene expression profiling of CD34+ cells from MDS patients using the Affymetrix 
GeneChip U133 plus 2.0 microarray was carried out using a gene set specific for 
telomere related genes. This list was unable to distinguish between subtypes of MDS. 
Additionally, according to the array data, the difference in hTERT expression between 
subtypes was not significant.
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However, when MDS patients were separated into those with and without a del(5q) 19 
genes were differentially expressed between these groups. Although the majority of 
these patients clustered together 8 were on separate branches of the tree. Genes 
identified as lower in patients with del(5q) include several positive regulators of 
telomere length such as SMYD3, TNKS, hCLK2 and RAD50. SMYD3 directly activates 
hTERT by binding the promoter and a reduction in SMYD3 leads to decreased 
expression of hTERT and telomerase activity (Liu et a l 2007). Reduction of SMYD3 
has been shown to inhibit cancer cell growth (Wang et al. 2008). TNKS (Tankyrase) 
and hCLK2 positively regulate telomere length and overexpression of hCLK2 increases 
telomere length (Smith and de Lange 2000; Jiang et a l 2003). RAD50 is part of the 
MRN (M rell-Rad50-Nbsl) complex that is essential for telomere length maintenance 
and has been reported to be reduced in B-CLL (Poncet et al. 2008).
The genes with higher expression in del(5q) tended to be those associated with 
increased telomerase activity such as PRKCA, FGF2 and SMN1. PRKCA 
phosphorylates hTERT to increase enzyme activity (Liu 1999). FGF2 can increase 
telomerase activity and has been reported to be increased in AML (Kurz et a l 2003; 
Ribatti et a l  2007). SMN1 is a telomerase associated protein that is likely to function 
to activate telomerase (Bachand et a l 2002).
Short telomere length is predictive of poor prognosis in MDS whereas patients with 
del(5q) have good prognosis. Genes that are associated with an increase in telomere 
length are decreased in patients with del(5q) suggesting that telomeres would be 
reduced in these patients. In fact patients with del(5q) and other karyotypic 
abnormalities have been observed to have shorter telomeres than those patients with 
normal karyotype (Ohyashiki et a l 1994; Sieglova et a l 2004). This could be partly
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due to the decreased expression of the telomere length regulators described here. 
Additionally, decreased expression of, SMYD3 in patients with del(5q) could be 
inhibiting cell growth and partly contributing to the good prognosis of these patients. 
Genes that are associated with an increase in telomerase activity are increased in 
patients with del(5q) suggesting that they would have an increase in telomerase activity 
when compared to other MDS patients. At present the amount of data on telomerase 
activity in patients with del(5q) is limited. Briatore et a l analysed telomerase activity in 
two patients with del(5q) but did not comment on any difference in telomerase activity 
between these and other MDS patients (Briatore et a l 2009). The data presented here 
suggests that patients with del(5q) have a differential telomerase gene expression 
pattern when compared to other patients with MDS. Further investigation into the 
changes in expression of genes that control telomere length and telomerase activity and 
analysis of telomerase activity and hTERT expression itself in patients with del(5q) will 
be of interest to further understanding of the importance of telomerase regulation in 
these patients.
Investigation of the most statistically significant differentially expressed genes between 
subtypes of MDS indicated some involvement of telomerase related genes, namely 
AURKA, EXOl, CASP3 and TRF2.
AURKA (aurora kinase A) shows decreased expression in patients with RAEB-2 MDS 
when compared to those with RA. AURKA has been reported as overexpressed in 
many cancers including breast, colorectal, gastric and pancreatic (Lens et al. 2010). 
The gene can be amplified in cancers and overexpression is associated with poor 
prognosis and genomic instability (Lens et al. 2010). In breast cancer it is frequently 
overexpressed and is known to induce telomerase activity through upregulation of c- 
MYC (Yang et a l 2004). However, c-MYC expression appears to be increased in the
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CD34+ cells of patients with MDS (Sloand et al. 2007; Vasikova et al. 2010). c-MYC is 
regulated by many proteins and in MDS cases AURKA may not be effecting c-MYC 
expression to regulate hTERT. In AML expression of AURKA is varied but those 
patients that have high expression have unfavourable cytogenetics (Lucena-Araujo et al. 
2011). Mutation of the gene can lead to decreased expression and this is thought to 
increase risk of oesophageal cancer (Lens et al. 2010). This suggests that decreased 
expression of AURKA can also lead to cancer and, although the gene may not be 
affecting hTERT, this may be the case in MDS.
EXOl has been studied in yeast and has been shown to directly contribute to telomere 
shortening (Bertuch and Lundblad 2004). Interestingly, in the absence of telomerase 
EXOl was shown to enhance telomere function and cell proliferation by a telomerase 
independent pathway. No data is available on the function of human EXOl on 
telomeres at present. If the function of human EXOl is related to that of yeast then it 
could be that the decrease in EXOl associated with MDS RAEB-2 allows some 
telomere maintenance to occur, keeping telomere length above the critical level and 
allowing cells to extend their proliferative potential.
Oshima et al. demonstrated that CASP3 (pro-apoptotic) is expressed in MDS in higher 
levels than in normal control cells (Ohshima et al. 2003). This was detected by 
immunohistochemistry of bone marrow biopsies. However, they did not differentiate 
between disease subtypes. They show that CASP3 expression coupled with a decrease 
in hTERT expression is associated with poor prognosis. However, in the study no 
interaction between these genes was identified. This correlation may be by chance. In a 
later study CASP3 was identified as significantly decreased in RAEB-2 patients when 
compared with RA patients (Pellagatti et al. 2006). CASP3 is a downstream target of
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TRF1 and overexpression of TRF1 increases CASP3 (Kishi et a l 2001). Reduced 
TRF1 could be partly causing the reduced CASP3 and allowing cells to continue to 
proliferate. In the current study CASP3 is reduced in the patients with RAEB2 
suggesting that there would be a reduction in apoptosis in these patients as has been 
documented (Parker et al. 1998).
The absence of mutation of TRF2 in patients with MDS shows that mutation is unlikely 
to be responsible for the reduced expression of TRF2 in patients with RAEB2. 
However, this reduced expression is still of interest. Decrease in expression of TRF2 
may lead to reduced binding of TRF2 at the telomere allowing telomerase to access the 
telomere repeats and lengthen shorter telomeres (Smogorzewska et al. 2000). TRF2 is 
known to function in telomere end protection so a dramatic reduction of TRF2 could 
leave telomere ends unprotected and activate the DNA damage response (de Lange 
2002).
Although the number of telomerase related genes differentially expressed between RA 
RAEB-2 MDS is small they indicate that regulation of telomerase and telomeres may 
contribute to disease progression. Reduction of TRF2 and EXOl contribute to telomere 
maintenance allowing telomere length to be maintained above the critical level. This is 
complemented by the reduction of CASP3 that leads to a reduction of apoptosis in these 
cells.
NPM1 exon 12 mutations are common in patients with AML. Patients with MDS are 
known to progress to AML. Eighty patients with MDS were tested for NPM1 exon 12 
mutations to see if the presence of the mutation could predict disease progression or 
prognosis in MDS. However, NPM1 mutations were not demonstrated in patients with
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MDS. This result is in agreement with several subsequent studies that used sequence 
analysis to assess the mutation status of NPM1 in MDS. These studies involved smaller 
sample size than the present study and the majority reported no mutations of NPM1 in 
MDS (Caudill et a l 2006; Oki et a l 2006; Shiseki et a l 2007; Zhang et a l 2007; 
Dicker et a l 2010). The study by Zhang et a l showed two MDS patients out of 38 
analysed had mutated NPM1 (Zhang et a l 2007) and they suggest that the mutation may 
be involved in the pathogenesis of MDS. Dicker et a l report one of 66 MDS patients in 
their study had mutated NPM1 (Dicker et a l 2010). This group also reported a low 
incidence (8.5%) of NPM1 mutation in AML arising from MDS and suggest a different 
disease mechanism for de novo AML in which 25% of cases are mutated. Two recent 
studies analysed larger cohorts of patients and report a higher incidence of mutation (Li 
et a l 2010; Bains et a l 2011). Li et a l report that nine of 232 patients have a mutation 
while Bains et a l found seven of 160 patients with mutated NPM1. In the study by 
Bains et a l no cases with only mutated NPM1 progressed to AML and authors 
suggested that the mutation is not sufficient to explain progression of MDS to AML. 
However, they did report that when NPM1 is mutated in combination with FLT3 
mutation all cases (four) progressed to AML and suggest these mutations are useful 
markers for predicting progression of MDS to AML. Taken together with the present 
investigation all of the above studies total an analysis of 684 MDS patients. This 
indicates that 2.7% of MDS patients could carry the mutation. The low incidence of 
mutation of MPN1 in the combined studies indicates that mutation of this gene as a sole 
genetic abnormality is unlikely to be an important prognostic indicator in the 
progression of MDS to AML. However, a recent study has reported NPM1 expression 
is reduced in patients with advanced del(5q) MDS and authors suggest that this decrease 
in expression contributes to the pathogenesis of advanced stage MDS by contributing to 
genomic instability (Pellagatti et a l 2011).
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Disease progression in MDS is clearly complex but the data presented here suggest that 
differential expression of genes associated with telomerase and telomere maintenance 
may be associated with the pathogenesis of MDS, in particular those patients with a 
del(5q).
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Chapter 7 
General Discussion
Real time PCR has been used to investigate gene expression levels of individual 
telomerase associated genes in CML. This analysis revealed that, in contrast to many 
studies of human cancer, hTERT, the catalytic component of telomerase is down 
regulated in patients with CML. Furthermore, expression is reduced with disease 
progression. This finding has many implications in the field of telomere biology, 
particularly with the advent of telomerase inhibitors for treatment of cancer.
Expression of hTERT was measured in combination with other telomerase related genes 
hTR, and TEP1, (subunits of telomerase), TRF1, TRF2 and Tankyrase, (telomeric- 
associated proteins) and c-Myc and PinXl, (positive and negative regulators of 
telomerase, respectively).
The reduced expression of hTERT in CML is likely to be caused by many interacting 
factors, several of which have been analysed in the present study. Interaction of these 
factors with hTERT is summarised in Fig 7.1. It is likely that the reduced expression of 
hTERT observed in the current study is partly due to the downregulation of c-Myc, 
which positively controls expression of hTERT. Interestingly, it has been shown by 
immunohistochemical methods that c-Myc expression in CML was lower in BC than in 
AP, this is in agreement with the current study (Vidovic et al. 2008).
Expression of c-Myc may be influenced by the expression of PinXl. Transfection of 
PinXl into PinXl negative gastric cancer cells reduced expression of c-Myc and 
telomerase activity (Wang et al. 2010). Furthermore, RNAi knockdown PinXl resulted 
in increased expression of c-Myc. Therefore, the presence of elevated PinXl expression 
above normal control levels could contribute to the resulting decrease in c-Myc 
expression which in turn leads to decreasing hTERT expression. It may also be
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suggested that this decrease in telomerase is a result of the BCR/ABL fusion gene in 
CML. In fact, it has been shown that antisense inhibition of BAR/ABL/c-ABL 
increases hTERT levels (Bakalova et al. 2004). Therefore, the presence of the 
BCR/ABL fusion in CML may contribute to the down regulation of hTERT observed in 
the CD34+/blast cells of the CML patients in this study. If this is the case it may be that 
the downregulation of hTERT in CML may be more pronounced in this disease as a 
result of the BCR/ABL fusion.
PINX1
c-Myc *• hTERT
Figure 7.1 Regulation of hTERT  expression in CML. WT1 and PINX1 negatively 
regulate c-Myc expression which results in decreased expression of hTERT. WT1 and 
BCR/ABL also decrease expression of hTERT. Reduction in PAX5 expression could 
decrease telomerase expression. In the absence of promoter methylation CTCF inhibits 
hTERT expression.
It appears that there are still many regulators of hTERT to be assessed and new 
candidate genes are being identified regularly. Recently PAX5, a B-cell specific 
transcription factor has been identified as an activator of transcription o f hTERT 
(Bougel et al. 2010). The binding site of PAX5 in the telomerase promoter was 
identified by EMSA and ChIP experiments. It was demonstrated that ectopic 
expression of PAX5 in a telomerase negative cell line was sufficient to activate hTERT
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transcription. As PAX5 expression is normally restricted to B cells it would be of 
interest to investigate expression of PAX  5 in CML. PAX5 is expressed on pre-B cells 
which are CD34+.
The Wilms’ tumour 1 ( WT1) gene was initially identified as a tumour suppressor gene 
but it has a number of target genes and has also been shown to have oncogenic effects. 
WT1 binds both the hTERT and c-Myc promoters and expression of WT1 results in a 
reduction of hTERT expression (Sitaram et al. 2010). WT1 is known to be 
overexpressed in CML and has shown to be increased with disease progression (Inoue 
et al. 1994; Gerber et al. 2011). Further studies of WT1 in CD34+ cells in combination 
with measurement of expression levels of hTERT and other telomerase associated genes 
could provide further insight into the regulation of telomerase in CML.
It was revealed that in CML the hTERT core promoter was not methylated and the 
absence of methylation could lead to the repression of hTERT transcription by the 
binding of CTCF which would lead to the observed reduction in transcription. Further 
investigation of this interaction is warranted and the entire CTCF binding site in the 
promoter could be investigated by bisulfite sequencing. This will allow analysis of 
individual CpG sites of the hTERT promoter and full characterization of the methylation 
status of the CTCF binding site. Recently DNA methylation microarrays have been 
used in combination with a methylated CpG island recovery assay to analyse genome 
wide methylation patterns in ALL (Dunwell et al. 2010). In the same study this group 
then analysed the genes that were frequently methylated in ALL in patients with CML 
to see if methylation correlated. They showed that methylation of this set of genes was 
increased in CML with disease progression. This study only analysed a small set of 
genes in CML patients and this showed a correlation with disease progression 
suggesting that methylation does play a role in progression of CML. Further studies of
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CML patient DNA methylation using whole genome CpG arrays could provide further 
clues into the specific genes involved in disease progression.
Patients with ET exhibiting the JAK2 V617F mutation were studied by cDNA 
microarray. It was shown the neutrophils from these patients were not heterogeneous 
when compared to normal neutrophils suggesting that the presence of the mutation does 
not have a major effect on gene expression changes in neutrophils and that the 
granulocyte lineage may not be involved in the pathogenesis of ET. It has been shown 
that JAK2 V617F positive myeloproliferative neoplasms can often give rise to AML that 
is negative for the mutation further suggesting that the presence of the JAK2 V617F 
alone is not sufficient for transformation (Theocharides et al. 2007). Genetic 
abnormalities in the neutrophils of patients with ET have been investigated by SNP 
microarray analysis in a study by Kawamata et al. (Kawamata et al. 2008). This study 
demonstrated that genomic abnormalities were rare in ET but the abnormalities 
observed were only in those patients with mutated JAK2. Three abnormalities were 
identified in three separate patients: Deletion of 5q23.1, Trisomy 9 and uniparental 
disomy at 9p. Uniparental disomy of 9p is known to be a mechanism of duplication of 
the mutated JAK2 allele (Kralovics et al. 2005)and trisomy of chromosome 9 could also 
be viewed to have this function. Further investigation of genetic changes in patients 
with ET in combination with gene expression profiling could provide further clues into 
the pathogenesis of this disease.
Expression of telomere related genes was also investigated in MDS by microarray 
analysis. A subset of genes were identified that could differentiate between those 
patients with and without a del(5q). Genes identified as lower in patients with del(5q) 
include several positive regulators of telomere length such as SMYD3, TNKS, hCLK2
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and RAD50. The genes with higher expression in del(5q) tended to be those associated 
with increased telomerase activity such as PRKCA, FGF2 and SMN1. This suggests 
that in these patients telomere length would be decreased but this is counteracted by 
increased expression of genes promoting telomerase activity. Direct measurement of 
hTERT expression in these patients would provide insight into the role of this gene in 
the prognosis of these patients.
Genes that could differentiate between RA and RAEB2 subtypes were mostly related to 
telomere maintenance. Of those genes identified TRF2 and EXOl are known to have 
functions that negatively regulate telomere length while AURKA can increase hTERT 
expression and CASP3 promoted apoptosis. Reduction of TRF2 and EXOl contribute 
to telomere maintenance allowing telomere length to be maintained above the critical 
level. This is complemented by the reduction of CASP3 that leads to a reduction of 
apoptosis in these cells. The patients with reduced expression of these genes were 
patients with RAEB2 which is also associated with leukaemic transformation 
suggesting that deregulation of this set of genes may be associated with disease 
progression.
Genes involved in expression and regulation of hTERT do not appear to play a major 
role in disease progression of MDS, in contrast to disease progression of CML. Rather, 
it is telomere length that seems to be important. Reduced telomere length has been 
shown to be important for disease progression of MDS. Erosion of telomeres is known 
to contribute to genetic instability by increasing the number of chromosome end to end 
fusions, especially when TRF2 is reduced. The reduction in TRF2 expression in 
RAEB2 MDS suggests that the telomere capping function of TRF2 will be reduced 
allowing an increase in chromosome end to end fusions and non reciprocal
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translocations which are characteristic of genomic instability. The resulting instability 
then leads to tumour formation. It is likely that for MDS cells to continue dividing they 
have lost cell cycle checkpoint control. Indeed, it has been reported that mutations in 
TP53 are present in up to 25% of primary MDS patients and preferentially in those 
patients with RAEB (Ludwig et al. 1992; Sugimoto et al. 1993; Wattel et al. 1994; 
Kaneko et al. 1995). p53 would normally cause a cell to enter cell cycle arrest after 
DNA damage such as chromosome fusions. Mutation of the gene inactivates the protein 
and allows the cell to continue cycling permitting further telomere erosion and genomic 
instability. Therefore it could be suggested that mutation of TP53 or a defect in another 
cell cycle checkpoint could allow the cells of MDS patients to continue cycling and 
result in decreased telomere length, which in conjunction with reduced TRF2 expression 
leads to chromosome end to end fusions. No data on TP53 gene status was available for 
the patients included in the present study but correlation of this with expression of TRF2 
could prove useful to predict those patients at greater risk of genomic instability and 
disease transformation. It is thought that telomerase is required to confer immortal 
growth on to cells that exhibit instability and it has been shown that hTERT is expressed 
in MDS.
Perhaps the mechanisms of disease progression in CML and MDS are similar; both 
have reduced telomere length which will increase genetic instability and lead to disease 
progression. However, in CML the presence of the BCR/ABL fusion product and 
deregulation of several telomerase associated genes appears to contribute to reducing 
hTERT expression. This is unlikely to be the case in MDS. To further elucidate the 
importance of telomerase in MDS direct measurement of hTERT and telomerase 
associated genes in the CD34+ cells of patients with specific disease subtypes and 
karyotypic abnormalities would be valuable.
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The data in the current study challenge the view that telomerase in always increased in 
cancer. It is accepted that most tumours express hTERT and are telomerase positive, but 
it is not usually clear whether the observable hTERT expression is due to their origin 
from telomerase positive stem cells or due to reactivation of the gene during 
tumorigenesis. Such studies, which have compared hTERT or telomerase activity in 
tumour cells with corresponding normal tissues, and not the normal stem cells of origin, 
have given rise to the observation that tumour cells have increased levels of telomerase. 
However, in solid tumours it is not possible to compare tumour cells with their 
corresponding stem cells as it is for leukaemia cells with CD34+ stem cells. The data 
presented here demonstrates that the CD34+/blast cells of patients with CML possess 
lower hTERT expression levels than CD34+/blast cells from normal individuals. Like 
other stem cells the telomeres of normal CD34+ cells are maintained by low levels of 
telomerase and show only gradual telomere shortening with ageing and rapid cycling. 
Telomerase activity ensures that the stem cell compartment will be able to respond 
adequately to large expansion demands and, whilst the telomeres still gradually shorten, 
the time to critically shortened length is delayed by telomerase. In CML the turnover of 
all types of Philadelphia positive stem and progenitor cells is known to be increased and 
several studies suggest that telomere length measurements may be a useful indication of 
stem cell turnover in vitro and in vivo (Brummendorf et al. 2000). This result suggests 
that telomerase may not always be increased in malignancy and that the reduction of 
hTERT expression in CML directly causes telomeres to shorten as the cells divide in 
order to increase genetic instability and drive disease progression. Whether this 
phenomenon is specific to CML cannot yet be speculated. However, recently it has 
emerged that other malignancies do not have increased hTERT expression or telomerase 
activity. This is particularly of note in Chronic Lymphocytic Leukaemia (CLL). It has 
been demonstrated by expression analysis that hTERT expression is more than two fold
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reduced in CLL patients when compared with normal controls (Poncet et al. 2008). 
More recently, reduced telomerase activity and telomere dysfunction have been 
identified in CLL (Lin et al. 2010). In both of these studies B-cell populations were 
isolated from patients and normal controls, allowing a direct comparison of the 
malignant cells with the cells of origin. This further demonstrates the importance of 
comparing like with like when analysing malignant cells.
Although more difficult to isolate in solid tumours Liu et al. have analysed homogenous 
populations of cells in breast carcinomas (Liu et al. 2004). Using rrTRNA in situ 
hybridisation they were able to compare expression of hTERT in only the cells of 
interest. This showed that expression of hTERT was high in normal breast tissue but 
significantly reduced in ductal carcinoma in situ.
Reduction of telomerase activity has also been demonstrated in B-cell lymphomas. 
Klapper et al. showed that telomerase activity was not significantly different from that 
of normal controls in mantle cell lymphoma, follicular lymphoma and diffuse large B 
cell lymphoma (Klapper et al. 2003). They were able to demonstrate significantly 
increased telomerase activity in Burkitt’s lymphoma which is characterised by the 
t(8;14) translocation which results in overexpression of c-Myc. This increase in 
expression of c-Myc is thought to directly cause the increase of telomerase activity in 
Burkitt’s lymphoma. This suggests that lymphomas do not show increased telomerase 
activity unless c-Myc is overexpressed.
The suggestion that telomerase is not increased in all malignancies has implications for 
the study of telomerase inhibitors as treatment for cancers. These drugs are designed 
with the idea that telomerase is increased in cancer cells and inhibition of telomerase is
196
expected to reduce telomere length and lead to death of the cancer cells. Telomerase 
inhibitors could have adverse effects on those cells that express telomerase normally, 
such as haematopoietic stem cells. It could be suggested that telomerase inhibitors may 
deplete, for example in the bone marrow, haematopoietic stem cells and not the low 
telomerase expressing cancerous cells thereby giving the cancer cells a growth 
advantage over the normal cells. It has even been suggested that telomerase inhibition 
could lead to an increase in genomic instability in surviving malignant cells and result in 
a more aggressive disease phenotype. Phase 1 clinical trials of oligonucleotides 
targeting hTR binding are currently being carried out in patients with CLL and other 
lymphoproliferative diseases (ClinicalTrials.gov identifier NCT00124189). As there is 
evidence of reduced hTERT expression in CLL it will be of great interest to see the 
results of this study especially in relation to the cell types that have been affected and 
progression of disease.
Mechanisms of telomerase regulation in malignancy are clearly complex and many 
factors influence both telomere length and hTERT expression. The data presented here 
show that reduced expression of hTERT and other telomerase associated genes is 
important for disease progression in CML and some other cancers. Whether this is the 
case with many other malignancies is not yet known but additional studies of cancer 
stem cells will allow further investigation of this important finding. Further studies 
comparing gene expression in solid tumours with their cells of origin may increase 
understanding of this issue.
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